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ABSTRACT
The initial goal of this work was the cloning and 
expression of the genes UL18/ UL19 and UL38 of HSV-1. 
These genes encode the three capsid proteins VP23/ VP5 
(the major capsid protein) and VP19C respectively/ which 
are all present in cored and in coreless intranuclear 
capsids. Cloning having been achieved/ each gene was 
expressed in a recombinant vaccinia virus; each 
recombinant producing a protein profile with a unique 
band of the correct size/ as judged by its comigration 
with the respective protein in preparations of purified 
capsids. A further recombinant vaccinia virus was 
constructed/ which expresses the HSV-1 assembly protein 
VP22a, the product of the gene UL26.5. Expression of 
VP22a by this recombinant was confirmed using a 
monoclonal antibody (5010) against VP22a. These viruses 
were used in a study of HSV-1 capsid structure and 
assembly.
One aim of this research was to be able to assemble HSV-1 
capsids using capsid genes cloned and expressed in a 
heterologous system. However/ electron microscopy 
demonstrated that the products of the four capsid genes 
UL18/ UL19/ UL26.5 and UL38 are insufficient for the
assembly of capsids or capsid-like particles in the 
vaccinia expression system. Possible reasons for this/ 
and implications for the capsid assembly process/ are 
discussed.
VP19C has previously been reported to be a DNA-binding 
protein. Attempts were made to confirm this using the 
VP19C expressed from a recombinant vaccinia virus/ but 
VP19C did not exhibit significant DNA-binding activity in 
this system.
The vaccinia virus expressing VP23 was used to identify 
VP23 as the target antigen for a previously unassigned
monoclonal antibody (1060). This antibody was then used 
to study the properties of the UL18 gene product in
HSV-l-infected cells. UL18 mRNA has been reported to be 
regulated with early-late kinetics in lytic infections. 
In an attempt to confirm this/ the kinetics of synthesis 
of VP23 were examined. VP23 was detectable by
immunoprecipitation from 2 to 3 hours post-infection 
(personal communication/ Dr A.M.Cross). Production of
VP23 was not affected by the presence of the DNA
synthesis inhibitor phosphonoacetic acid. Thus VP23 is 
produced early in infection and is not dependent on viral 
DNA synthesis/ in agreement with the designation of this 
gene as an early-late.
To investigate the subcellular distribution of VP 5/ 
VP19C, VP23 and VP22a when expressed from the vaccinia 
vectors/ cells infected with the recombinant viruses were 
separated into cytoplasmic and nuclear fractions. A 
control experiment using wild-type HSV-1 showed these 
proteins to separate predominantly with the nuclear 
fraction. By contrast/ in recombinant-vaccinia-infected 
cells expressing VP5 or VP23/ these proteins were almost 
exclusively cytoplasmic. However/ when expressed by a 
recombinant vaccinia virus/ VP19C and VP22a showed 
intrinsic ability to locate to the nucleus/ the site of 
capsid assembly.
The availability of antibodies against VP23 and VP22a 
allowed further investigation of the subcellular 
distributions of these proteins by immunofluorescence 
experiments on infected cells. These experiments again 
showed that when expressed by the recombinant vaccinia 
virus/ VP23 remains localised in the cytoplasm in 
contrast to the situation obtaining during infections 
with wild-type HSV-1/ when VP23 localised to the nucleus.
It was thought unlikely that this failure of the herpes 
protein to accumulate in the nucleus was a consequence of 
the vaccinia vector interfering with the normal transport
mechanisms since other herpesvirus proteins expressed 
from the same vector are known to enter and to accumulate 
in the nucleus. However/ to eliminate this possibility 
the distribution of VP23 expressed from a plasmid vector 
was examined. The UL18 coding sequences were placed under 
the control of the HSV-1 glycoprotein D promoter/ and 
this construct was cotransfected into cells along with 
plasmids expressing the two HSV-1 immediate early 
transactivating proteins VmwllO and Vmwl75. When the 
distribution of VP23 expressed in these cells was 
examined by fluorescent staining with 1060/ it was
identical to that in the recombinant vaccinia-infected 
cells/ ie predominantly cytoplasmic.
Use of 5010/ directed against VP22a in immunofluorescence 
experiments showed that when expressed from the vaccinia 
vector/ VP22a localises to the nucleus as in wild-type 
infections/ in direct contrast to the cytoplasmic 
location of VP23. This observation provides further
confirmation that the vaccinia vector does not interfere 
with the processes of transport of the foreign protein. 
This result has been confirmed by immunoelectron
microscopy.
A significant finding was that immunofluorescence studies 
suggest that VP22a is able to affect the subcellular 
location of VP23. Use of 1060 showed that while VP23 
adopted a cytoplasmic location when expressed by a 
recombinant vaccinia virus/ in a dual infection with a 
VP22a-expressing recombinant VP23 localised predominantly 
in the nucleus. VP22a is thought to function as a 
scaffolding protein during HSV capsid assembly/ and this 
result suggests that it may also function in 
intracellular transportation of another capsid protein.
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INTRODUCTION
1 CLASSIFICATION OF THE HERPESVIRIDAE
Herpesviruses are ubiquitous viruses of vertebrates, with 
112 species being listed by Roizman et al. (1992) for
inclusion in the family Herpesviridae. Membership of this 
family is based on common virion architecture. The 
-typical herpesvirion viewed by electron microscopy is 
120-200 nm in diameter, and comprises four principal 
structural elements: a core, including the nucleic acid
complement; an icosahedral capsid approximately 100- 
125 nm in diameter? an amorphous proteinaceous layer 
designated tegument, present in variable amounts; the 
envelope, a bilayered membrane surrounding the tegument. 
The nucleic acid of herpesviruses is a double-stranded, 
linear molecule of DNA, of between 32-75 % moles G+C, and 
a molecular weight of between 80-150 x 10^ Da, according 
to species.
Three subfamilies of herpesviruses are distinguished, on 
the basis of differences in their biological properties 
in respect of host range, duration of reproductive cycle, 
cytopathology and characteristics of latent infection 
(Roizman et al., 1981; Matthews, 1982; Brown, 1989? 
Francki et al., 1991). Members of the subfamily 
Alphaherpesvirinae are primarily distinguished by their 
relatively permissive in vitro host range and ganglionic 
site of latent infection, although this is not the site 
of latency in all members. The genus Simplexvirus 
includes the two human herpesviruses HSV-1 and HSV-2. The 
genus Varicellovirus includes the varicella-zoster virus 
(reviewed by Davison, 1991) of humans. Members of the 
subfamily Betaherpesvirinae are primarily distinguished 
by their relatively long reproductive cycle and their 
distinctive cytopathology, especially the phenomenon of 
cytomegalia. The genus Cytomegalovirus contains the human 
cytomegalovirus (HCMV). Members of the subfamily 
Gammaherpesvirinae are primarly distinguished by a 
relatively restricted in vitro host range and lymphoid
1
site of latent infection. The genus Lymphocryptovirus 
includes the human herpesvirus Epstein-Barr virus.
The biological properties used in this scheme do not 
represent strictly defined criteria, resulting in a 
classification with many exceptions and inconsistencies. 
The ever-increasing amounts of sequence data becoming 
available have largely provided a better basis for the 
present classification, although some discrepancies have 
been identified. Two avian herpesviruses, Marek's disease 
virus (MDV) and the serologically related herpesvirus of 
turkeys (HVT), previously assigned to the 
Gammaherpesvirinae because of their tropism for 
lymphocytes, have significant sequence homology with the 
Alphaherpesvirinae (Buckmaster et al., 1988; Scott et 
al., 1989). Similarly, human herpesvirus 6 (HHV-6)
(reviewed by Thomson et al., 1991), thought to be a 
gammaherpesvirus because of its isolation from peripheral 
blood lymphocytes and its propagation in cultures of 
lymphoblastoid cells, has been found to have significant 
sequence similarity to the betaherpesvirus HCMV (Lawrence 
et al.,- 1990). The recent sequencing of the entire genome 
of Channel Catfish Virus (CCV), previously thought to be 
an alphaherpesvirus, yielded the unexpected finding that 
there was no detectable significant homology with any 
known herpesvirus sequence. The lack of homology was so 
marked that the author was prompted to suggest that this 
virus should be assigned to a separate subfamily, or even 
that it be removed from the family Herpesviridae 
altogether, despite its status as a herpesvirus as judged 
by the classical criterion of virion morphology (Davison, 
1992). Human herpesvirus 7 (HHV-7), recently isolated
from peripheral blood lymphocytes, remains unclassified, 
as HHV-7 DNA did not show any hybridisation with probes 
derived from other human herpesviruses, except to a 
limited degree with HHV-6 (Frenkel et al./ 1990). HHV-7 
does show significant antigenic dissimilarity to HHV-6, 
sufficient to allow seroepidemiological discrimination 
(Wyatt et al., 1991).
2
2 BIOLOGY OF HSV-1
2.1 Natural host
The natural host of HSV-1 is man, although experimental 
infections can be achieved in a variety of laboratory 
animals. A ubiquitous pathogen, HSV-1 is the cause of a 
variety of human diseases ranging from the common but 
relatively mild condition of cold sore lesions of the 
lips and mouth to an occasional life-threatening 
infection of the central nervous system. The majority of 
primary infections are asymptomatic (reviewed by Whitley,' 
1990).
2.2 Latency
An interesting feature of the biology of herpesviruses is 
the phenomenon of latency. Latency has been defined as a 
type of persistent infection in which the viral genome is 
present but infectious virus is not produced except 
during intermittent episodes of reactivation, and the 
subject has been reviewed by Stevens (1989) and by 
Roizman & Sears (1987). HSV-1 establishes latency in 
peripheral sensory ganglia, although experimental latent 
infection has been attained in non-neuronal sites 
(Clements & Subak-Sharpe, 1988). No viral gene product is 
known to be essential for the establishment of the latent 
state, but the recent report of Harris & Preston (1991) 
presents evidence that lack of transactivation of 
immediate-early transcription by Vmw65 predisposes to 
latency, which supports the suggestion that failure of 
Vmw65 to initiate IE transcription is an event leading to 
latency. Viral DNA in latently infected cells is not 
integrated into cellular DNA but exists as separate 
extrachromosomal elements (Mellerick & Fraser, 1987). It 
is maintained in a non-linear state, probably a circular 
episome, and associates with nucleosomes in a chromatin­
like structure (Rock & Fraser, 1983; Rock & Fraser, 1985; 
Efstathiou et al., 1986; Deshmane & Fraser, 1989). The 
only viral RNAs detectable during latency is a related 
family, the latency-associated transcripts, or LATs.
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Figure 1. Gross organisation of the HSV-1 genome.
A conventional representation of the HSV-1 genome is shown, with 
unique sequences (U|_ and U3) as solid lines and major repeat
elements (TR|_ and IR|_, IR3 and TR3) as open boxes. The locations
of the L and S segments are marked. Terminal a sequences and the 
internal, opposite orientation a'sequence are indicated.
This figure is adapted with permission from McGeoch et al. (1988a).
These transcripts were initially observed by Stevens et 
aJL. (1987). The LATs are 2.0, 1.5 and 1.45 kb in length
(Spivak & Fraser, 1987), and their 3' ends overlap with 
and are complementary to the 3' end of the immediate- 
early gene IE110 in the long internal and terminal repeat 
regions. This observation led to the suggestion that the 
LATs may downregulate IE110 by an antisense mechanism 
(Rock et al.,- 1987; Stevens et al., 1987). An essential 
role of the LATs in the establishment of latency was 
ruled out by the work of Javier et al. (1988) and Steiner 
et al. (1989). The latter report did present findings
suggestive of a role of the LATs in facilitating 
efficient reactivation from latency in a mouse model; 
similar findings were made using a rabbit eye model 
system by Hill et al. (1990). A protein with an apparent
molecular weight of 80 kDa has been detected in latently 
infected neurons, using an antiserum raised against a 
bacterially expressed fusion protein containing part of a 
LAT-encoded polypeptide. The function of this protein is 
not known (Doerig et al., 1991). The molecular basis of 
the phenomenon of latency remains to be fully resolved.
2.3 Structure of the HSV-1 genome
The DNA of HSV-1 is a double-stranded, linear molecule 
with molecular weight of 96 x 106 Da. It has a base 
composition of 68.3% G+C, although this figure is not 
constant throughout the genome. The entire genome of 
HSV-1 strain 17 has been sequenced,' and was found to 
consist of 152,260 base pairs (McGeoch et al., 1988a; 
McGeoch et al., 1986; McGeoch et al., 1985; Perry & 
McGeoch, 1988). The structure of the HSV-1 genome and 
those of the other human herpesviruses have been reviewed 
by McGeoch (1989).
HSV-1 DNA consists of two covalently linked components, 
termed the long and the short regions. Each component is 
composed of a unique sequence flanked at each end by an 
inverted repeat element, as shown in Figure 1. Thus the 
unique sequence of the long region (U-^ ) is flanked by its
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Figure 2. Layout of genes in the genome of HSV-1. The
HSV-1 genome is shown on four successive lines/ with 
unique regions represented by solid lines and major 
repeat elements as open boxes/ as in Figure 1. The lower 
scale represents kilobases/ numbered from the left 
terminus/ and the upper scale represents fractional map 
units. The sizes and orientations of proposed functional 
ORFs are shown by arrows. Overlaps of adjacent/ similarly 
oriented ORFs are not shown explicitly. Locations of 
proposed transcription polyadenylation sites are 
indicated as short vertical bars. Locations of origins of 
DNA replication are shown as X. In the Ut region, on the 
first three lines/ genes ULI to UL56 are labelled. In the 
Ug region/ on the bottom line/ genes US1 to US12 are 
labelled. The locations of introns in the coding regions 
of gene ULI5 and the two copies (TRl and IRr) of the 
IE110 gene are indicated. This figure is reproduced with 
permission from McGeoch et al. (1988a).
repeat elements, termed either the terminal (TRl) or the 
internal (IRL ) repeat, depending upon their location in 
the genome. Thus also there is a short unique region (Ug) 
with terminal (TRg) and internal (IRS) repeat elements. 
The long and the short regions are covalently linked 
between IR^ and IRg. The L and S regions can invert 
relative to one another. Thus, four sequence-orientation 
isomers of HSV-1 DNA are possible, and preparations of 
purified HSV-1 DNA contain these four isomers in 
equimolar amounts (reviewed by Roizman, 1979). The 
sequences of RL and Rg are unrelated, except that they 
have in common a 400-bp direct repeat present at both 
genome termini, with one or more copies present in 
inverted orientations at the junction of IRL and IRg. 
More than one copy can also be present at the long unique 
terminus. This element is known as the a^ sequence 
(Davison & Wilkie, 1981; Roizman, 1979; Mocarski & 
Roizman, 1982b)•
2.4 Genetic content of HSV-1
Seventy-two open reading frames (ORFs) were identified on 
the HSV-1 genome by McGeoch et al. (1988a). Most of these 
have been confirmed as functional genes, with gene 
products being identified. The locations of these ORFs 
are shown in Figure 2. With 56 genes in UL, 12 in Us and 
one in each copy of RL and Rg, there would be a total of 
72 genes. Since the four genes present in the repeat 
regions actually represent two copies each of two genes, 
there were predicted to be only 70 distinct proteins 
coded by HSV-1. The existence of other functional ORFs is 
debated, and four instances are of interest. The 3,500-bp 
region in RL downstream of the IE110 gene from where the 
LATs originate contains two partially overlapping 5' co­
terminal potential ORFs (Wagner et al., 1988; Wechsler ejt 
al., 1989), and a protein product has been detected
(Doerig et al., 1991). However, the function of the LATs 
is uncertain, as discussed above. A gene designated 
7^34.5 has been proposed in RL, upstream of the IE110 
gene, originating from a proposed promoter in the ci
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sequence (Chou & Roizman, 1986). This ORF is present in 
HSV-1 and HSV-2 (Chou & Roizman, 1990; McGeoch et al., 
1991; Dolan et al., 1992). A 43.5-kDa protein product, 
ICP34.5, has been identified (Ackerman et al., 1986; Chou 
et al., 1990), and evidence suggests it has a role in 
neurovirulence (Thompson et al., 1989; Taha et al., 
1989a; Taha et al., 1989b; Chou et al., 1990; Harland & 
Brown, 1991; McGeoch & Barnett, 1991; Chou & Roizman, 
1992). The work of Liu & Roizman (1991) demonstrates the 
existence of two transcriptional units within the UL26 
gene, and identifies the protein products of each. An 
ORF, designated UL49.5, has been identified between genes 
UL49 and UL50 by Barker & Roizman (1992). Promoter 
activity has been demonstrated, but a protein product has 
not been identified.
3 THE LYTIC CYCLE
3.1 Entry into target cell
3.1.1 Attachment
The initial stages of infection are attachment of the 
virion to the cell and fusion of the viral envelope with 
the plasma membrane (Morgan et al., 1968; Campadelli- 
Fiume et al., 1988). It is generally assumed that the 
nine glycoproteins present on the outside of the viral 
envelope are involved in the infectious process. Whilst 
only three of these are essential for lytic infection, 
gB,- gD and gH, none is essential for attachment (Cai jet 
al., 1988; Ligas & Johnson, 1988; Johnson & Ligas,> 1988; 
Desai et al., 1988). Infection is initiated by binding to 
the cell surface heparan sulphate proteoglycans (WuDunn & 
Spear, 1989), which explains the ability of the related 
glycosaminoglycan heparin to inhibit infection by HSV in 
vitro. WuDunn & Spear (1989) thought that binding to 
heparan sulphate was the first step in a cascade of 
virion-cell interactions, culminating in fusion of the 
virion with the plasma membrane. The reasons for this
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proposal were that both gB and gD are necessary for 
penetration of the virus into the cell (Sarmiento et al./ 
1979; Highlander et al., 1988; Cai et al., 1988; Fuller & 
Spear, 1987; Highlander et al., 1987; Ligas & Johnson, 
1988), and that these molecules are found on 
morphologically distinct spikes projecting from the 
virion envelope (Stannard et al.,- 1987), Glycoprotein H 
has also recently been shown to be essential for 
penetration of virus into the cell (Forrester et al., 
1992).
A further stage in the attachment process was proposed by 
Kaner et al. (1990) and Baird et al, (1990). They
reported that the cellular basic fibroblast growth factor 
(FGF) receptor is involved in viral uptake after initial 
attachment by means of heparan sulphate. This process was 
said to be mediated by host-cell derived basic FGF 
present in infecting virions. However, other workers have 
been unable to confirm these findings (Herold et al.,
1991; Mirda et al., 1992; Muggeridge et al., 1992).
Glycoprotein C appears to play a role in attachment, 
although there seems to be more than one mechanism
involved, because gC is not essential for lytic infection 
(Draper et al., 1984). The demonstration that HSV-2 gC~ 
strains could have their attachment blocked by
polycationic molecules such as neomycin and polylysine 
whilst gC+ strains were unaffected, showed that gC can 
mediate attachment to cells through its own receptor, 
independent of other routes (Campadelli-Fiume et al.,
1990; Langeland et al., 1990). A monoclonal antibody 
raised against gC reduced attachment of gC+ strains but 
did not affect a gC” mutant. This mutant attached at a 
reduced rate even in the absence of the antibody 
(Svennerholm et al., 1991). Thus HSV has alternative 
mechanisms of attachment, possibly allowing it to 
increase its tissue tropism.
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Kuhn et al. (1990) studied formation of complexes by
HSV-1 virion proteins with biotinylated cell membrane 
components, finding that HEp-2 cells bound gB, gC and gD 
in a noncooperative manner. Herold et al. (1991) showed
that gB and gC showed strong binding to a heparin- 
Sepharose column. They also found that gC was principally 
responsible for the binding of wild-type virus to HEp-2 
and Vero cells, in that the binding of gB" mutants was 
not impaired while binding of gC" mutants was ten-fold 
less efficient. Since heparin could also block attachment 
by gC" virus, the alternative mechanisms of binding also 
involved a heparan sulphate receptor. Sears et al. 
(1991), using a strongly polarised cell line showed that 
at least two different sets of receptors for HSV-1 were 
present, asymmetrically distributed on the cell surface. 
Infection via one of the receptors was dependent upon gC. 
Thus a gC" strain was unable to infect when exposed only 
to the apical surfaces of these cells but could infect 
via the basal surface. gC+ virus could infect via either 
surface.
3.1.2 Penetration
Morgan et al. (1968) observed entry of virus into cells
both by endocytosis and by membrane fusion, but were 
unable to determine by EM which route led to infection. A 
consensus of opinion had built up that the primary route 
of infection was by membrane fusion (reviewed by Roizman 
& Furlong,- 1974), but infection by endocytosis could not 
be ruled out. Results suggesting that infection occurs by 
membrane fusion only were presented by Addison et al.
(1984). The mutant _tsl204 with a lesion in gene UL25 had 
a defect in penetration. At the NPT this virus could 
attach,- and sufficiently high multiplicities could block 
subsequent infection by wild-type HSV-1. The defect in 
penetration could be overcome at the NPT by treatment 
with polyethylene glycol, a membrane fusion agent. Using 
a cell line which constitutively expressed gD, 
Campadelli-Fiume et al. (1988) showed that HSV attached
to these cells and although EM showed entry of virus was
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occurring by endocytosis, no virions were observed in the 
process of membrane fusion,' and no lytic infection 
resulted. Presumably the cellular gD sequestered all the 
cellular receptors of gD, showing also that gD is 
essential for fusion but not attachment. Cai et al. 
(1988) showed that while gB” virus retained the ability 
to attach, infection only resulted following treatment 
with polyethylene glycol. Thus gB is necessary for 
penetration.
3.1.3 Release of viral DNA
Following fusion with the cell membrane, the capsids are 
transported to the vicinity of the nuclear pores. Viral 
DNA is released from the capsids and translocated into 
the nucleus. A function essential for this process has 
been mapped to a region within UL36 (Batterson et al., 
1983), which encodes the 273-kDa tegument protein VP1.
3.2 The effect on host cell macromolecular synthesis
3.2.1 Virion host shutoff
Early in infection there is a rapid virus-induced 
interruption of host cell macromolecular synthesis; DNA, 
RNA and protein synthesis all being significantly 
impaired. There are two distinct phases of HSV-induced 
host shutoff,- which have been termed ’early1 and 
’delayed’; these and other aspects of shutoff have been 
reviewed by Fenwick (1984).
The first phase is also termed ’virion-associated’, after 
it was shown that one or more components of the infecting 
virion was responsible for a rapid disaggregation of 
cellular polyribosomes accompanied by destabilisation and 
degradation of host mRNA (Fenwick & Walker, 1978; 
Nishioka & Silverstein, 1978; Schek & Bachenheimer, 
1985). A related virion-associated shutoff event is an 
indiscriminate destabilisation and degradation of viral 
immediate-early, early and late mRNAs. This interference
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with viral mRNA is not easy to explain, but destruction 
of one regulatory class of RNA may facilitate transition 
to translation of the next class, since only recently 
transcribed mRNA would be functional (Kwong & Frenkel, 
1987; Oroskar & Read, 1989). These virion-associated 
functions map to the region of the gene UL41 in HSV-1 
(Kwong et al., 1988). The product of UL41 is predicted to 
have a molecular weight of 54914 (McGeoch et al., 1988a), 
and a 58-kDa phosphorylated protein has recently been 
detected in HSV-l-infected cells and in HSV-1 virions 
using an antiserum raised against a synthetic peptide 
corresponding to a region of the UL41 predicted amino 
acid sequence (Smibert et al.,- 1992). The action of this 
protein, known as the vhs (virion host shutoff) protein, 
remains unclear, although it is thought to activate a 
cellular nuclease (Strom & Frenkel,- 1987). Experiments 
with mutants defective in the shutoff function have 
demonstrated that this is not an essential function for 
growth in cell culture (Fenwick & Clark, 1982; Read & 
Frenkel, 1983). Viruses with the shutoff gene inactivated 
are also viable in tissue culture, confirming that the 
vhs function is not essential (Fenwick & Everett, 1990). 
Since the vhs protein is present in virions it is a point 
of interest whether it is an essential structural 
component of the virion. It was conceivable that mutant 
forms of the vhs protein might still perform an essential 
structural role despite having lost their shutoff 
activity. However, since inactivation of the UL41 gene 
yielded viable, shutoff-defective viruses, it is 
concluded that the vhs protein does not have an essential 
structural role (Fenwick & Everett, 1990). The recently 
developed in vitro RNA degradation assay of Krikorian & 
Read (1991) has confirmed a marked increase in rates of 
decay of host and viral cytoplasmic mRNAs induced by a 
virion component, and it is hoped that this assay system 
will prove useful in making a more detailed analysis of 
vhs function.
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The second phase of shutoff is also termed ’expression- 
dependent', as it requires de novo viral protein 
synthesis. Using mutants deficient in the virion- 
associated shutoff functions, a further degradation of 
cellular mRNA has been demonstrated, which is dependent 
upon synthesis of one or more viral E or L proteins (Read 
& Frenkel, 1983). Which proteins are involved is not 
known.
3.2.2 Induction of cellular proteins
Other research has focussed on the induction of specific 
cellular proteins by HSV. Infection with HSV-1 can 
activate a range of cellular promoters (Everett, 1985), 
and a small number of cellular proteins are known to 
accumulate to high levels (Patel et al., 1986; Kemp et 
al., 1986). One host cell polypeptide which accumulates
in HSV-2-infected cells also accumulates in heat-shocked 
cells, suggesting that it might function in the shut off 
of cellular gene expression (LaThangue et al., 1984). The 
induction of several stress proteins by abnormal forms of 
the immediate-early protein Vmwl75 has led to the 
suggestion that these proteins may act to eliminate 
aberrant forms of Vmwl75 during infection or to 
neutralise their damaging effects (Russell et al., 1987). 
Preston (1990) has demonstrated the induction of a 56-kDa 
cellular protein which occurs specifically by the binding 
of HSV-1 to the cell surface. The work of Macnab et al.
(1985) has raised the possibility that stress proteins 
may play a role in transformation by HSV. They 
demonstrated that an antibody raised against a host cell 
polypeptide which accumulates in HSV-2-infected cells 
cross-reacted with several polypeptides expressed by 
established transformed cell lines. Since these 
polypeptides are not specific to HSV-transformed cells, 
but are found in cells immortalised by other transforming 
agents, it appears that HSV upregulates cell polypeptides 
which may play a role in immortalisation.
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3.3 Regulation of polypeptide synthesis
Herpesvirus DNA is transcribed in the nucleus (Wagner & 
Roizman,' 1969a; Wagner & Roizman, 1969b), and use of a 
specific inhibitor of cellular RNA polymerase II revealed 
this enzyme to be the agent of transcription (Costanzo et 
al. ,■ 1977). Herpesvirus mRNAs are capped, methylated and 
polyadenylated in a similar fashion to cellular mRNAs 
Silverstein et al., 1976; Moss et al.,- 1977). Many
proteins undergo some form of post-translational
processing,' such as cleavage, phosphorylation,'
%
sulphation,- myristilation, glycosylation and poly(ADP) 
ribosylation(reviewed by Roizman & Sears, 1990).
3.3.1 Temporal classification of HSV genes 
HSV genes (and their products) have been classified into 
three main groups according to the temporal kinetics of 
their expression. These groups are expressed in a 
sequentially ordered cascade (Wagner, 1972; Honess & 
Roizman,' 1974; Honess & Roizman, 1975; Clements et al., 
1977). Honess & Roizman (1974; 1975) designated the three 
groups as &, |3 and y. These three groups are also known as 
immediate-early (IE), early and late respectively, 
following work which had demonstrated this phenomenon in 
PRV (Rakusanova et al.,- 1971; Ben-Porat & Kaplan, 1973). 
Using inhibitors of mRNA and of protein synthesis, Honess 
& Roizman (1974; 1975) found that the rates of synthesis 
of IE polypeptides were highest between 3 and 4 hours 
post infection and thereafter declined. The rates of 
synthesis of early polypeptides were maximal from 5 to 7 
hours post infection, before a similar decline, and 
polypeptides of the late class were made at increasing 
rates until at least 12 hours after infection. They also 
found that control of switching from synthesis of one 
group to the next was mediated by one or more 
polypeptides in each group. IE polypeptides were 
synthesised without the need for prior viral protein 
synthesis,' but one or more functional IE proteins were 
required to turn on synthesis of the early and late
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groups. In addition, presence of functional polypeptides 
of the early and late classes was required to shut off 
synthesis of those of the IE class. It was also observed 
that synthesis of viral DNA was a requirement for maximal 
expression of late proteins.
3.3.2 Extensions of the classification
Although this classification of HSV genes and their 
products has been useful, it is apparent that the 
distinctions between temporal classes are not as clear as 
is sometimes implied. The definition of IE genes as those 
which are expressed in the absence of de novo viral 
protein synthesis is of great significance, but although 
the peak of expression of these genes ended at about 4 
hours p.i.,- synthesis could still be detected at late 
times (Honess & Roizman 1974; 1975). More recent studies 
have shown that significant levels of some IE mRNAs 
persist late into infection (Harris-Hamilton & 
Bachenheimer, 1985; Weinheimer & McKnight, 1987). 
Furthermore, it is now known that in the case of the IE 
gene IE110, accumulation of the protein product continues 
late in infection (Everett, 1991; Everett & Orr, 1991), 
although the functional significance of this is not 
understood. Early genes require for their expression the 
presence of functional IE proteins, but their expression 
is not dependent upon synthesis of viral DNA, indeed, 
many early proteins are involved in viral nucleic acid 
metabolism. Pereira et al. (1977) divided the early genes 
into two subclasses, on the basis of sensitivity to the 
arginine analogue canavanine. Thus (3 ^ genes were 
expressed in canavanine-treated cells as well as IE genes 
and small amounts of the late protein VP5. Genes of 
the P 2 subclass were not expressed in the presence of 
canavanine. Expression of and (32 genes may be ordered 
sequentially, with canavanine blocking the transition 
from to P2* Alternatively, there may exist amongst the 
IE polypeptides different inducers, not all of which are 
blocked by canavanine, each promoting the synthesis of a 
different subset of early proteins.
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The y genes have also been divided into two subclasses,- 
although they exhibit much greater variation in the 
timing of their appearance. The (3^ , early-late, or
leaky-late genes show some expression prior to viral DNA 
synthesis, whereas the y 2 or true-late genes are 
expressed at late times after infection and only 
appreciably following the onset of DNA synthesis (Holland 
et al., 1980; Conley et al., 1981; Silver & Roizman, 
1985). A commonly cited example of a y^ gene is UL19 
(Costa et al.,- 1985a),- the gene encoding the major capsid 
protein VP5. Although readily detected from at least 2 
hours p.i. (Honess & Roizman,- 1974; Bibor-Hardy et al., 
1985a; Harris-Hamilton & Bachenheimer, 1985),- VP5 becomes 
very abundant at late times, following the onset of DNA 
synthesis,- and accumulation of the mRNA transcript is 
greatly reduced in the presence of inhibitors of DNA 
synthesis (Holland et al., 1980; Conley et al., 1981). 
The distinction between an early protein and a y protein 
is at times unclear. For example, the 65-kDa DNA-binding 
protein has been classified as an early protein, despite 
the fact that accumulation of the protein is greatly 
reduced in conditions of inhibition of DNA synthesis. The 
early classification is based on the fact that 
accumulation of the mRNA transcript peaks at about 6 
hours p.i. and that this peak is not appreciably affected 
by lack of DNA synthesis (Goodrich et al., 1989).
It is also difficult to formulate a definition of the 
second subclass of late genes, the y2 or true-late genes. 
Following a study of the gene US11, Johnson et al. (1986) 
reported that even under conditions of the most
restricted DNA synthesis attainable, very small amounts 
of the gene products were still detectable. Thus it is 
not certain that expression of US11 is absolutely
dependent on prior DNA synthesis. These authors offered a 
definition of a true-late gene as one whose expression is 
"most severely reduced, compared to all other groups of 
genes, under conditions of severely inhibited DNA
replication." The degree of reduction of expression
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implied in the term 'most severely reduced1 was stated to 
be 95%. A satisfactory explanation for this dependence on 
DNA synthesis is lacking, but it is possible that true- 
late genes, although transcribed early in infection, have 
very weak promoters, which require a high copy number 
achieved through DNA replication for abundant expression.
3.3.3 The (X-trans-induction factor, Vmw65
The expression of IE genes prior to de novo viral protein 
synthesis is induced by a structural component of the 
infecting virion (Batterson & Roizman, 1983). This
protein, known as VP16, ocTIF, VF65 or Vmw65,' is located
in the tegument in 500-1000 copies per particle (Heine et 
al. ,■ 1974). The gene encoding this transactivator was
mapped by Campbell et al. (1984) and is now identified as 
UL48. Vmw65 is an essential structural component of the 
virion (Moss et al., 1979; Ace et al.,- 1988). Analysis of 
a mutant deficient only in transinducing activity 
suggests that transinduction by Vmw65 is not essential 
for HSV gene expression at high multiplicities of 
infection, although it is possible that this mutant did 
have some residual Vmw65-mediated transinducing activity 
(Ace et al., 1989). Vmw65 is also essential for virulence 
after intracranial or intraperitoneal inoculation in mice 
(Ace et al., 1989).
3.3.4 Mode of action of Vmw65
Vmw65 does not bind DNA directly (Marsden et al., 1987),
but participates in the formation of a multiprotein 
complex involving host proteins (Preston et al., 1988), 
which initiates transcription of IE genes. Two functional 
regions of the 490-residue Vmw65 protein have been 
identified. An acidic domain in the carboxyl-terminal 78 
amino acids,- including a critical phenylalanine residue 
at position 442, is responsible for the transactivation 
function. An amino-terminal domain between residues 49 
and 75 confers specificity for IE genes by interaction 
with host proteins that bind IE cis-regulatory elements 
(Cress & Triezenberg, 1991; Greaves & O'Hare, 1990).
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Details of the Vmw65-IE gene complex are not fully 
elucidated,- but it is known that a cis-acting site 
present in one to several copies in the 5' transcribed 
noncoding domains of IE genes binds to the cellular host 
factor the octamer-binding protein known variously as 
Oct-1, aHl, NFIII and OTF-1 (Kristie & Roizman/ 1988). 
The IE cis-acting site is of consensus sequence TAATGARAT 
(where R is a purine), although the flanking sequences 
affect the magnitude of the response (Mackam & Roizman, 
1982; O'Hare & Hayward, 1987; Preston et al./ 1988). Many 
of the TAATGARAT elements have overlapping ATGCTAAT 
octamer motifs that are similar to the Oct-1 binding site 
ATGCAAAT, and Oct-1 also binds to these TAATGARAT sites 
(Aprhys et al., 1989; Spector et al., 1990; Spector et 
al./ 1991). Vmw65 does not bind directly to Oct-1, but at 
least one other cellular factor is involved, which 
mediates the complexing of Vmw65 with the Oct-1/IE 
assembly (Xiao & Capone, 1991; Greaves & O'Hare, 1991).
3.4 The immediate-early genes and their products
3.4.1 IE175
The properties and functions of herpes virus IE 
polypeptides were reviewed by Everett (1987b). The 
immediate-early gene IE175, also known as IE-3 and 0C4/ is 
present in two copies in HSV, being carried in the short 
repeat region. The polypeptide encoded by this gene is 
known as Vmwl75 or ICP4. Newly translated Vmwl75 has an 
apparent molecular weight of 175 kDa (Preston et al., 
1978; Watson et al., 1979)/ but it is post-translation- 
ally modified, and electrophoretic separation yields 
three bands of apparent molecular weights of 170, 163 and
160 kDa (Pereira et al., 1977; Wilcox et al., 1987).
Vmwl75 is phosphorylated (presumably with ester phosphate 
residues) (Pereira et al., 1977; Marsden et al., 1978),
poly(ADP) ribosylated (Preston & Notarianni, 1983), and
adenylated and guanylated (Blaho & Roizman, 1991). 
Phosphorylation of Vmwl75 is essential for its
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interaction with early and late genes, but not for 
interaction with IE genes (Papavassiliou et al., 1991). 
Although it carries its own nuclear localisation signal 
(Paterson & Everett, 1988; DeLuca & Schaffer, 1988) and 
can readily be demonstrated in the nucleus (Pereira et 
al., 1977), Vmwl75 was recently reported to associate
also with the inside of the plasma membrane of infected 
cells (Yao & Courtney, 1991). Vmwl75 was recently 
reported to be present in the tegument of purified 
virions in approximately 100-200 copies per particle (Yao 
& Courtney, 1991). The significance of this is not known 
but it is possible that these low levels of Vmwl75 may 
result from the presence in virion preparations of L
particles, which are known to contain Vmwl75 (Szilagyi & 
Cunningham, 1991; McLauchlan & Rixon, 1991).
Vmwl75 is involved in the regulation of expression of its 
own gene. This autoregulation is mediated by a cis-acting 
site, including the motif ATCGTC, at the cap site of 
IE175, which is specifically bound by Vmwl75 (Roberts £t 
al, 1988; Paterson & Everett,- 1988; Everett et al., 
1991a)• The gene IE110, although possessing an identical 
site, was not downregulated by Vmwl75 in these
experiments. However, viruses with mutations in IE175 do 
overproduce other IE proteins (Preston, 1979a; Preston, 
1979b; Dixon & Schaffer,- 1980; DeLuca et al., 1985), and
recent studies have shown that Vmwl75 does act to repress
the IE110 promoter in transfection assays,- although it 
does not appear to do so during infection in tissue 
culture (Resnick et al., 1989; Everett & Orr, 1991). 
Mutants in IE175 also fail to produce early and late 
proteins, and this function of Vmwl75, as the major 
transactivator of HSV genes (Preston, 1979a; Preston, 
1979b), is of great importance. Vmwl75 is continuously 
required for both early and late transcription (Watson & 
Clements, 1980), and has been shown to participate in 
complexes with promoter-regulatory regions of many early 
and late genes (Tedder et al., 1989), but the mechanisms
responsible for repression and activation are not known.
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However, the sites involved differ substantially from the 
site involved in autoregulation of IE175, and it would 
seem that additional proteins are involved in these 
complexes (Papavassiliou & Silverstein, 1990).
3.4.2 IE110
The immediate-early gene IE110,- also known as IE-1 
and a0, is present on the long repeat regions of the 
genome and is therefore, like IE175, diploid. The gene is 
spliced,- being composed of three exons encoding a 775 
amino acid protein (Perry et al., 1986). The product of 
IE110, known as ICPO or VmwllO, has an apparent molecular 
weight of 110 kDa (Preston et al., 1978; Watson et al., 
1979). It is phosphorylated, and locates to the nucleus 
of infected cells (Pereira et al., 1977). Unlike Vmwl75,- 
VmwllO is not essential for viral growth in tissue 
culture, although viruses lacking this protein grow very 
poorly at low multiplicities of infection, and it is 
required for fully efficient infection (Stow & Stow, 
1985) .
VmwllO is an efficient transactivator of early genes 
(Gelman & Silverstein, 1985; O'Hare & Hayward, 1985) and 
of late genes (Mavromara-Nazos et al., 1986b). In concert 
with Vmwl75 there is a strong synergistic effect: in a 
transient expression assay using the glycoprotein D 
gene promoter, cells transfected with both IE genes 
accumulated 12-60 times more reporter RNA than cells 
transfected with either one alone (Everett, 1984). Other 
workers have produced comparable results (Gelman & 
Silverstein, 1986; Quinlan & Knipe, 1985). Efficiency of 
promoter activation by VmwllO alone and its degree of 
synergy with Vmwl75 vary with cell type,- promoter DNA 
sequence and method of transfection (Everett, 1988b).
There are several reports of detailed mutational analyses 
of IE110. Several functional domains have been 
identified, including those involved in its intrinsic and 
synergistic (in association with Vmwl75) activation
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effects (Everett, 1987a; Everett, 1988a). This work was 
performed using a plasmid transfection system, and 
subsequent work using mutant viruses derived from the 
same plasmids has showed similar results (Everett, 1989; 
Cai & Schaffer, 1989). Purified VmwllO expressed by a 
recombinant baculovirus forms multimers, including 
dimers,- in solution. Although it is able to bind DNA in a 
non-specific manner, it is apparently unable to bind to 
specific sequences or to form a stable interaction with 
DNA in solution (Everett et al., 1991b).
3.4.3 IE-2
The immediate-early gene IE-2, also known as 0C27, encodes 
a protein of an apparent molecular weight of 63 kDa 
(Honess & Roizman, 1973; Preston et al., 1978; Watson et 
al., 1979), which is designated ICP27 and Vmw63. The
protein is phosphorylated, and locates to the nucleus of 
infected cells (Fenwick et al., 1978). Vmw63 is encoded 
by gene UL54 (Watson et al., 1979; Whitton et al., 1983).
Vmw63 appears to have an essential role in the modulation 
of early and late gene expression at the level of 
transcription. Temperature-sensitive and deletion mutants 
in IE-2 fail to complete the lytic infectious cycle,- 
overproducing early proteins but not synthesising many 
late proteins, especially those of the y2 class (Sacks et 
al., 1985; McCarthy et al., 1989). Work using plasmid
transfection assays has identified the region responsible 
for repression of early genes to the carboxy-terminal 78 
amino acids, and the region determining activation of 
late genes to the carboxy-terminal half of Vmw63 
(Hardwicke et al., 1989). A further series of mutant 
viruses has been constructed from a series of plasmids 
containing UL54 truncated to various extents at the 
carboxy terminus. This has enabled identification of 
genetically separable transactivation functions: one
activity stimulates, but is not required for, the 
expression of genes, the other is a requirement for
expression of genes. These mutants also showed a down-
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regulation of early genes late in infection, supporting 
the view that Vmw63 has a role in switching to late gene 
expression (Rice & Knipe, 1990).
3.4.4 IE-4 and IE-5
The immediate-early genes IE-4 (0C22) and IE-5 («47) are
both spliced, each having one intron, and display the
interesting feature of having identical promoters. The 
genes lie at opposite ends of the short unique region of 
the genome, and their promoters and splice sites are 
located in the repeat sequences bounding this region 
(Rixon & Clements, 1982).
The product of IE-4, Vmw68, or ICP22, has an apparent 
molecular weight of 68 kDa (Preston et al., 1978), and 
was mapped to the region of US1 by Watson et al. (1979). 
Little is known about the role of this protein in natural 
infections. Vmw68 is not essential for growth in some 
cell lines (Post & Roizman, 1981), but in other lines 
Vmw68” virus grows poorly; viral DNA is made but some 
late genes are not efficiently expressed. It would seem
that some cell lines express a function similar to that
of Vmw68,‘ and are able to complement it (Sears et al.,
1985) .
Vmwl2, or ICP47, is the product of the gene US12, or 
IE-5, and has an apparent molecular weight of 12 kDa 
(Watson et al., 1979). It is the only one among the IE 
proteins which is not phosphorylated; nor does it 
localise to the nucleus (Marsden et al., 1982). It is not 
essential for growth in some cell lines (Longnecker & 
Roizman, 1986). However, in a similar fashion to Vmw68, 
some cell lines do not support efficient growth of Vmwl2 
virus. It may be that Vmw68 and Vmwl2 act to complement 
functions missing in some natural host cells (Mavromara- 
Nazos et al., 1986a).
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3.5 Synthesis of viral DNA
Synthesis of herpesvirus DNA occurs in the nucleus (Munk 
& Sauer,- 1964; Rixon et al., 1983), and is detectable
from about 3 hours p.i., continuing until at least 12-15 
hours (Roizman et al., 1963; Roizman et al., 1964) . This 
process was reviewed by Challberg & Kelly (1989). 
Restriction endonuclease profiles of viral DNA 
synthesised from about 4 hours p.i. reveal that the DNA 
lacks free ends and consists either of circles or head- 
to-tail concatemers (Jacob et al., 1979; Jongeneel & 
Bachenheimer, 1981). The high sedimentation rate of this
DNA in comparison to that of genome-length DNA indicates 
that it exists in a concatemeric state (Ben-Porat & 
Tokazewski, 1977; Jacob & Roizman, 1977; Jacob et al., 
1979; Ben-Porat & Rixon, 1979).
HSV DNA synthesis conforms well to the accepted model of 
prokaryotic and eukaryotic DNA replication (Bramhill & 
Kornberg, 1988), whereby sequence-specific initiation 
begins with the recognition of and binding to an origin 
of replication by an initiator protein. There are three 
origins of DNA replication on the HSV-1 genome. Two 
copies of oris are located in the short repeat regions, 
origl between the promoters of IE genes IE175 and US1, 
oris2 between the promoters of IE genes IE175 and US12 
(Spaete & Frenkel, 1982; Mocarski & Roizman, 1982a; Stow 
& McMonagle, 1983). The third, oriL, maps in the long 
unique segment between the promoters of the two early 
genes UL29 and UL30 (Weller et al., 1985). OriL is not 
essential for viral growth (Polvino-Bodnar et al., 1987), 
and at least one copy of oris is dispensible (Longnecker 
& Roizman, 1986; Smith et al., 1989). To date, no HSV 
variant lacking both copies has been reported.
3.5.1 The UL9 origin-binding protein
The initiator protein is the HSV-specified origin-binding 
protein (OBP), the 94-kDa product of UL9. DNase 
footprinting and gel retardation experiments have
21
demonstrated that the OBP binds to two sites within oris 
(Elias & Lehman, 1988; Olivio et al., 1988; Weir et al., 
1989). These sites lie within a 45-base-pair imperfect 
palindrome and are of identical sequence YGYTCGCACT (Koff 
& Tegtmeyer, 1988; Deb & Deb, 1989). More recently it has 
been shown that the presence of both sites is necessary 
for efficient origin activity, and that a third cis- 
acting site, also within orig, does not bind the OBP but 
is essential for efficient DNA replication (Weir & Stow,- 
1990; Martin et al., 1991). Dabrowski & Schaffer (1991) 
have found that one or more cellular factors, as yet 
unidentified, bind to one of the origin-binding sites and 
also enhance complex formation of the OBP with DNA at 
this site.
3.5.2 Other trans-acting viral gene products essential 
for replication of viral DNA
Plasmid DNAs containing either oris or or^L are 
replicated when introduced into HSV-infected cells (Stow,
1982). Analysis in a complementation assay of cloned 
restriction fragments of HSV-1 DNA identified seven genes 
- all in the long unique region - without which there was 
no detectable origin-dependent amplification of DNA (Wu 
et al., 1988; McGeoch et al., 1988b). The seven protein
products of these genes, when expressed by recombinant 
baculoviruses, have recently been shown to be competent 
for replication of a plasmid containing the viral orig 
(Stow, 1992). These genes are reviewed by Weller (1991). 
One of these genes, UL9, has already been discussed. The 
other six genes are listed, and their products are 
discussed below; UL5, UL8, UL29, UL30, UL42 and UL52.
UL30: DNA polymerase
The 140-kDa polypeptide product of UL30 (Powell & 
Purifoy, 1977; Knopf, 1979; Quinn & McGeoch, 1985) 
exhibits novel DNA polymerase activity readily 
distinguishable from host enzymes. It is,- for instance, 
inhibited by the pyrophosphate analogue phosphonoacetic 
acid (PAA) (Hay & Subak-Sharpe, 1976), thus affording the
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basis for a convenient experimental method of preventing 
viral DNA replication. The enzyme has intrinsic 3'-5' 
exonuclease activity serving a proofreading function 
(Knopf, 1979; O'Donnell et al., 1987b). It also has 
intrinsic ribonuclease activity that specifically 
degrades RNA-DNA heteroduplexes as well as DNA duplexes
in the 5'-3' direction (Crute & Lehman, 1989), thus
enabling removal of the RNA primers that initiate synthesis of
Okazaki fragments during lagging strand synthesis, when expressed
in yeast or by in vitro transcription and translation the 
polymerase is enzymatically active (Haffey et al., 1988;
Dorsky & Crumpacker, 1988). However, other virus-encoded 
proteins may act to increase the efficiency of the 
polymerase or to modify its activity. In one report, the 
HSV-2 DNA polymerase was co-purified with a 55-kDa 
protein later identified as the product of the gene UL42, 
also essential in DNA synthesis (Vaughan et al., 1984),
and this finding has been confirmed by Gallo et al.
(1988) in respect of the type 1 proteins (see section 
5.2.3). DNA polymerase also associates with ICP8, the 
product of UL29, and its activity is greatly stimulated 
by this protein (O'Donnell et al., 1987a). Recently it 
has been shown that although DNA polymerase exhibits 
intrinsic nuclear localising capability, correct 
localisation of the polymerase to prereplicative sites 
within the nucleus is effected by ICP8 (Bush et al.,
1991).
UL29: Single-strand-specific DNA-binding protein 
The 128-kDa product of UL29 is known as the major DNA- 
binding protein and infected-cell protein 8 (ICP8). It
binds strongly to single-stranded DNA with a 
stoichiometry of one ICP8 molecule per 12 nucleotides; it 
also binds to double-stranded DNA but not so tightly 
(O'Donnell et al., 1987a).
ICP8 has intrinsic ability to localise to the nucleus of 
infected cells. Before onset of viral DNA synthesis, it 
locates to nuclear framework-associated structures called 
prereplicative sites. During viral DNA synthesis, ICP8
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localises to randomly distributed replication 
compartments, where it is bound to replicating viral DNA. 
Migration of ICP8 from prereplicative site to replication 
compartment is initiated with the onset of DNA synthesis, 
and prereplication sites are thought to serve as nuclear 
reservoirs of ICP8 (Quinlan et al., 1984). The work of de 
Bruyn Kops & Knipe (1988) has shown that ICP8 sequesters 
components of the cellular DNA replication apparatus to 
the replication compartments, and these authors suggest 
that the organising of structure and composition of these 
compartments may be a function of ICP8. In this 
connection the work of Bush et al. (1991) is interesting, 
in that they demonstrate the role of ICP8 during 
infection in directing HSV DNA polymerase to the 
replication compartments.
Evidence has been presented which implicates ICP8 in the 
down-regulation of expression of the IE protein Vmwl75 
(Godowski & Knipe, 1986), and recently results were 
presented suggesting that, notwithstanding the indirect 
requirement for ICP8 in true-late gene expression in 
respect of the need for prior DNA synthesis, ICP8 has a 
distinct role in the direct stimulation of late gene 
expression (Gao & Knipe, 1991). In these experiments, 
cells expressing a mutant ICP8 protein with a trans­
dominant phenotype synthesised reduced amounts of viral 
DNA which should still have been sufficient to support 
some true-late gene expression, but virtually no true- 
late expression was detected. By contrast, infection in 
wild-type cells when viral DNA replication was reduced 
using PAA to a similar level to that in the mutant-ICP8 
cells, significant amounts of true-late protein were 
expressed.
UL42: Double-stranded DNA-binding protein
The product of UL42 is a 65-kDa protein (Parris et al.,
1988) known as the 65K DNA-binding protein (65K^gp). It 
binds strongly to double —stranded DNA (Marsden et al.,
1987), and localises to the nucleus during infection
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(Olivo et al., 1989). Gallo et al. (1988) observed a
physical association of the 65KDBp with the DNA 
polymerase, and noted that highly purified 65KDBp was 
free from polymerase activity and did indeed have 
intrinsic DNA-binding capabilities. The 65KDBp-polymerase 
complex is composed of the two proteins in a 1:1 ratio 
(Crute & Lehman, 1989). Purified polymerase, which 
clearly does possess intrinsic polymerase activity, is 
stimulated up to 10-fold by the addition of purified 
65KDBp; similar stimulation is exhibited by plasmid- 
expressed polymerase in the presence of plasmid-expressed 
65KDBp (Gallo et al., 1989). The recent isolation of a 
deletion mutant in UL42 and a stably-transformed UL42- 
expressing cell line has enabled confirmation that the 
65KDBp is essential for virus replication, and suggests 
potential for further work in elucidation of the function 
of the 65KDBp and its relationships with other DNA
replication proteins by the construction of defined UL42
mutants (Johnson et al., 1991). The UL42 protein acts to increase
the processivity OT The DNA polymerase (Gottleib et al., 1990).
UL52, UL5, UL8: Helicase-primase complex
The three remaining genes essential for HSV-1 DNA 
replication, UL52, UL5 and UL8, encode proteins having 
molecular weights of 120, 97 and 70 kDa respectively.
These three proteins copurify from infected cells and 
constitute the three subunits of a helicase-primase 
enzyme which exhibits DNA-dependent ATPase, DNA-dependent 
GTPase, DNA helicase and DNA primase activities (Dodson 
et al., 1989; Crute et al., 1988; Crute et al., 1989).
All the enzymic activities of the complex are associated 
with the UL5 and UL52 proteins (Calder & Stow, 1990; 
Dodson & Lehman, 1991). A ts and a null mutant in UL8 
have been used to confirm the requirement for the 70-kDa 
protein in viral DNA synthesis (Carmichael & Weller,
1989), and it seems that one role of this protein within 
the complex is to effect efficient nuclear localisation 
of the complex (Calder et al., 1992).
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3.5.3 Other virus-specified proteins involved in DNA 
synthesis
HSV specifies several other proteins which play a
significant role in viral DNA synthesis, although most
are not essential for growth in tissue culture. An
exception is the alkaline deoxyribonuclease, the product
of UL12. Thus, although the seven genes discussed above
are necessary and sufficient for DNA replication in
transient expression assays, the DNase has been shown by
marker rescue of a type 2 tjs mutant in DNase activity to
be essential for virus replication in tissue culture 
(Moss, 1986). However, experiments with a UL12 insertion mutant 
have shown that the DNase is not essential for viral DNA 
synthesis but may play a role in the processing or packaqinq of 
viral DNA into infectious virions (Weller et al./ 1990).
The gene UL23 encodes the viral thymidine kinase (TK),
which is not essential for growth in dividing cells but
is required in serum-starved cells (Jamieson et al.,
1974). However, TK is essential for normal virus
multiplication in vivo (Tenser & Dunstan, 1979). The
successful anti-herpetic drug acyclovir is an acyclic
nucleoside analogue which is phosphorylated by the viral
TK but not to any significant degree by equivalent host
cell enzymes. Following conversion from the monophosphate
to triphosphate form by cellular enzymes, it exhibits
potent inhibition of the viral DNA polymerase (Elion,
1983). A single amino acid change in the TK protein is
sufficient to eliminate sensitivity to acyclovir; such
resistant strains retain full neuropathogenicity (Chatis
& Crumpacker, 1991).
The gene UL2 specifies a uracil DNA-glycosylase. In a 
virus such as HSV with an extremely high G+C content, 
this enzyme plays a significant role, in that its 
function is to remove uracil residues from DNA during 
proofreading. However, this enzyme has been shown to be 
dispensible for growth in tissue culture (Mullaney et 
al., 1989).
The product of UL50 is a deoxyuridine triphosphatase 
(dUTPase), hydrolysing dUTP to dUMP, thus preventing dUTP
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being incorporated into DNA (Wohlrab & Francke, 1980; 
Preston & Fisher, 1984). This enzyme is not essential for 
growth in tissue culture (Fisher & Preston, 1986).
HSV types 1 and 2 encode their own ribonucleotide 
reductases (Dutia, 1983; Preston et al.,
1984), which catalyse conversion of the four 
ribonucleoside diphosphates to their corresponding 
deoxyribonucleoside diphosphates, creating a pool of 
substrates for DNA synthesis (Thelander & Reichard,
1979) . The active HSV-1 enzyme consists of two subunits, 
Rl the large subunit, and R2 the small subunit. Each 
subunit is itself a dimer; Rl of the 140-kDa UL39 gene 
product, R2 of the 40-kDa UL40 gene product (Ingemarson & 
Lankinen, 1987). A nonapeptide of sequence YAGAWNDL, 
representing the C-terminal nine amino acids of R2, has 
been shown to inhibit the activities of both the type 1 
and type 2 enzymes (Dutia et al., 1986; Cohen et al.,
1986) . This inhibition results from competition between 
the nonapeptide and R2 for interactive sites with Rl 
(Paradis et al., 1988). Although the viral enzyme is
largely dispensible for virus growth in actively dividing 
cells maintained at 37°C, it is required for efficient 
growth in resting cells or cells maintained at 39.5°C
(Preston et al., 1988; Goldstein & Weller, 1988; Jacobson 
et al.,' 1989). It is also required for the virulence of 
HSV in mice, and for reactivation from latent infection 
(Cameron et al., 1988; Jacobson et al., 1989). Thus the 
inhibitory nonapeptide is considered to have potential as 
an antiviral drug, especially in view of the fact that it 
also inhibits the ribonucleotide reductases of PRV (Cohen 
et al., 1987) and EHV (Telford et al., 1990). The
investigation of this potential requires structural
studies of the enzyme, and to this end both the large and 
small subunits have been expressed in a bacterial system 
and purified (Furlong et al., 1991; Lankinen et al.,
1991) .
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Figure 3, Cryoelectron micrograph of a virion of HSV-1.
The major structural features,' capsid (C),> tegument (T) 
and envelope with associated glycoprotein spikes (E),< are 
indicated. Scale bar is 100 nm. This figure is reproduced 
with permission from Schrag et al. (1989).
4 STRUCTURE AND ASSEMBLY
This section will contain a discussion of the main 
structural components of the herpes virion, and in 
particular of the capsid and its assembly. There will be 
a concentration on features of HSV-1, but because much 
structural research has been carried out on other 
herpesviruses, relevant details will be noted, and these 
other viruses specified. Two major reviews of structural 
aspects of herpesviruses are those of Dargan (1986) and 
O'Callaghan & Randall (1976). A recent review covering 
some aspects of capsid assembly and virion maturation is
that of Roizman & Sears (1990).
The four structural components of herpesvirions, DNA-
containing core, capsid, tegument and envelope have 
already been mentioned. The characteristic 'fried egg1 
morphology in many electron micrographs of negatively 
stained virus is the result of fixation and dehydration 
procedures; Schrag et al. (1989) present micrographs of
undamaged, ice-embedded virions manifesting a spherical 
shape which probably represents the natural state (Figure 
3). The herpes virion is a highly complex structure, 
purified HSV-1 virions containing approximately 33 
polypeptide species (Spear & Roizman, 1972; Heine et al., 
1974; Cassai et al., 1975; Powell & Watson, 1975; Marsden 
et al., 1976).
4.1 Core
The DNA of mature virions is contained within the capsid 
in a structure termed the core. Until recently the core 
was thought to consist of a cylindrical protein plug 
around which the DNA was spooled. Details of this model 
are reviewed by Dargan (1986). The plug was first 
described by Furlong et al. (1972), and was conjectured
to be composed of the capsid protein VP21 (Furlong et 
al., 1972; Gibson & Roizman, 1972).
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Although the cylindrical plug continued to be reported by 
many workers in a variety of herpesviruses, an 
inconsistency was noted in this model in that the 
estimated volume of the DNA molecule was almost as large 
as the observed volume of the core, thus leaving little 
space for any appreciable amount of core protein (Gibson 
& Roizman, 1973). Core protein was felt to be necessary 
in order to effect condensation of the viral DNA into a 
sufficiently tight configuration to allow packaging 
inside the capsid. The demonstration by Gibson & Roizman 
(1971; 1973) that the highly basic polyamine spermine is 
present in the capsid in amounts sufficient to neutralise 
40% of the electronegativity of the DNA offers a partial 
solution. The small size of the spermine molecule would 
allow it to fit between the strands of the DNA spool. 
More recently doubt was cast over the status of the core 
by Puvion-Dutilleul et al. (1987). They showed, in
several herpesviruses including HSV-1, that the 
configuration of encapsidated DNA was critically 
determined by the dehydrating agent used in the fixation 
procedures for electron microscopy. Thus by using 
methanol as the dehydrating agent the plug with spooled 
DNA previously observed was replaced by a swollen mass 
with an intricate internal structure of DNA fibres. This 
structure completely filled the internal cavity of the 
capsid. They were unable, however, to determine which 
structure most closely represents the state of the DNA in 
vivo.
The most recent model of the herpesvirus core is 
presented by Booy et al. (1991). They also had noted that 
the volume of the internal cavity of the capsid is 
probably not sufficient to accomodate a protein plug. 
Using the data of Lepault et al. (1987) they calculated
the packing density of DNA inside the capsids of phages 
T4 and . The same calculation for HSV-1 revealed that 
the inner dimensions of the capsid as determined by 
Schrag et al (1989) would necessitate a DNA packing 
density 2.5 times higher than that calculated for the two
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phages. They determined the configuration of DNA within 
the capsid by cryoelectron microscopy and computerised 
image reconstruction. The images obtained of the core 
showed a uniformly dense ball of DNA with an interstrand 
spacing of approximately 2.6 nm. The internal diameter of 
the capsid was found to be 86 nm, compared to the figure 
of 62 nm given by Schrag et al. (1989), and the mass of 
DNA extended radially as far as the inner surface of the 
capsid. The uniform density of the DNA ball did not show 
a central region attributable to a protein plug, and 
since there were no candidate proteins for such a plug in 
their reconstructions, the authors proposed that the core 
contains no protein at all, but comprises only DNA. These 
observations reveal that the internal organisation of 
encapsidated HSV-1 DNA is essentially identical with that 
of phages T4 and \ (Lepault et al., 1987). Booy et al. 
(1991) note the work of Puvion-Dutilleul (1987), and 
suggest that the 'core' of cylindrical protein plug is an 
artefact of collapsed DNA produced during specimen 
preparation.
4.2 Tegument
The term tegument was first used to define the material 
between capsid and envelope by Roizman & Furlong (1974). 
The existence of tegument as a distinct virion component 
was not fully recognised by early observers, who, for 
instance, saw 'a zone of low density', present only in 
some virions (Nii et al., 1968a); the review of Roizman 
(1969) discusses the uncertain existence of an 'inner 
envelope'. This is due to a lack of distinctive features 
in the tegument - it is usually described as being 
'amorphous'. Tegument thickness varies amongst the 
herpesviruses, and great variation is often observed
between individual virions in the same preparation of
HSV, but this is probably an artefact resulting from
specimen damage - Vernon et al. (1982) noted that
tegument morphology and thickness were dependent upon the
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method of preparation for electron microscopy. The 
observations of Schrag et al. (1989) showed that
undamaged HSV-1 virions in ice-embedded sections are 
roughly spherical in shape, with a fairly even 
distribution of tegument of approximate thickness of 
447 A. Working with EHV-1, Vernon et al. (1982) showed
that the tegument exists as a defined layer with a degree 
of structural integrity, and that it is probably attached 
to the capsid vertices. Shrinkage of the tegument during 
critical point drying suggested that the tegument has a 
high water content. That the tegument possesses 
structural integrity independent of either envelope or 
capsid has been shown by McLauchlan & Rixon (1992). Using 
NP40, they removed the envelope from L-particles (which 
consist of tegument and envelope but do not contain 
capsids), and found that the residual tegument material 
retained its shape and stability. It is not known which 
components are essential to the structural integrity of 
the tegument.
The tegument is often described as 1proteinaceous1, but 
the exact protein composition was hard to determine, due 
to the difficulty of obtaining purified tegument material 
free from other virion components. In practice, proteins 
seen in virion protein profiles are defined as tegument 
proteins if they are not known to be part of either the 
capsid or the envelope. A recent aid in the 
identification of tegument proteins is the discovery of L 
particles (Szilagyi & Cunningham, 1991). Proteins known 
to be located in the tegument are commonly designated by 
the nomenclature originally used for virion protein 
profiles (Spear & Roizman, 1972; Heine et al., 1974). VP1 
is the 273-kDa product of UL36, essential for release of 
viral DNA from capsids at nuclear pores and VP16 is the 
trans-activator Vmw65. The vhs protein is a component of 
virions and has recently been shown to be located in the 
tegument (McLauchlan et al., 1992). These three proteins 
are discussed elsewhere in this text. Further components 
of the tegument are the related Vmw82 and Vmw81, the 82-
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and 81- kDa products of the gene UL47 (McLean et al.,
1990). These proteins are abundant components of the 
virion, yet can be stripped from virions by NP40. They 
are iodinated in virions in the presence but not in the 
absence of NP40, indicating a location in the tegument 
(McLean et al., 1990). Experiments with mutants in UL47 
reveal that this gene functions to enhance significantly 
the efficiency of Vmw65-mediated transactivation during 
the infection process (Zhang et al., 1991). These authors 
suggest also that the UL46 gene product might also be a 
tegument protein. By comparison with other published 
virion protein profiles, McLean (1990) suggested that 
Vmw82 and Vmw81 are equivalent to VP13 and VP14 
respectively, and this was confirmed by Whittaker et al. 
(1991) who showed that VP13 and VP14 are products of 
UL47. Whittaker & Meredith (1990) report purification of 
VP13, VP14 and another tegument protein, VP22, by 
reverse-phase high performance liquid chromatography. In 
a further report, Meredith et al. (1991) show that VP13
and VP14 are phosphorylated in virus-infected cells, but 
not in preparations of purified virus, and that VP13,' 
VP14 and VP22 contain ^-linked oligosaccharide units 
which suggest a possible role for these proteins in 
transcriptional control. VP22 was recently shown to be 
encoded by the gene UL49 (Elliott & Meredith, 1992).
Several proteins have been assigned to the tegument by 
workers not using the VP nomenclature, and they remain 
uncorrelated with the original virion protein profiles. 
The protein kinase activity associated with herpes 
virions was located by Lemaster & Roizman (1980) to de­
enveloped particles of HSV -1 and -2 consisting of 
capsids with attached tegument material. Stevely et al. 
(1985) located this activity in PRV to the tegument, and 
showed that both HSV-1 and PRV virions contained several 
distinct protein kinases, one of which was the host cell- 
derived casein kinase II. HSV-1 does specify at least one 
protein kinase, in the gene US3 (Frame et al., 1987;
Purves et al., 1987), which is a homologue of a PRV-
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specified protein kinase (reviewed by Leader & Katan,
1988). The US3 protein kinase post-translationally 
modifies the phosphoprotein encoded by the UL34 gene 
(Purves et al., 1991). The product of UL13, which appears 
to be a protein kinase which undergoes autophos­
phorylation, has been shown to be a component of the 
virion (Smith & Smith, 1989; Cunningham et al., 1992). 
The 10-kDa phosphorylated product of the gene US9 studied 
by Frame et al. (1986) is also thought to be a tegument
protein - although present in virions and in NP40- 
solubilised extracts of envelope/tegument, this protein 
is not found in capsids. It does, however, associate with 
unenveloped capsids within the nucleus. This protein, 
known as 10K, undergoes extensive post-translational
processing in connection with phosphorylation, but only 
the lower molecular weight forms are incorporated into 
virions. The function of 10K is not known. The gene ULll 
encodes two myristylated polypeptides, with apparent
molecular weights of 13-16 kDa (MacLean et al., 1989; 
MacLean et al., 1992). These are present in L particles, 
and separate partially with the membrane fraction of 
purified virions and partially with the NP40-insoluble 
fraction. They are thus are deemed to be tegument
components (Maclean et al., 1992).
4.3 Envelope
Virions of HSV-1 have a diameter ranging from 1875-2370 A 
with a mean of 2145 A (Schrag et al., 1989), and as in 
all herpesviruses they are completely enclosed by a 
trilaminar membrane (Morgan et al., 1954; Wildy et al., 
1960). This envelope is host cell-derived (see section on 
envelopment) but is modified by the presence of viral 
proteins. A characteristic of herpesvirus envelopes is 
the possession of numerous spikes distributed over their 
surface, often clearly visible in the electron microscope 
(Wildy et al., 1960; Schrag et al., 1989). The study of 
Stannard et al. (1987) showed that the various viral
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glycoproteins, major polypeptide components of the 
envelope, are constituents of these spikes. Monoclonal 
antibodies coupled to colloidal gold permitted
identification of glycoproteins present in the different 
structures projecting from the envelope. The most 
prominent spikes, 14 nm long with a flattened T-shaped 
top, contain gB. Long spikes, some up to 24 nm, contain
gC, and the shortest spikes, 8-10 nm long, contain gD.
The gC spikes have an even distribution whereas the gB 
and gD spikes appear to be clustered, although this may 
be an artefact of fixation procedures (cp Schrag et al.,
1989). Other shapes of spike were seen in this study 
which did not bind the monoclonals used, and it was
suggested that these spikes comprised other
glycoproteins.
Nine glycoproteins have been identified in HSV-1. Four 
are encoded by genes in the unique long region; these are 
gL (UL1), gH (UL22), gB (UL27) and gC (UL44). Four are
encoded by genes in the unique short region: gG (US4), gD 
(US6), gl (US7) and gE (US8) (McGeoch et al., 1988a;
Hutchinson et al., 1992). The ninth glycoprotein is
predicted to be specified by the gene US5 (McGeoch et 
al., 1985), and Roizman & Sears (1990) state that it has 
been identified and designated gJ.
Glycoproteins B, D and H were discussed in the sections 
on attachment and penetration. They are all essential for 
viral replication in tissue culture. Glycoprotein C, 
whilst dispensible for lytic infection, has a function in 
attachment. Glycoprotein B has been shown to exist as
homodimers (Sarmiento & Spear, 1979; Highlander et al., 
1991). Glycoprotein G is dispensable for growth in cell 
culture, as is the product of US5 (Longnecker & Roizman, 
1987; Weber et al., 1987), as well as gE (Longnecker & 
Roizman, 1986) and gl (Longnecker et al., 1987). The 
functions of these glycoproteins are unclear, but it is 
thought they may be involved in alternative pathways of 
attachment and/or penetration, enabling the virus to make
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use of a greater variety of cell receptors on different 
cell types. Glycoprotein L forms a complex with gH and is 
essential for the correct processing and surface 
expression of gH (Hutchinson et al., 1992).
On the basis of the published DNA sequence of HSV-1, the 
genes UL10, UL20, UL43 and UL53 were predicted to encode 
proteins with multiple hydrophobic regions which would 
have potential for interaction with membranes (McGeoch et 
al., 1988), They are predicted to cross a membrane 
several times. Their properties suggest a role in signal 
transduction or as ion channels, or an involvement in 
tegument-envelope interactions. UL10 and UL43 have been 
shown to be dispensable for growth in tissue culture 
(MacLean et al.,- 1991; Baines & Roizman, 1991). UL20 is 
not necessary in tissue culture for assembly, envelopment 
or maturation of infectious virions but in some cell 
lines it is essential for egress of mature virions from 
the infected cell (Baines et al., 1991). However, it 
seems that UL53 may be an essential gene (MacLean et al.,
1991), since these workers were unable to obtain lacZ 
insertion mutants in this gene. An antiserum raised 
against the carboxy-terminal region of the UL10 ORF 
detected the gene product in infected-cell extracts but 
not in virions. Similar experiments respecting UL20 
suggest that this gene product is a component of the 
virion (MacLean et al., 1991). The UL20 gene product has 
been shown to be membrane-associated in infected cells, 
and it shares some of the properties of intrinsic 
membrane proteins, in that it is resistant to extraction 
with alkali and that it aggregates on boiling with SDS 
(Baines et al., 1991). The gene UL45 was predicted to 
encode a protein with a hydrophobic N terminus, and was 
also thought potentially to be membrane-associated 
(McGeoch et al., 1988). Subsequently, the product of UL45 
was shown to be present in the virion (McLean, 1990).
4.3.1 L Particles
A non-infectious herpes simplex virus-related particle
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has been described by Szilagyi & Cunningham (1991) which 
consists of an envelope and some tegument material but no 
capsid or DNA. Although containing many of the usual 
envelope and tegument proteins, these particles, termed L 
particles, contain in addition at least five phospho- 
proteins not found in virions. One of these is the IE 
protein Vmwl75 (McLauchlan & Rixon, 1991). It is 
interesting to note that Vmwl75 has been reported to be a 
minor component of HSV tegument (Yao & Courtney, 1989; 
Yao & Courtney, 1991), and the VZV homologue of Vmwl75, 
IE62, has been shown to be a major component of VZV 
tegument (Kinchington et al., 1992). This may in fact 
represent the presence of contaminating L particles in 
the virion preparations used for these experiments. The 
status of L particles is uncertain, and the presence of 
the additional proteins may indicate differences in the 
pathways of assembly of virions and L particles. L 
particles may have potential as a vaccine, since when 
purified from infectious virions they still possess many 
immunogenic virion proteins. A lack of DNA also means 
that L particles have reduced potential for oncogenicity. 
However, there is some evidence that a component of the 
HSV virion has mutagenic properties, with the implication 
that this may play a role in cellular transformation by 
mutagenising cellular genes (Clarke & Clements, 1991). 
Experiments with L particles have shown them to be 
significantly less mutagenic than wild type virus, 
implying that the mutagenic activity is due either to a 
capsid protein or to the viral DNA (Clarke, 1990). The 
residual mutagenic activity of the L particles was 
probably due to wild type virus contaminating the L 
particle preparation, indicating that great care would be 
necessary in preparing L particles for use in 
vaccinations. One way to reduce the background of 
infectious virions is to make use of the mutant ts!201. 
At the NPT, this mutant produces virions only at low 
levels, but L particles are produced in quantities
similar to those generated by wild-type virus (Rixon et: 
al., 1991). L particles, although non-infectious, have
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Name Gene
Gibson & 
Roizman, 1972
Mr (kDa) estimated bv:
Zweia et al.. Cohen et al.. 
1979a 1980
Rixon et alTI 
1990
VP5 UL19 155 155 154 150
VP19C UL38 53 50 50 54
VP21 UL26 44 40 42
VP22a UL26.5 38.8 40 38 40
VP23 UL18 33 32 33 34
VP24 UL26 25 25 26 24
VP26 UL35 12 12 12
Table 1. The capsid proteins of HSV-1
been shown to facilitate infection by HSV-1 by supplying 
two tegument proteins , VP16 and
the vhs protein (McLauchlan et al., 1992).
4.4 Proteins of the capsid
Studies on the composition and structure of capsids of 
HSV-1 have identified seven capsid proteins, although 
only five are associated with all capsid forms. These 
proteins are listed in order of descending molecular 
weight in Table 1. Properties of each of these proteins 
and the genes encoding them will be discussed in turn, 
before a separate consideration of structural aspects of 
the capsid.
4.4.1 VP5
In this thesis the nomenclature of capsid proteins 
follows that of their first description (Spear & Roizman, 
1972; Gibson & Roizman, 1972). It is of some importance 
to note other names which have been used for these capsid 
proteins; in the case of VP5 these include ICP5 (Honess & 
Roizman, 1973), VP1 (Powell & Watson, 1975), ICP155 
(Powell & Purifoy, 1976), Vmwl55 (Marsden et al., 1976), 
M155 (Marsden et al., 1978), pl55 (Zweig et al., 1979a), 
NCI (Cohen et al., 1980) and p5 (Newcomb et al., 1989). 
It is generally referred to as the major capsid protein 
(MCP).
The gene encoding VP5 was first mapped on the genome by 
Morse et al. (1978) and Marsden et al. (1978) in an
analysis of HSV intertypic recombinants. The approximate 
map locations of the 51 and 31 ends of an unspliced 6-kb 
mRNA originating in this region were determined by Costa 
et al. (1981) by SI nuclease mapping. Costa et al. (1984) 
mapped this mRNA more accurately, and following in vitro 
selection and translation of the mRNA they were able to 
precipitate the 155-kDa product using an antibody raised 
against VP5 purified from capsids. A comparison of
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tryptic peptides of the translation product with those of 
VP5 confirmed their identity. The DNA sequence of this 
ORF was presented by Davison & Scott (1986b), and was 
designated UL19 by McGeoch et al. (1988). The gene is
leftward oriented with a single 1374-codon ORF, and is 
31-coterminal with the distal gene UL18 (Costa et al., 
1981; Costa et al., 1984), which specifies the capsid
protein VP23 (Rixon et al., 1990). The predicted 
molecular weight of the product of UL19 is 149075, which 
is in close agreement with the observed size of VP5 made
in HSV-l-infected cells - 150 kDa (Rixon et al., 1990),
155 kDa (Gibson & Roizman, 1972; Killington et al., 1977; 
Zweig et al., 1979a) and 154 kDa (Cohen et al., 1980).
This suggests that extensive post-translational 
modification does not occur. Zweig et al. (1979) did not 
detect a type-specific difference in molecular weight of 
the MCP, but Killington et al. (1977) found the Mrs of
HSV types 1 and 2 to be 155 and 158-160 kDa respectively. 
UL19 is considered to be an essential capsid gene after 
the report of Weller et al. (1987) which described two
capsid negative _ts mutants, tsG3 and tsG8, which 
synthesised reduced levels of VP5. A lesion was mapped in 
both of these mutants to a region containing part of 
genes UL18 and UL19. However, UL18 is now known to be an 
essential capsid gene (Rixon et al., 1990). These authors 
stated that each mutant had a second lesion, in ICP36 
(tsG3) and in ICP40 (tsG8), on the basis that the mutants 
produced reduced levels of these proteins at the non- 
permissive temperature. Celluzzi & Farber (1990) report 
that production of another capsid protein, VP19C, is 
affected in these two mutants. Clearly more work is 
necessary to clarify the status of tsG3 and tsG8. In view 
of the proposed role of VP5 as the constituent of the 
hexameric capsomers, it would appear that UL19 is indeed 
an essential capsid gene.
UL19 is widely regarded as an early-late gene (Costa et 
al. „ 1985a), and production of UL19 mRNA is greatly
reduced in the presence of inhibitors of DNA synthesis
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(Holland et al., 1980; Conley et al., 1981). VP 5 is 
readily detectable in infected cells from 2 hours post­
infection (Honess & Roizman,' 1974; Bibor-Hardy e t a l .,- 
1985a), and Harris-Hamilton & Bachenheimer (1985) 
detected VP5 mRNA at 2 hours p.i. The HCMV MCP mRNA is 
only detectable at late times p.i., and is not detectable 
at all in the presence of inhibitors of DNA synthesis 
(Rudolph et al./ 1990b), and the MCP of EBV is not 
detectable in the presence of DNA synthesis inhibitors 
(Takada et al., 1983; Vroman et al., 1985).
Major capsid protein counterparts of VP5 have been 
identified in many other herpesviruses, and comparisons 
at the sequence level are available in a number of cases. 
The VZV MCP has predicted and apparent molecular weights 
of 154,971 (Davison & Scott, 1986a) and 155,000 (Zweerink 
& Neff, 1981; Grose et al., 1983) respectively. The gene 
sequence was determined by Davison & Scott (1986a) and 
designated gene 40, and there is a 50% amino acid 
homology between the MCPs of HSV-1 and VZV (Davison & 
Scott, 1986b) . The MCP of PRV has predicted and apparent 
molecular weights of 146 and 142 kDa respectively, and 
has 58% amino acid homology with VP5 (Ladin et al., 1982; 
Lomniczi et al., 1987; Yamada et al., 1991). The MCP of 
HCMV has only a 25% amino acid homology withvthat of HSV- 
1 and has predicted and apparent molecular weights of 
154,000 and 153,000 respectively (Chee et al., 1989; 
Gibson, 1983). In the published analysis of the genome 
sequence of HCMV the MCP gene is designated UL86 (Chee ei: 
al., 1990). The MCP of HHV-6 has an amino acid homology
of 43.8% with its HCMV counterpart,' but only 24.7% with 
that of HSV-1, and has predicted and apparent molecular 
weights of 152,000 and 135,000 respectively (Littler £t 
al., 1990). The HHV-6 MCP gene is designated reading 
frame 4L by Lawrence et al. (1990). The MCP of EBV has a
27% amino acid homology with that of HSV-1 (Baer et al., 
1984; Davison & Scott, 1986b), and has predicted and 
apparent molecular weights of 153,909 and 160,000 
respectively (Baer et al., 1984; Dolyniuk et al., 1976),
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and in the published DNA sequence of EBV the MCP gene is 
designated BcLFl (Baer et al., 1984). Random sequencing
of MDV and HVT has revealed that there are homologues of 
VZV gene 40 in both viruses (Buckmaster et al., 1988). A 
similar analysis of MHV-68 revealed a homologue of the 
EBV gene BcLFl (Efstathiou et al., 1990). The MCP gene of 
EHV-1 is gene 42 (personal communication, Dr E.Telford).
(jtJforA ti- 1992)
The smallest known herpesvirus MCP is that of CCV, which 
has a molecular weight of approximately 127 kDa (personal 
communication, Dr A.J.Davison). It is interesting to note 
that the DNA sequence of CCV does not reveal any gene 
homologous to other known herpesvirus MCP genes (Davison,
1992) .
Studies of human immune sera have shown VP 5 to be a 
dominant antigen (Eberle & Mou, 1983), as is the case 
with the MCPs of EBV (Mueller-Lantzsch et al., 1979) and 
of VZV (Zweerink & Neff, 1981; Weigle & Grose, 1984). In 
contrast is the MCP of HCMV, which is of limited 
antigenicity in the natural host (Jahn et al., 1987),' and 
that of HHV-6, which elicits a strong response in only a 
limited number of patients (Shiraki et al., 1989; Littler 
et al., 1990). Antigenic cross-reactivity of the HSV MCP 
has been demonstrated with the MCPs of VZV (Shiraki et 
al., 1982; Vafai et al., 1990), bovine mammillitis virus 
(and weakly with PRV and equine abortion virus) (Yeo et 
al., 1981) and HCMV (Rudolph et al., 1990a). Mayyasi et
al. (1967) failed to demonstrate antigenic cross­
reactivity between capsids of HSV and EBV, and in the 
epitope-mapping study of Middeldorp & Meloen (1988), 
although ten dominant antigenic epitopes were identified 
in the EBV MCP, only one was in a region of sequence 
homology with the MCPs of HSV-1 and VZV.
The VP5 of HSV types 1 and 2 has been reported to be DNA- 
binding (Powell & Purifoy, 1976; Purifoy & Powell, 1976).
4.4.2 VP19C
A 53-kDa c a p s i d  p r o t e i n  w a s  f i r s t  r e p o r t e d  b y  G i b s o n  &
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Roizman (1972) and was named VP19. However, they thought 
that a second, non-capsid protein was migrating at the 
same position as VP19. Heine et al. (1974) detected three 
comigrating proteins, the third of which they identified 
as the capsid protein, renaming it VP19C. Amongst other 
terms which have been used to denominate this protein are 
ICP31 (Honess & Roizman, 1973), Vmw53 (Marsden et al., 
1976), p50 (Zweig et al., 1979a), NC2 (Cohen et al.,
1980) and ICP32 (Braun et al., 1984a).
The first reported mapping of VP19C was that of Costa et 
al. (1983). Using SI nuclease analysis they mapped four
partially overlapping mRNAs to between 0.16 and 0.19 map 
units. Two of these were in vitro translated, and the 
translation products shown to react weakly with the 
polyclonal rabbit serum raised against VP19C by Cohen et 
al. (1980), and they concluded that one or both of these
mRNAs encoded the capsid protein. This work was based on 
the assumption that the gene specifying VP19C had 
previously been mapped to this region by Lemaster & 
Roizman (1980). This, however, was a profound 
misinterpretation of Lemaster & Roizman1s work, since 
they had specifically stated that the gene they had 
mapped was that encoding VP18.8, a phosphoprotein which 
comigrated with VP19C in virion protein profiles. Knipe 
et al. (1981) mapped ICP32 using intertypic recombinants
to a region between 0.58-0.61 map units. Braun et al. 
(1984a) identified VP19C with ICP32 on the basis of these 
mapping data, noting that the genome fragment under study 
specified only one protein of the correct molecular 
weight, and showing that VP19C in capsid profiles 
comigrated with ICP32 in infected-cell profiles. ICP32 
had also been mapped some years earlier by marker rescue 
to between approximately 0.49-0.52 map units by the same 
research group (Morse et al., 1978). None of these three 
map locations is correct - the first suggestion of the 
true map location of VP19C being made by Pertuiset et al.
(1989). These workers described a _ts mutant, ts2, which 
did not assemble capsids at the non-permissive
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temperature and which had a lesion in the region between 
0.553-0.565 map units, corresponding to the ORF UL38. 
Because the only known structural protein with a 
molecular weight comparable to that predicted for the 
UL38 gene product was VP19C, it was suggested that UL38 
might specify this protein, although adherence to the 
mapping data for VP19C of Knipe et al. (1981) and Braun
et al. (1984a) led them to reject this suggestion. The
proposal of UL38 as the gene specifying VP19C was 
investigated further by Yei et al. (1990), who used
antibodies predicted to react with the UL38 gene product 
to demonstrate that this gene product in infected-cell 
profiles is the protein ICP32. However, the claim of 
these authors to have established that UL38 encodes the 
capsid protein VP19C rested upon the earlier 
identification by Braun et al. (1984a) of VP19C with
ICP32, and was not well-founded. Convincing evidence that 
the capsid protein VP19C is the product of UL38 was 
furnished by Rixon et al. (1990), who extracted VP19C
from protein gels of purified capsids and sequenced the 
amino terminus of the purified protein. Comparison of the 
amino acid sequence obtained for VP19C with that 
predicted for the product of UL38 confirmed its identity.
UL38 is rightward oriented with a single 465-codon ORF. 
Two unspliced mRNAs, having a common 5' end, originate 
from UL38. The first is of 1.9 kb and the second is a 7- 
kb transcriptional readthrough product, and is 31- 
coterminal with the distal genes UL39 and UL40 (Anderson 
et al., 1981). Northern blotting analysis is claimed to
have shown UL38 to be regulated as a true-late gene 
(Anderson et al., 1980; Flanagan et al., 1991). However, 
small amounts of the 1.9-kb UL38 mRNA were clearly 
detectable in the presence of an inhibitor of DNA 
synthesis. Yei et al. (1990) showed that in HSV-1, some
ICP32 was made in the presence of an inhibitor of DNA 
synthesis, but they could not detect the HSV-2 protein 
under equivalent conditions. UL38 was again claimed to 
regulated as a true-late gene on the basis of Northern
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blotting analysis by Goodart et al. (1992). However,
small amounts of mRNA produced under the control of the 
UL38 promoter were clearly detectable in the presence of 
an inhibitor of DNA synthesis. The designation of UL38 as 
a true-late gene can also be questioned on the grounds 
that whilst HSV-1 capsid assembly is dependent upon 
expression of UL38 (Pertuiset et al., 1989), it is not 
dependent upon virus DNA replication (reviewed by Dargan, 
1986) .
The predicted molecular weight of the UL38 gene product 
is 50260. The 1.9-kb and 7-kb mRNAs both specify a 54-kDa 
protein on in vitro translation (Anderson et al., 1981). 
The size of VP19C as measured on protein gels of purified 
capsids is of the same order - 53 kDa (Gibson & Roizman, 
1972), 50 kDa (Zweig et al., 1979a) and 54 kDa (Rixon et
al., 1990), suggesting that extensive post-translational
modification does not occur. Yei et al. (1990) state that 
the mobility of the HSV-2 ICP32 increases during the 
course of infection, possibly reflecting the use of 
different translational initiation sites or proteolytic 
processing of a precursor. They did not detect similar 
changes in the type 1 protein. It is interesting to note 
that Celluzzi & Farber (1990) state that the type 1 
mutants tsG3 and tsG8 both manifest a shift in mobility 
of this capsid protein from 53 kDa at the permissive to 
51 kDa at the non-permissive temperature.
VP19C has been shown to be covalently linked by 
disulphide bonds to VP5 in capsids of HSV-2 (Zweig et 
al., 1979a), and the type 1 and type 2 proteins have been 
reported to be DNA-binding (Braun et al., 1984a).
A number of genes homologous to UL38 have been identified 
in other herpesviruses and sequenced. The HSV-2 UL38 has 
78% amino acid homology with the HSV-1 gene (Yei et al.,
1990) . The VZV gene 20 (Davison & Scott, 1986a) shares 
34% amino acid identity (McGeoch et al., 1988), and the
EBV gene B0RF1 (Baer et al., 1984) shares 22% amino acid
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identity. Random sequencing of MDV revealed a counterpart
of VZV gene 20 (Buckmaster et al., 1988). The EHV-1
homologue is gene 22 (personal communication,
Dr E.Telford). EHV-1 capsids contain a 59-kDa protein 
(TeJfWl eUL, im j
(Perdue et al., 1974; Perdue et al., 1975). In the case 
of HCMV, a potential counterpart (UL46) was identified on 
a positional basis, but there was no significant homology 
with the other known sequences (Chee et al., 1990). This 
is especially interesting, given the essential structural 
role of VP19C in HSV-1 capsids (Pertuiset et al., 1989), 
and in the light of reports that neither human nor simian 
CMV capsids contain a protein of size comparable to VP19C 
(Gibson, 1981; Irmiere & Gibson, 1985). EBV capsids 
contain a 52-kDa protein (Dolyniuk et al., 1976), but the 
predicted molecular weight of gene B0RF1 is 39,191 (Baer 
et al., 1984). Amongst those herpesviruses for which 
sequence data are not available, possible VP19C- 
counterpart capsid proteins have been reported in EHV-3 
(59-kDa) (Allen & Bryans, 1976) and in PRV (63 kDa - 
Stevely, 1975) (62 kDa - Ladin et al., 1982). A 62-kDa
protein produced by in vitro translation of an mRNA 
transcribed from a cloned fragment of the PRV genome was 
immunoprecipitated by antiserum raised against purified 
PRV capsids (Lomniczi et al., 1987). It is interesting to 
note that the equine CMV (EHV-2) has a capsid protein of 
52 kDa (Caughman et al., 1984). The DNA sequence of CCV 
does not show homology with any herpesvirus structural 
genes (Davison 1992), and it is interesting to note that 
CCV capsid protein profiles do not show any protein 
likely to be a counterpart of VP19C (personal 
communication, Dr A.J.Davison). The herpesvirus capsid is 
a highly defined structure which presumably means that 
architectural constraints select against gross variations 
in the conformations of constituent proteins (Heine et: 
al., 1974; Dargan, 1986), so it seems unlikely that an
essential structural component in one type of herpesvirus 
would be dispensible in another. However, amongst those 
genes of known sequence, the UL38 equivalents do vary in 
size much more than the other known capsid genes. The
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largest is VZV gene 20, having 483 codons. HSV-2 UL38 has 
466, and HSV-1 UL38 has 465. EHV-1 gene 22 also has 465 
codons. EBV BORF1 has 364 and HCMV UL46 has only 290. The 
degree of relatedness of these genes is generally low, 
with the exception of HSV -1 and -2, with the N-terminal 
regions in particular showing considerable divergence. 
Further understanding of the structure of herpesvirus 
capsids and of the role of VP19C is necessary in order to 
resolve this anomaly.
4.4.3 VP21
A 44-kDa capsid protein was detected by Gibson & Roizman 
(1972) and named VP21. Other names given to this protein 
have been ICP34 (Honess & Roizman, 1973), Vmw43 (Marsden 
et al., 1976), p45 (Zweig et al., 1979b) and NC3 (Cohen 
et al., 1980). It is not an essential structural 
component of the capsid, not being present in all capsid 
forms (Gibson & Roizman, 1972).
Probable counterpart proteins have been identified in 
capsids of the following herpesviruses: simian CMV strain 
Colburn (45 kDa), but not HCMV strain AD169 (Gibson, 
1981; Irmiere & Gibson, 1985), EBV (47 kDa) (Dolyniuk et 
al., 1976), PRV (41 kDa) (Stevely, 1975), EHV-1 (46 kDa, 
47 kDa) (Perdue et al., 1974; Perdue et al., 1975) and 
EHV-3 (48 kDa) (Allen & Bryans, 1976).
Several polypeptide species have been identified in HSV- 
1-infected cells which have molecular weights of about 
43 kDa, and this has been the source of some confusion. 
VP21 has been tentatively identified with the viral 
thymidine kinase, but this suggestion is now rejected 
(reviewed by Dargan, 1986). An infected-cell protein with 
DNA-binding properties identified by Bayliss et al.
(1975) was said to be VP21, but Braun et al. (1984a)
could not detect DNA-binding activity in the protein
present in capsids. The molecular weight of VP21 present
in capsids as measured by other workers agrees well with 
the original observation: 45 kDa (Zweig et al., 1979b),
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40 kDa (Cohen et al., 1980) and 42 kDa (Rixon et al.,
1990). As discussed above, VP21 was at one time thought 
to be the constituent protein of the virion core, but 
this theory is now discounted. Following the report of 
Zweig et al. (1979b) of immunological cross-reaction
between VP21 and the capsid protein VP22a, and at the 
suggestion of Braun et al. (1984a), VP21 is now
considered to be a higher molecular weight form of VP22a, 
and as such it is specified within the UL26 ORF of 
McGeoch et al. (1988). It will be discussed further in
the following section and in the Discussion.
4.4.4 VP22a
The 38.8-kDa capsid protein first described by Gibson & 
Roizman (1972) was named by them VP22a. It was so named 
because it did not have an electrophoretically identical 
counterpart in virion protein profiles, but was thought 
to be a precursor to the 37-kDa virion protein VP22, 
first described by Spear & Roizman (1972). The shared 
staining and radiolabelling properties of VP22a and VP22 
lent weight to the proposal that they are related (Gibson 
& Roizman, 1974). Other names used to designate VP22a 
include P22A (Friedmann et al., 1975), p40 (Zweig et al., 
1979a), NC4 (Cohen et al., 1980) Vmw40 (Preston et al., 
1983) and NC3 (Dargan, 1986). It is one of a series of 
related proteins, the 'ICP35 family', and is 
electrophoretically identical to the member of that 
family known as ICP35e (Braun et al., 1984b). It is also 
known as the 'scaffolding protein' (Newcomb & Brown,
1991) and the 'assembly protein' (Gibson, 1983; Irmiere & 
Gibson, 1983; Preston et al., 1992). Like VP21, it is not 
an essential structural component of the capsid, not 
being present in all capsid forms (Gibson & Roizman, 
1972) .
The gene encoding VP22a was mapped by analysis of 
intertypic recombinants to the region between 0.3-0.38 
map units (Marsden et al., 1978), and using the mutant
tsl201 to between 0.331-0.335 map units (Preston et al.,
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1983), The published sequence of the long unique region 
of HSV—1 identifies the gene as UL26, which is rightward 
oriented and unspliced (McGeoch et al., 1988a). The UL26 
ORF has recently been shown to contain a second
transcriptional unit (Liu & Roizman, 1991a). The promoter 
and coding sequences of this second reading frame,
UL26.5, lie entirely within the UL26 ORF. The initiation 
codon of UL26.5 is located 1099 base-pairs downstream 
from that of UL26, and the two reading frames are in­
frame and 3'-coterminal. Two mRNAs spanning this region 
were detected by Holland et al. (1984). These were of
2.4- and 1.4- kb, and it would seem that these are the
transcripts of UL26 and UL26.5 respectively (Liu & 
Roizman, 1991a). Experiments using an inhibitor of DNA 
synthesis led Braun et al. (1984b) to conclude that the
ICP3 5 proteins are y polypeptides which are not 
stringently dependent on viral DNA replication for their 
synthesis. After similar experiments Holland et al. 
(1984) concluded that the 2.4-kb transcript is regulated 
with y kinetics, and that the 1.4-kb transcript is
terminology is confused, and the kinetics of expression 
of UL26 and UL26.5 remain to be clearly established.
VP22a has long been known to be one of a member of 
related proteins ranging in size from 45 kDa-37 kDa 
(Preston et al., 1983; Braun et al., 1984b), which were 
immunoprecipitated by a monoclonal antibody against VP22a 
(Heilman et al., 1979; Zweig et al., 1980). VP22a was 
also shown to cross-react with VP21, thus confirming that 
they are related (Zweig et al., 1979b). Braun et al. 
(1984b) detected six species ICP35a_f, which resolved 
into at least 20 different species on two-dimensional gel 
electrophoresis. The major species ICP35c and  ^ were 
processed during the course of infection to become the 
two lowest molecular weight forms, ICP35e (38 kDa) and  ^
(37 kDa), said to be equivalent to VP22a and VP22 
respectively (Braun et al., 1984b). One of the higher
molecular weight forms is presumed to be equivalent to
regulated with However, their use of this
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VP21. However, Rixon et al. (1988) showed that a
monoclonal antibody which reacted with VP22a did not 
react with VP22, and Elliott & Meredith (1992) confirmed 
that VP22 is distinct from VP22a by demonstrating that 
VP22 is encoded by the gene UL49. Liu & Roizman (1991a) 
pointed out that the predicted product of UL26 is about 
twice as large as the observed sizes of the ICP35 
proteins, the putative products of that gene. The 
predicted molecular weight of the UL26 gene product is 
62466 (McGeoch et al., 1988a). The estimated size of
VP22a in purified capsids has been given as 38.8 kDa 
(Gibson & Roizman, 1972), 40 kDa (Zweig et al., 1979a;
Rixon et al., 1990) and 38 kDa (Cohen et al., 1980). It 
was this fact which prompted the discovery of UL26.5. It 
has now been demonstrated that the principal products of 
UL26.5 are ICP35c and which subsequently have the
carboxy-terminal 20 amino acids proteolytically removed, 
producing ICP35e and ^. The protease responsible for this 
cleavage is the 75-80 -kDa product of UL26, which, having 
an identical carboxy-terminal region to that of the 
UL26.5 products, undergoes autocleavage of its own 20 
carboxy-terminal amino acids (Liu & Roizman, 1991b; 
Preston et al., 1992).
VP22a is not an essential structural component of the 
capsid (Gibson & Roizman, 1972), but it is essential for 
completion of the lytic cycle. The mutant described by 
Preston et al. (1983), t_sl201, has a lesion in the UL26
ORF, and at the non-permissive temperature it assembles 
capsids but does not package DNA, and does not process 
VP22a from the higher molecular weight forms. Although 
the mapping data obtained using this mutant assigned 
VP22a to the UL26 ORF, more recent knowledge of details 
of this reading frame show that the lesion does not lie 
within UL26.5. The lesion lies upstream of UL26.5, in the 
amino-terminal region of UL26, affecting the protease, 
and it is the defective protease which is the cause of 
the failure of tsl201 to process VP22a properly. The role 
of VP22a in assembly of capsids and in packaging of DNA
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will be discussed in a later section.
P o s s i b l e  c o u n t e r p a r t s  h a v e  b e e n  d e s c r i b e d  in s e v e r a l
other herpesviruses. Ladin et al. (1982) detected a 35-
kDa protein in PRV which was processed during capsid
assembly from higher molecular weight forms of 41, 42 and
44 kDa. Stevely (1975), working with the same virus, also
described a 41-kDa capsid protein. (These higher
molecular weight species are possible counterparts of
VP21). EHV-1 has been shown to have two capsid proteins
of 46 and 30 kDa which are not present in all capsid
forms (Perdue et al., 1975; Perdue et al., 1976). The
EHV-1 DNA sequence has a UL26 homologue in gene 35
(personal communication, Dr E.Telford). Friedrichs &
(TeJfori 1992/)
Grose (1986) detected cross-reacting capsid proteins in 
VZV of 32, 34, 36 and 38 kDa. The published sequence of
the VZV genome (Davison & Scott, 1986a) enabled 
identification of gene 33 as a homologue, having 34% 
amino acid identity with UL26 (McGeoch et al., 1988). The 
gene BVRF2 is the EBV homologue (Baer et al., 1984), and
in MHV-68 there is a homologue in reading frame 14
(Efstathiou et al., 1990). The sequence of a UL26 
homologue from infectious laryngotracheitis virus has 
been published by Griffin (1990). A recent focus of 
attention has been the cytomegalovirus homologue. The 
simian CMV (strain Colburn) has a 37-kDa assembly protein 
which is processed from a 40-kDa precursor (Robson & 
Gibson, 1989). This processing involves the cleavage of 
the 32 carboxy-terminal amino acids from the precursor 
(Gibson et al., 1990). There is also a 45-kDa protein 
which is an amino-terminal extension form of the assembly 
protein. It also is produced during capsid assembly by 
processing from precursor and intermediate forms of 48 
and 47 kDa respectively (Schenk et al., 1991). These
workers also detected 39- and 38- kDa related proteins 
which are either intermediates in the transition of the 
40-kDa to the 37-kDa form, or aberrant forms. It may be 
that a multistep processing pathway is involved. The 
report of Welch et al. (1991a) reveals four 3'-coterminal
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transcripts within the simian CMV assembly protein gene. 
Four overlapping proteins are predicted, of molecular 
weights 64, 46, 34 and 27 kDa, and in infected-cell
extracts four corresponding proteins were detected using 
an antiserum to the common carboxy-terminal portion. A 
further report (Welch et al., 1991b) demonstrates that 
the N-terminal 249-amino-acid portion of the assembly 
protein contains the proteolytic activity responsible for 
cleavage of the C-terminal 32 amino acids. Welch et al. 
(1991a) also predicted four overlapping proteins to 
originate from the HCMV (strain AD169) homologous gene, 
UL80 (Chee et al., 1990), and detected the four 
corresponding proteins in HCMV-infected-cell extracts. 
They present a brief review of the homologous sequences 
in other herpesviruses and from a consideration of 
possible promoter elements within these sequences point 
out that the EBV gene BVRF2 could contain two reading 
frames, and the VZV gene 33 as many as eight.
Anti-VP22a IgG is prominent in latently infected human 
patients and is the first anti-HSV IgG detectable 
following primary infection (Eberle et al., 1985). The 
HCMV homologue is a major IgM-reactive antigen (Landini 
et al., 1985; Landini et al., 1986), and shares an 
antigenic epitope with a 60-kDa membrane component of 
human embryonic fibroblasts (Landini et al., 1991a).
4.4.5 VP23
The 33-kDa capsid protein described by Gibson & Roizman
(1972) was named by them VP23. It is also variously 
referred to as ICP40 (Honess & Roizman, 1973), Vmw37 
(Marsden et al., 1976), P38 (Marsden et al., 1978), p32
(Zweig et al., 1979a), NC5 (Cohen et al., 1980) and ICP39 
(Braun et al., 1984b).
A report of the map location of VP23 derived using 
intertypic recombinants was published by Lemaster & 
Roizman (1980). The protein they mapped was found to be 
phosphorylated by a viral protein kinase, and was
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referred to by them as ICP39.3, which they identified 
with the capsid protein VP23 . The map location given was 
between 0.66-0.76 map units. However, the report of Braun 
et al. (1984b) retracted this finding, showing that VP23
is properly identified with ICP39, not ICP39.3, and that 
ICP39 is unphosphorylated. In this respect it is 
important to correct an error in the review of Roizman & 
Sears (1990). They state that the capsid protein VP23 is 
ADP-ribosylated, citing the work of Preston & Notarianni 
(1983), which was in turn based on the identification of 
the phosphorylated species as VP23 by Lemaster & Roizman
(1980). However, that the phosphorylated species is not 
VP23 was demonstrated by one of the authors of the review 
(Braun et al., 1984b).
The gene encoding VP23 was identified as UL18 by Rixon et 
al. (1990), following determination of the N-terminal
amino acid sequence of VP23 prepared from purified 
capsids. UL18 is leftward oriented with a single 318- 
codon ORF (McGeoch et al., 1988). A 1.5-kb unspliced mRNA 
originating from this ORF has been mapped; it is 3'- 
coterminal with the proximal gene UL19, the major capsid 
protein gene (Costa et al., 1981; Costa et al., 1984). 
Mutants in UL18 have not been reported, but, as discussed 
above in the section on VP5, mapping data for the two 
mutants tsG3 and tsG8 (Weller et al., 1987) are 
insufficient to exclude UL18 as the location of the 
lesion. UL18 is stated to be regulated as an early-late 
gene by Costa et al. (1985b), but experimental evidence
for this claim is not presented. The kinetics of 
expression of UL18 are addressed in this thesis.
The predicted molecular weight of the UL18 gene product 
is 34,268 (McGeoch et al., 1988). This is in close 
agreement with the in vitro translation product (35 kDa) 
(Costa et al., 1984), and with the estimated size of the 
protein in purified capsids: 33 kDa (Gibson & Roizman,
1972; Cohen et al., 1980), 32 kDa (Zweig et al., 1979a) 
and 34 kDa (Rixon et al., 1990). This suggests that
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extensive post-translational modification does not occur. 
It migrates as two species on two-dimensional PAGE (Braun 
et al., 1984b), is not phosphorylated, sulphated or 
glycosylated (personal communication, Dr A.Cross), and 
the N-terminus is not modified following translation 
(Rixon et al., 1990).
Genes homologous to UL18 are known in several other 
herpesviruses. Gene 41 of VZV (Davison & Scott, 1986a) 
shares 43% amino acid identity with UL18 (McGeoch et al.,
1988) . The predicted molecular weight of the product of 
gene 41 is 34,387 (Davison & Scott, 1986a), and purified 
VZV capsids have been shown to contain proteins with 
molecular weights of 34.5 kDa and 31.5 kDa (Zweerink & 
Neff, 1981). Other known homolgues are genes UL85 of HCMV 
(Chee et al., 1990), 3L of HHV-6 (Lawrence et al., 1990), 
gene 43 of EHV-1 (personal communication. Dr E.Telford)
(TeJfori 1992?)
and genes in MDV and HVT corresponding to VZV gene 41 
(Buckmaster et al., 1988). Capsids of both human and 
simian CMV contain a 34-kDa protein (Irmiere SGibson,
1985). The EBV homologue is gene BDLF1, predicted to 
encode a product of molecular weight of 33,624 (Baer et 
al., 1984), and purified EBV capsids have been shown to
contain a protein having a molecular weight of 37 kDa 
(Dolyniuk et al., 1976). PRV capsids contain a 32-kDa 
protein (Stevely, 1975; Ladin et al., 1982). A 32-kDa 
protein produced by in vitro translation of an RNA 
transcribed from a cloned fragment of the PRV genome was 
immunoprecipitated by serum raised against purified PRV 
capsids (Lomniczi et al., 1987).
4.4.6 VP24
Little is known about the 25-kDa capsid component listed 
by Gibson & Roizman (1972), which was called by them 
VP24, and is variously referred to in the literature as 
ICP45 (Honess & Roizman, 1973), p25 (Zweig et al., 1979a) 
and NC6 (Cohen et al., 1980). The reported molecular 
weights of this protein in capsid profiles are 25 kDa 
(Gibson & Roizman, 1972; Zweig et al., 1979a), 26 kDa
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(Cohen et al., 1980) and 24 kDa (Rixon et al., 1990). 
Possible counterparts in other herpesviruses include a 
28-kDa protein in capsids of human and simian CMV 
(Irmiere & Gibson, 1985), a 28-kDa protein in capsids of 
EBV (Dolyniuk et al., 1976), a 22-kDa protein in capsids 
of PRV (Stevely, 1975), an 18-kDa protein in capsids of 
EHV-1 (Perdue et al., 1975) and an 18-kDa protein in 
capsids of VZV (Zweerink & Neff, 1981). A recent report 
based on determination of amino acid sequences of 
fragments of VP24 prepared from purified capsids shows 
that VP24 is encoded by the N-terminal region of UL26 
(Davison et al., 1992). The significance of this will be 
considered in the Discussion.
4.4.7 VP26
This protein was not detected in capsids by Gibson & 
Roizman (1972),- nor in virions by Spear & Roizman (1972), 
and was first recognised as a component of HSV -1 and -2 
capsids by Heilman et al. (1979), being named by them
pl2. Another name used of this protein is NC7 (Cohen et 
al., 1980). The term VP26, recently adopted for this
protein by Newcomb & Brown (1989) is without precedent, 
but in this thesis the term VP26 will be used for 
consistency. The molecular weight of VP26 as determined 
by PAGE of purified capsids is 12 kDa (Zweig et al., 
1979a; Cohen et al., 1980; Rixon et al., 1990).
A recent report suggests that VP26 may be the product of 
the gene UL49.5, on the basis of similarities between 
VP26 and the predicted polypeptide product of UL49.5 
(Barker et al., 1992). However, the results of other 
workers show that the product of UL49.5 is probably a 
transmembrane protein (Barnett et al., 1992). 
Furthermore, VP26 was shown by J. W. Palf reyman to map 
between 0.44-0.52 map units (cited in Al-Kobaisi, 1989). 
This region of the genome contains coding sequences of 
several genes, including UL33 and UL35, both of which 
specify polypeptides of the approximate size of VP26. The 
gene encoding VP26 has recently been identified as UL35,
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following expression of the carboxy-terminal region of 
UL35 as a fusion protein (McNabb & Courtney, 1992), and 
by determination of amino acid sequences of fragments of 
VP26 prepared from purified capsids (Davison et al.,
1992). The study of McNabb & Courtney (1992) also found 
that the UL35 protein is regulated with true-late 
kinetics.
Gene 23 of VZV is predicted to encode a protein of 235
amino acids which has only 15% identity with the 112-
amino acid predicted product of UL35 (Davison & Scott,
1986a; McGeoch et al., 1988a). The only other known
homologue is gene 25 of EHV-1, which is predicted to
encode a protein of 119 amino acids (personal
communication,, Dr E.Telford). Gene BFRF3 of EBV has no 
(TdfW. etJl,., 1992.)
detectable homology with VZV gene 23, but these genes 
were considered to be potential counterparts because they 
are aligned positionally on their respective genomes and 
are of similar size and are in the same orientation 
(Davison & Taylor, 1987). BFRF3 is predicted to encode a 
protein of 192 amino acids (Baer et al., 1984). As an 
alternative to BFRF3, Davison & Taylor (1987) also 
suggested that the adjacent EBV gene BFRF2 might be a 
counterpart of VZV gene 23, again on positional 
considerations, although BFRF2 is predicted to encode a 
protein of 656 amino acids (Baer et al., 1984). Gene UL49 
of HCMV has been identified as a potential counterpart of 
UL35 because it is positionally conserved (Chee et al.,
1990) . It is predicted to encode a protein of 570 amino 
acids. Another, previously unidentified HCMV gene, 
designated UL49A, has been reported as a possible 
homologue of UL35 (Davison et al., 1992). UL49A is
predicted to encode a protein of 109 amino acids, having 
an Mr of 8480. HCMV is known to have an 11-kDa capsid 
protein (Irmiere & Gibson, 1985), and simian CMV has a 
12-kDa capsid protein (Irmiere & Gibson, 1985). 
Herpesvirus saimiri has a 12-kDa capsid protein (Keil e_t 
al., 1983).
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Figure 4. Diagram of a single triangular face of a 
herpesvirus capsid, illustrating the bonding 
relationships between capsomers. This figure is 
reproduced with permission from Schrag et al. (1989),
I
4.5 Structure of the capsid
As viewed in the electron microscope, the HSV-1 capsid is 
icosahedral in shape and exhibits 2-, 3- and 5- fold 
axial symmetry. It is composed of 162 capsomers, which 
are arranged in accordance with a T=16 icosahedral 
lattice (Wildy et al., 1960; Caspar & Klug, 1962; Schrag 
et al., 1989). The average diameter of the capsid was 
measured by Wildy et al. (1960) to be 105 nm and by
Schrag et al. (1989) to be 125 nm.
There are two main types of capsomer. At each of the
twelve vertices of the icosahedron is a pentagonal 
capsomer, whilst the remaining 150 are hexagonal in shape 
(Wildy et al., 1960). Transmission electron microscopy 
studies of the hexagonal capsomers led some workers to 
conclude that they were trimers (Vernon et al., 1974), 
but further work provided evidence of their 6-fold 
symmetry which led to the suggestion that they are 
hexamers (Palmer et al., 1975; Furlong, 1978; Almeida ejt 
al., 1978) The work of Steven et al. (1986) confirmed the 
six-fold symmetry, showing in addition that they are
hexamers of the MCP, on the basis that the mass of a 
hexagonal capsomer was found to be approximately that of 
six 155-kDa molecules. The twelve pentagonal capsomers 
are generally held to be pentamers of the MCP, although 
the possibility that they may be composed of a larger 
number of smaller subunits cannot yet be ruled out
(Schrag et al., 1989; Baker et al., 1990; Newcomb & 
Brown, 1991). Although each hexamer is surrounded by six 
other capsomers, the bonding arrangements of the hexamers 
are of three quasi-equivalent types, depending upon their 
position on the icosahedral lattice. These bonding 
arrangements are illustrated in Figure 4, which depicts 
in schematic form the capsomers lying on a single 
triangular face of the icosahedral lattice. Type E 
hexamers lie on the icosahedral two-fold axis, and type C 
hexamers surround the icosahedral three-fold axis. Each 
of the vertex pentamers is surrounded by five type P
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hexamers (Steven et al., 1986).
The centre-to-centre distances between E, P, and C 
hexamers were found to be 12.2 nm by Furlong (1978) and
16.0 nm by Schrag et al. (1989), who also measured the
centre-to-centre distance of P hexamers from pentamer to 
be 16.0 nm. Palmer et al. (1975) found the hexamer
diameter to be 8-9 nm, whilst Schrag et al. (1989) found
the diameter to be 11-12.5 nm and the height to be 
12.5 nm. A channel runs through the centre of each 
pentamer and hexamer, which has a diameter of
approximately 4-5 nm (Wildy et al., 1960; Palmer et al., 
1975; Schrag et al., 1989). Baker et al. (1990), working 
with capsids of EHV-1, were able to reconstruct images of 
these channels in cross-section, and they found that the 
bore was not uniform, there being two noticeable
constrictions. They suggested that a channel could 
function as a portal of entry of viral DNA during 
packaging of DNA into new capsids.
Interconnections between capsomers were observed by 
Vernon et al. (1974) and Palmer et al. (1975) in HSV-1
and in EHV-1. These structures, lying at a depth of about
5 nm below the outermost extent of the capsomers, each 
interconnect three capsomers, and they appear to be 
trimers of a single protein, although this is. not certain 
(Schrag et al., 1989; Baker et al., 1990). These trimers 
are represented in Figure 4 as thin lines interconnecting 
adjacent capsomers. Beneath the level of the capsomers 
there appears to be a further layer of density of 
undetermined structure, termed the capsid floor (Newcomb
6 Brown, 1989; Schrag et al., 1989). The total thickness 
of the T=16 shell was found to be 20 nm (Schrag et al., 
1989) and 14-15 nm (Booy et al., 1991) in HSV-1, and 
15 nm in EHV-1 (Baker et al., 1990). The inner diameter 
of the capsid was found by Booy et al. (1991) to be
86 nm. Schrag et al. (1989) found the inner diameter of
the T=16 shell to be 85 nm. they also found evidence for 
a second distinct icosahedral shell of T=4 structure
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lying within the T=16 shell, but this finding was not 
confirmed by the study of Booy et al. (1991). The inner
diameter of the EHV-1 capsid was found to be
approximately 95 nm by Baker et al. (1990).
Three types of capsid have been isolated from HSV-1- 
infected cells and characterised, which differ in their 
protein and DNA content (Gibson & Roizman, 1972; Cohen et 
al., 1980). Type A and B capsids are isolated from
nuclei, and type C capsids from the cytoplasm. B capsids 
contain all seven capsid proteins, and have internal 
structural features. They consist of a mixture of DNA- 
containing 'full1 capsids and 'partially cored' capsids 
lacking DNA but containing proteinaceous internal
structures (Sherman & Bachenheimer, 1988; Rixon et al.,
1988). A capsids contain only five of the capsid 
proteins, lacking VP21 and VP22a, and having no internal 
structure. They are often referred to as 'empty' capsids, 
and, by analogy with the capsid maturation process of 
EHV-1 (Perdue et al., 1976), are thought to be abortive 
by-products of the assembly process. C capsids are 
nucleocapsids obtained by removal of envelope and 
tegument material from virions isolated from the
cytoplasm of infected cells. They contain six of the 
capsid proteins, lacking VP22a. The situation in EHV-1 is 
similar, though not identical. Three types of capsid have 
been described, but they are all isolated from the 
nucleus of infected cells. 'Heavy' (H) capsids appear to 
be mature nucleocapsids and contain all the capsid 
proteins. 'Intermediate' (I) capsids contain very little 
DNA and only very small amounts of a 30-kDa capsid 
protein thought to be a counterpart of VP22a. 'Light' (L) 
capsids also contain very little DNA and lack the 30-kDa 
protein and a 46-kDa capsid protein thought to be a 
counterpart of VP21 (Perdue et al., 1975).
In both viruses, the structural differences between the 
capsid forms appear to be restricted to internal 
features. The icosahedral shells of HSV-1 A and C capsids
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are indistinguishable by cryoelectron microscopy (Schrag 
et al., 1989; Booy et al., 1991), as are those of EHV-1 L 
and I capsids (Baker et al., 1990). Schrag et al. (1989) 
calculated the dry mass of empty capsids to be
4.56 x 10”16g, and the dry mass of full capsids 
(excluding the mass of the core material) to be
4.58 x 10 xog. The former figure compares well with the 
earlier estimate of Lampert et al. (1969), who calculated 
the dry mass of empty capsids to be 5.22 x 10”1^g.
4.6 Locations of capsid proteins within the capsid 
VP5 was first located on the external surface of the
capsid by Powell & Watson (1975), who found that capsids 
were agglutinated by anti-VP5 antibody. Vernon et al.
(1981) found that anti-VP5 antibody coated capsids in a 
distribution which covered the entire capsid surface. The 
study of Steven et al. (1986) established the hexameric
structure of the capsomers by calculating that the volume 
of a hexamer was sufficient to contain six copies of the 
MCP. Schrag et al. (1989) also calculated that the massm
of each hexamer was sufficient to accomodate six copies 
of a 155-kDa protein. They also calculated that the mass
m
of a pentamer was sufficient to accoirjbdate five copies of 
a 160-kDa protein, and suggested that the pentamers might 
also be composed of VP5, as it is the only known capsid 
component with a mass in this range. 150 hexamers would 
require 900 copies of VP5, and 12 pentamers would require 
a further 60 copies. A figure of 960 copies of VP5 per 
capsid is in agreement with the previously published 
estimate of 690-1000 (Heine et al., 1974). VP5 accounts 
for 61.9% of total B capsid protein (Newcomb & Brown, 
1989). Newcomb et al. (1989) estimate that EHV-1 I 
capsids contain 913 +/- 38 copies of the MCP.
Vernon et al. (1981) also located VP19C to the capsid 
surface. In this case, anti-VP19C antibody coated the 
regions surrounding the vertex pentamers, leading to the 
suggestion that the pentamers might be composed of VP19C. 
However, Schrag et al. (1989) found that the mass of a
58
pentamer was such that it was unlikely to be composed of 
molecules of 50 kDa, and Newcomb & Brown (1991) concluded 
that VP19C could not comprise the pentamers because they 
could remove these using guanidine hydrochloride (GuHCl) 
with only minimal loss of VP19C•
Newcomb & Brown (1989) also found that VP19C was somewhat 
exposed on the capsid surface, as it was rapidly etched 
from capsids by a stream of Ar+ ion plasma. They 
considered that VP19C was a good candidate for the 
material comprising the floor or base material in which 
capsomers appear to be embedded. VP19C is not 
sufficiently exposed to be susceptible to surface 
iodination. Braun et al. (1984b) attempted this with both 
empty and full capsids, but were unable to label VP19C, 
although VP19C was readily labelled in disrupted capsids. 
A location of VP19C in the basal region of the capsomers 
is supported by the fact that VP19C is covalently linked 
to VP5 (Zweig et al., 1979), suggesting a role in 
anchoring of VP5. Furthermore, the report that VP19C is a 
DNA-binding protein (Braun et al., 1984a) suggests that, 
whilst anchoring VP 5 on the outer side of the capsid 
wall, VP19C could have a role in making contact with DNA 
on the inside. Heine et al. (1974) estimate that there
are 680-890 copies of VP19C per virion, which amounts to 
9.4% of the total B capsid protein (Newcomb & Brown,
1989) .
VP21 is a component of B and C capsids but not A capsids. 
It is a very minor component, being present in C capsids 
in 230-270 copies (Heine et al., 1974) and comprising 
only 2.1% of total B capsid protein (Newcomb & Brown,
1989). Schrag et a^ L. (1989) thought that it was an
internal component of the capsid, as did Newcomb & Brown 
(1989), who found that it was not easily removed from 
capsids by Ar+ plasma etching.
VP22a is a component only of B capsids. However, it has 
been shown that B capsids consist of two populations
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'full' capsids which contain a DNA core and 'partially 
cored' capsids which contain a proteinaceous core
(Sherman & Bachenheimer, 1988). Previously VP22a had been 
thought to be located on the outer surface, following the 
labelling of VP22a in immunoelectron microscopy 
experiments (Vernon et al., 1981) and during surface
iodination of DNA-containing capsids (Braun et al., 
1984b). However, VP22a is now known to be strongly 
associated with partially cored capsids and not with full 
capsids, and it appears that the proteinaceous core is 
composed of VP22a and that it is involved in the process 
of DNA packaging (Rixon et al., 1988; Sherman & 
Bachenheimer, 1988). Rixon et al. (1988) demonstrated by
immunoelectron microscopy that VP22a is strongly 
associated with the internal surfaces of the capsid, and 
the same was demonstrated for the HCMV counterpart by 
Landini et al. (1991b). Newcomb & Brown (1989) also
thought that VP22a is an internal component, because it 
is not easily removed from capsids by Ar+ plasma etching. 
In a further report (Newcomb & Brown, 1991), they
confirmed this finding by treating B capsids with GuHCl. 
This resulted in the removal of VP22a and of the internal 
proteinaceous core. Newcomb & Brown (1989) report that 
VP22a comprises 15.4% of total B capsid protein, but
since the B capsid population consists of a mixture of 
full (VP22a~) and partially cored (VP22a-containing) 
capsids, the relative amount of VP22a per partially cored 
capsid is uncertain.
VP23 was first shown to be exposed on the surfaces of 
capsids by Braun et al. (1984b), in their surface
iodinations of full and empty capsids. On the basis of 
this observation, Schrag et al. (1989) suggested that
VP23 could be the constituent of the intercapsomeric 
trimers. This would require 960 copies of VP23, a figure 
lower than the estimate of 1240-1720 given by Heine et 
al. (1974). The possibility exists that there is more
than one structural location of VP23 in the capsid. An 
exposed surface location was also suggested by the study
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of Newcomb & Brown (1989), who found that VP23 was easily- 
dislodged from capsids exposed to Ar+ ion plasma. They 
suggested that VP23 could comprise either the trimers or 
the pentamers, or be a constituent of the capsid floor. 
That VP23 cannot comprise the pentamers was shown by 
Newcomb & Brown (1991), who extracted the pentamers from 
capsids using GuHCl without removal of appreciable 
amounts of VP23. Newcomb & Brown (1989) report that VP23 
comprises 10.2% of total B capsid protein.
Little is known about the location of VP24. Schrag et al. 
(1989) suggested that it may be located in the capsid 
floor. Since it was not easily eroded from capsids by Ar+ 
ion plasma, Newcomb & Brown (1989) also concluded that 
VP24 is located internally. These workers report that 
VP24 comprises only 1% of total B capsid protein. There 
are no published estimates of the number of copies of 
VP24 per particle.
Again, little is known as to the location of VP26 within 
capsids. Schrag et al. (1989) suggested that it may be
located in the relatively continuous band of protein they 
observed at a radius of 450-500 A. Newcomb & Brown (1991) 
suggest that VP26 may be located in or around the capsid 
vertices because removal of the vertices with GuHCl 
involves loss of VP26. The only published estimate for 
the amount of VP26 present per capsid is for 1355 +/- 145 
copies of the VP26 counterpart in I capsids of EHV-1 
(Newcomb et al., 1989).
4.7 Assembly of capsid
Herpesvirus capsid assembly takes place in the nucleus of 
infected cells (Morgan et al., 1954). VP5 has been shown 
by immunofluorescent staining to be heavily localised to 
the nucleus during infection (Powell & Watson, 1975), and 
was found to separate with the nuclear fraction of 
infected cells (Fenwick et al., 1978). Cohen et al.
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(1980) were able to demonstrate by immunofluorescent 
staining that VP5, VP19C, VP21/VP22a, VP23 and VP26 each 
localise to the nucleus. (They were unable to demonstrate 
this for VP24 because they could not obtain sufficient 
amounts of protein to raise antibody.) VP5 is strongly 
associated with the cytoplasmic cellular cytoskeleton 
within five minutes of synthesis, and moves directly from 
the cytoplasmic to the nuclear framework without 
appearing in a soluble phase (Knipe & Spang, 1982; 
Quinlan & Knipe, 1983; Bibor-Hardy et al., 1985a). VP5, 
VP19C and VP23 have all been shown to be strongly 
associated with the nuclear framework, leading to the 
suggestion that capsid assembly may take place within 
this framework (Bibor-Hardy et al., 1982; Bibor-Hardy et 
al., 1985b). Little is known about the mechanics of
assembly of the various capsid proteins. The only capsid 
protein which has been shown to associate with partially 
formed capsids in vitro is VP26. Purified B capsids were 
treated with GuHCl, which removed the pentamers and the 
internal core material (primarily VP22a) and also 
involved the loss of VP26. When the reaction mixture was 
purified of GuHCl, VP26 reassociated with these capsids. 
Since this process did not involve re-forming of the 
pentamers, it is concluded that VP26 is not the 
constituent of those elements. These experiments 
demonstrate that stable capsid structures can exist 
without the need for the vertex pentamers or any internal 
material, either VP22a or DNA. (Newcomb & Brown, 1991). 
The existence of A capsids also demonstrates that stable 
capsids can exist without any VP21, or any internal 
material•
Heilman et al. (1979) first demonstrated by immuno-
fluo-rescent staining that VP22a localises to the nucleus 
of infected cells, and Cohen et al. (1980) showed the
same for either or both of VP21 and VP22a using a cross­
reacting antibody. Conflicting results have been reported 
concerning the subcellular locations of the unprocessed 
forms of VP22a • Braun etal. (1983) and Braun e t a 1.
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(1984b) reported that the precursor forms ICP35 andc d
fractionated with the cytoplasm, and that the processed 
forms VP22a and VP22 (lCP3 5e and fractionated with the 
nucleus, and surmised that the processing event is 
concomitant with location to the nucleus. However, Rixon 
et al. (1988) disputed this finding in a study using
tsl201 (which fails to process VP22a from higher 
molecular weight forms at the NPT). They found that 
unprocessed forms of VP22a did enter the nucleus and that 
they were incorporated into 'partially cored' capsids.
Condensations of VP22a, about 60 nm in diameter, are 
often seen in the centre of B capsids in vivo (Friedmann 
et al., 1975; Preston et al., 1983; Rixon et al., 1988). 
Similar structures have also been noted in EHV-1 (Perdue 
et al., 1976) and in simian CMV (Lee et al., 1988). They 
are also found in capsids in vitro after capsid 
purification (Sherman & Bachenheimer, 1988; Perdue et 
al., 1975; Newcomb et al., 1989). VP22a extracted from
capsids in vitro also exists as discrete condensations of 
about 60 nm in diameter (Newcomb & Brown, 1991). These 
authors suggest that such aggregations of VP22a would be 
capable of acting as scaffolds around which other capsid 
proteins could condense to form the capsid shell.
A herpesvirus protein which acts in this fashion was 
first postulated by Mark & Kaplan (1971). They observed 
that in cells infected with PRV under conditions of 
arginine deprivation, viral structural proteins were 
synthesised normally but not transported to the nucleus. 
They postulated an arginine-dependent protein which would 
have a role in nuclear localisation. The protein would 
act to condense structural proteins in the nucleus, 
creating reduced levels of these proteins and leading to 
a flow of structural proteins into the nucleus. They 
point out that such a protein would have to be made in 
the nucleus, otherwise it would also condense structural 
proteins in the cytoplasm. Ladin et al. (1982) report
work on a 35-kDa PRV capsid protein which is processed
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from 41-, 42- and 44- kDa forms. The 35-kDa form was only 
detectable in the nucleus, whilst the higher molecular 
weight forms were restricted to the cytoplasm. They 
inferred that the processing event occurs either in the 
nucleus or in the cytoplasm immediately before transport. 
Since processing to the 35-kDa form did not occur in 
three capsid” mutants, processing to the 35-kDa protein 
and capsid assembly were inferred to be interdependent 
events. The mechanism of assembly they proposed was one 
whereby the processing event occurred, with capsid 
assembly as a concomitant. Assembly would create reduced 
levels of capsid proteins in the nucleus which would lead 
to increased transport or diffusion of capsid proteins 
into the nucleus. According to this model, a defect in 
any capsid protein would therefore not only prevent 
capsid assembly but would prevent processing of the 
assembly protein.
The report of Braun et al. (1984b) that unprocessed forms 
of VP22a were restricted to the cytoplasm whilst VP22a 
and VP22 were found only in the nucleus appears to 
present a similar situation in HSV-1. However, the 
situation is not identical, because in the case of 
tsl201, unprocessed forms of VP22a do locate to the 
nucleus and capsid assembly does occur in the absence of 
the processing event (Rixon et al., 1988). Furthermore, 
in the mutant ts2, which is defective in the essential 
capsid protein VP19C, processing of VP22a does occur in 
the absence of capsid formation, and VP22a is correctly 
localised to the nucleus (Preston et al., 1992).
4.8 DNA packaging and capsid maturation
Newly replicated herpesvirus DNA molecules consist of 
large head-to-tail concatemers (Ben-Porat & T o k a z e w s k i ,  
1977; Ben-Porat & Rixon, 1979; Jacob et a l ., 1979; 
Roizman, i979), which are cleaved to single-genome 
molecules during the encapsidation process. Stow et al.
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(1983) demonstrated that signals required for both 
cleavage and encapsidation of DNA reside within the a 
sequence. Specific regions within the a sequence appear 
to be critical for this process (Varmuza & Smiley, 1985; 
Deiss Sc Frenkel, 1986; Deiss et al., 1986; Nasseri & 
Mocarski, 1988). Two virus-specific proteins of >250 kDa 
and 140 kDa have been identified which bind specifically 
to sites within the a^ sequence and which might have a 
function in the cleavage/packaging process (Chou & 
Roizman, 1989). The cleavage and packaging events appear 
to be coupled, inasmuch as that in experiments reported 
to date, cleavage always results in packaging (Ladin et 
al., 1980; Deiss & Frenkel, 1986; Sherman & Bachenheimer, 
1987; Addison et al., 1990; Al-Kobaisi et al., 1990).
Addition of drugs which block DNA synthesis significantly 
reduces the rate of synthesis of VP 5 (Holland et al., 
1980; Conley et al., 1981), and also reduces the rate of 
nuclear transportation of the residual VP5 (Knipe & 
Spang, 1982). However, under conditions where synthesis 
of viral DNA is suppressed by the use of inhibitory 
agents or in DNA” t^s mutants, assembly of partially cored 
capsids occurs normally, although many of the ts mutants 
produced capsids in lower-than-normal numbers (Nii <et 
al., 1968b; Friedmann et al., 1975; Schaffer et al.,
1974; Cabral & Schaffer, 1976; Atkinson et al., 1978; 
Dargan & Subak-Sharpe, 1983).
Evidence from electron microscopic studies suggested that 
DNA is packaged into preformed capsids. Strands of 
electron-dense material, thought to be nucleoprotein 
complexes, can be observed penetrating empty capsids (Nii 
et al.. 1968a; Friedmann et al., 1975; Haguenau &
Michelson-Fiske, 1975). This is confirmed by several ts 
mutants which are DNA+ and assemble partially cored 
capsids at the NPT but which fail to package DNA (Addison 
et al.. 1984; Addison et al., 1990; Al-Kobaisi et al.,
1991). A further mutant, tsl201, assembles only partially 
cored capsids at the NPT, which upon downshift to the PT
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and under conditions of inhibition of protein synthesis 
mature to become full nucleocapsids (Preston et al., 
1983). Sherman & Bachenheimer (1988) studied several ts 
mutants which assembled partially cored capsids at the 
NPT. Of particular interest was the observation that 
these mutants did not make any detectable A capsids at 
the NPT. Empty or A capsids were only made during growth 
at the PT, suggesting that A capsids are generated 
during, as an alternative to, or subsequent to, packaging 
of DNA. The empty or L capsids of EHV-1 likewise appear 
to be by-products of the maturation process rather than 
precursors. Pulse-chase experiments showed that partially 
cored or I capsids were made first, and that the 
appearance of L capsids correlated with the appearance of 
mature, full nucleocapsids or H capsids (Perdue et al.,
1986) .
Friedmann et al. (1975) first proposed a mechanism of
capsid assembly which involved VP22a as a scaffolding 
protein, on the basis of similarities with the 
scaffolding proteins of double-stranded DNA 
bacteriophages (see Discussion). The fact that VP22a when 
extracted from capsids exists in condensations of about 
60 nm in diameter is consistent with its proposed role as 
a scaffold, around which other capsid proteins could 
condense to form a partially cored capsid (Newcomb & 
Brown, 1991). VP22a is lost from these capsids at or near 
the time that viral DNA is packaged (Sherman & 
Bachenheimer, 1988; Rixon et al., 1988). It is not clear 
whether VP22a actually has a role in the packaging of 
DNA, or whether it is simply removed in order to allow 
entry of the DNA. Neither is it known whether VP5 or 
VP19C, capsid proteins reported to have DNA-binding 
activity, play any role in securing DNA during the 
packaging process. The genes UL25, UL28 and UL33 have all 
been shown to be essential for the assembly of full 
capsids. Mutants in these genes form partially cored 
capsids but fail to package DNA. The precise roles of the 
gene products is not known (Addison et al., 1984; Addison
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et al., 1990; Al-Kobaisi et al., 1991). A recently 
constructed UL48 deletion mutant exhibited a defect in 
capsid assembly at the level of DNA encapsidation. The 
reason for this is not clear, but this report 
demonstrates a second key function during HSV-1 infection 
of the product of UL48, the transactivating tegument 
protein VP16 (Weinheimer et al., 1992).
4.9 Addition of Tegument
The maturation of capsids to virions involves addition of 
tegument and envelope. About 25% of enveloped, 
cytoplasmic virions contain empty capsids, leading to the 
suggestion that lack of VP22a is the marker inducing 
virion maturation (Schrag et al., 1989). However, it 
should be noted that, at least in HCMV, partially cored 
capsids (ie containing the VP22a counterpart) are matured 
to become cytoplasmic virions (Irmiere & Gibson, 1983; 
Irmiere & Gibson, 1985). Furthermore, in the mutant 
tsl201, the only defect is a lack of the processed form 
of VP22a, but capsids do not leave the nucleus or acquire 
tegument (Preston et al., 1983). The formation of L 
particles during infections by ts_1201 demonstrates that 
condensation of tegument material and its subsequent 
envelopment is not necessarily initiated by capsids 
(Rixon et al., 1992). Characterisation of L particles has 
shown that when stripped of envelope, tegument has 
intrinsic structural stability, and it is clearly able to 
condense without the need for a capsid as a scaffold 
(McLauchlan & Rixon, 1992). Mutants have been isolated 
which are deficient in the tegument genes ULll, UL41, 
UL46, UL47 and US9 but which do form tegument, showing 
that these gene products do not play an essential role in 
the structure or assembly of tegument (MacLean et al., 
1989; MacLean et al., 1991; Read & Frenkel, 1983; Fenwick 
& Everett, 1990; Zhang et al., 1991; Umene, 1986; 
Longnecker & Roizman, 1986).
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The site of tegument aquisition in HSV-1 is not known. In 
HHV-6 it is reported to be in a specific region of the 
cell termed the tegusome, which appears to be an 
invagination of the cytoplasm into the nucleus (Roffman 
et al., 1990). This report shows capsids with tegument in 
various stages of deposition. Stackpole (1969) observed 
capsids in the cytoplasm of cells infected with a frog 
herpesvirus, which appeared to be in the process of 
aquisition of a layer of tegument. Smith & de Harven
(1973) observed the same in infections with HCMV. 
However, although this report also found unenveloped 
capsids of HSV-1 in the cytoplasm, these were never seen 
in association with tegument.
4.10 Envelopment and Egress
Confusion exists over the means by which progeny capsids 
become enveloped. The main reason for this is the 
difficulty in interpreting electron micrographs in 
reconstructing the pathway of envelopment. A further 
complication is that studies on different herpesviruses 
have given conflicting results, and it may be that 
several different pathways of envelopment occur amongst 
the Herpesviridae. There does appear to be general 
agreement that the primary site of envelopment of 
herpesviruses is the inner nuclear membrane. Many studies 
have observed nuclear capsids deriving an envelope from 
this membrane by budding into the perinuclear space (Nii 
et al.. 1968a; Darlington & Moss, 1968; Stackpole, 1969;
McCracken & Clarke, 1971; Wharton et al., 1981; Johnson & 
Spear, 1982; Poliquin et al., 1985; Whealy et al., 1991; 
Campadelli-Fiume et al., 1991; Cheung et al., 1991). 
Darlington & Moss (1968) presented evidence showing that 
for HSV, PRV and EHV-1, a second envelope was acquired 
upon passing through the outer nuclear membrane, to 
produce a cytoplasmic vesicle containing a virion. These 
vesicles then migrated to the cell membrane and the 
virions were released by exocytosis. In a study of a frog
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herpesvirus, Stackpole (1969) found that the envelope 
acquired at the inner nuclear membrane was lost upon 
passing through the outer membrane, and that the capsid 
re-acquired an envelope when budding into a cytoplasmic 
vesicle. These vesicles then migrated to the cell 
membrane and released the virions by exocytosis. Similar 
sequences of de-envelopment and re-envelopment have been 
observed by other workers for HSV and PRV (Morgan et al., 
1959; Nii et al., 1968a; McCracken & Clarke, 1971).
Johnson & Spear (1982) demonstrated the involvement of 
the Golgi apparatus in envelopment by studying HSV-1- 
infected cells treated with the ionophore monensin, which 
blocks the transit of membrane vesicles from the Golgi 
apparatus to the cell surface. Yield of extracellular 
virus was almost eliminated by treatment with monensin, 
whereas cell-associated virus continued to accumulate, 
albeit at reduced levels. Electrophoretic analyses showed 
that these intracellular virions contained immature forms 
of the envelope glycoproteins. The pathway of envelopment 
proposed in this report was one which began with capsids 
acquiring an envelope at the inner nuclear membrane. 
Enveloped particles would then move via cytoplasmic 
vesicles to the Golgi, the site of glycoprotein 
maturation, and from there would move to the cell 
membrane and be exocytosed from the cell. It is not clear 
whether the virions actually enter the Golgi or interact 
with it via Golgi-derived enzyme-containing vesicles. 
This model is also presented by Torrisi et al. (1992),
who demonstrate the aquisition of immature glycoproteins 
by nascent virions in the perinuclear space, and the 
transition from immature to mature glycoprotein forms 
during transport to the extracellular space. Involvement 
of the endoplasmic reticulum (ER) has been demonstrated 
for HSV-1 and PRV (Cheung et al., 1991; Whealy et al., 
1991). Transport of molecules through the ER to the Golgi 
and their subsequent processing are disrupted by the 
fungal metabolite brefeldin A (BFA). BFA causes a rapid 
redistribution of the Golgi apparatus by inducing a
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retrograde transport of Golgi components throughout the 
ER. Treatment of virus-infected cells with BFA resulted 
in the accumulation of enveloped virus particles in the 
perinuclear space and the ER. BFA also interfered with 
glycoprotein maturation. In the case of PRV, Whealy et 
al. (1991) suggest that transport through the ER and
transport in cytoplasmic vesicles via the Golgi may 
represent two alternative pathways of virus egress.
Jones & Grose (1988) reported that capsids of VZV pass 
into the cytoplasm without any process of envelopment, 
and that an envelope is acquired by budding into a 
cytoplasmic vesicle, which then undergoes processing by 
the Golgi. In their study of HHV-6, Roffman et al. (1990) 
proposed that tegumented capsids pass from tegusomes into 
the cytoplasm at points where the membranes of the 
tegusome and nucleus have fused. Acquisition of envelope 
was again proposed to be by budding into cytoplasmic 
vesicles. Campadelli-Fiume et al. (1991) concluded that
the unenveloped capsids observ-able in the cytoplasm 
during infections with HSV-1 represent an abortive stage 
in the pathway of envelopment, which occurs when the 
virion envelope fuses with the membrane of the vesicle in 
which it is being transported. This report was based on 
studies of a virus carrying a mutation in gD, which had a 
reduced restriction on the ability of the virion envelope 
to fuse with cytoplasmic membranes. This mutant 
accumulated unenveloped capsids in the cytoplasm and had 
a greatly reduced yield of extracellular virus.
The gene product of UL20 appears to be essential for 
egress of virus. A virus inactivated in this gene 
produces mature infectious virions but fails to transport 
them to the cell membrane. Instead there is an 
accumulation of enveloped virions in the perinuclear 
space (Baines et al., 1991). The UL20 gene product is
membrane-associated, but the mechanism of its action in 
egress is not clear. Some cell lines are able to 
complement its function (Baines et al., 1991).
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MATERIALS AND METHODS
2A MATERIALS
1 Chemicals
Chemicals were supplied by BDH Chemicals UK, Koch-Light 
Laboratories, Sigma (London) Ltd, May & Baker Ltd, 
Pharmacia LKB Ltd, Du Pont Ltd, Bio Rad Laboratories Ltd, 
James Burroughs Ltd and Fluka Chemicals Ltd.
2 Radiochemicals
All radiochemicals were obtained from NEN Dupont and 
Amersham International pic.
3 Enzymes
Restriction endonucleases, DNA-modifying enzymes, and 
enzyme buffers were obtained from Bethesda Research 
Laboratories, New England Biolabs, Northumbria 
Biologicals Ltd, Boehringer Mannheim GmbH and Promega 
Biotech. RNase and lysosyme were supplied by Sigma.
4 Oligonucleotides
Synthetic restriction enzyme linker oligonucleotides were 
obtained from New England Biolabs. Oligonucleotides A, B, 
C and D, used in the cloning of UL19, were synthesised by 
Dr J.McLauchlan using a Biosearch 8600 DNA Synthesiser.
5 Cell Lines
The BHK cells used were from the BHK-21 clone 13 
fibroblastic cell line derived from baby hamster kidney 
cells (MacPherson & Stoker, 1962). The CV-1 cells used 
were from a Green Monkey kidney epithelial cell line
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(Jensen et al., 1964; Kit et al., 1965). The TK” cells 
used were from the TK”143 human osteomyeloma cell line 
(Rhim et al., 1975; Panicali & Paoletti, 1982). A 
continuous line of Spodoptera frugiperda cells (Brown & 
Faulkner, 1977) was routinely used for the growth of 
wild-type and recombinant AcNPV.
6 Tissue Culture Media
BHK cells were grown in ETC^q , consisting of Glasgow- 
modified Eagle's medium (GMEM; Busby et al., 1964) 
supplied by Gibco Ltd, supplemented with 10% tryptose 
phosphate broth, 10% calf serum, 100 units/ml penicillin 
and 100 ug/ml streptomycin.
CV-1 and TK” cells were grown in Dulbecco's-modified 
Eagle's medium (MEM) supplied by Gibco Ltd, supplemented 
with 5% foetal calf serum, 4-mM L-glutamine, 100 units/ml 
penicillin and 100 ug/ml streptomycin. TK” cells were 
always grown in the presence of 25 ug/ml of BUdR, to 
prevent the outgrowth of TK+ reversion mutant cells.
S.frugiperda cells were grown in TC100/5 medium, which 
consisted of TC100 medium (Gibco) supplemented with 5% 
foetal calf serum, 100 units/ml penicillin and 100 ug/ml 
streptomycin.
7 Viruses
The wild-type HSV-1 virus was strain 17 syn+ (Brown et: 
al., 1973). The phosphonoacetic acid-resistant mutant
PAAr-l was derived from HSV-1 strain 17 syn+ (Hay & 
Subak-Sharpe, 1976); the mutation has been mapped within 
the DNA polymerase gene (Crumpacker et al., 1980). The
wild-type vaccinia virus was the Western Reserve strain 
(Parker et al., 1941). The wild-type baculovirus AcNPV 
was the MP strain of Autographa californica nuclear
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polyhedrosis virus (Hink & Vail, 1973). The recombinant 
baculovirus AcRP231acZ contains the lacZ gene (Possee & 
Howard, 1987).
8 Plasmids
pill contains the HSV-1 IE-3 gene under the control of 
the SV40 early promoter and enhancer (Everett, 1986).
pl75 contains the HSV-1 IE-3 gene under the control of 
the SV40 early promoter and enhancer (Everett, 1986).
pAcYMl is the baculovirus transfer vector described by 
Matsuura et al. (1987). This vector contains a section of 
the Autoqrapha californica nuclear polyhedrosis virus 
EcoRI fragment I with a BamHI cloning site 3f of the 
polyhedrin gene promoter.
pG35a consists of an HSV-1 BamHI k joint-spanning region 
containing two a_ sequences, cloned into the BamHI site of 
pATl53 (Twigg & Sherratt, 1980), and was constructed by 
Stow et al. (1983).
pgDCAT contains the promoter of the HSV-1 gene encoding 
gD (US6) fused to the CAT gene in the vector pBLW2 
(Everett, 1986; Gaffney et al., 1985).
pGX79 contains the HSV-1 DNA restriction fragment 
Hindlll W inserted into the Hindlll site of the vector 
pAT153 (Matz et al., 1983).
pGX128 contains the HSV-1 DNA restriction fragment K p n l  i_ 
in the vector pATl53, and was constructed by D a v i s o n  & 
Wilkie (1983). Kpnl i was inserted into the PstI site of 
pAT153 following addition of homopolymer tracts of 
deoxycytidine residues to the Kpnl fragment and 
deoxyguanosine residues to the PstI fragment.
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pGX142 contains the HSV-1 DNA restriction fragment Kpnl t 
in the vector pAT153, and was constructed by Davison & 
Wilkie (1983) in the same manner as pGX128.
pGX237 contains a truncated HSV-1 UL26 gene ORF in the 
vector pFJIO (Rixon & McLauchlan, 1990), and was 
constructed by Preston et al. (1992). It is described
further in the Results.
pGX239 contains the HSV-1 UL26.5 gene ORF in the vector 
pFJIO, and was constructed by Preston et al. (1992). It
is described further in the Results.
pMJ601 and pMJ602 are the vaccinia transfer vectors 
constructed by Davison & Moss (1990), and are described 
further in the Results.
pUC18 and pUC19 are the cloning vectors described by 
Vieira & Messing (1982) and Norrander et al. (1983), and 
were supplied by Bethesda Research Laboratories.
9 Antibodies
1060 is a monoclonal antibody against the HSV-1 capsid
protein VP23, the product of UL18. It was produced by 
Dr J .Palfreyman, and initially characterised by 
Dr A.M.Cross. Further characterisation is reported in 
this thesis.
5010 is a monoclonal antibody against the HSV-1 capsid
protein VP22a, the product of UL26.5, and was produced
and characterised by Dr A.M.Cross (Rixon et al., 1988).
10555 is a rabbit antiserum raised against HSV-1 strain 
17-infected Rabbit Kidney cells (personal communication, 
Dr H.S.Marsden).
The goat anti-mouse antibody used in the immuno­
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fluorescence experiments was an anti-mouse IgG (Southern 
Biotechnology), and was the kind gift of Dr I.Sommer. The 
goat anti-rabbit antibody was an anti-rabbit IgG 
(Jackson), and was the kind gift of Dr I.Sommer.
10 Bacterial Strains
All plasmids used in this study were propagated in 
Es-cherichia coli K12 strain DH5CC (F“, endAl, hsdR17, 
supE44, thi-1, recA, gyrA96, relAl, del(argF- 
lac zya)U169, <p80dlacZ M15) (Hanahan, 1983). Library- 
efficiency E.coli DH5d competent cells were supplied by 
Bethesda Research Laboratories.
11 Bacterial Culture Media
L Broth 10 g/1 NaCl, 10 g/1 bactopeptone and 5 g/1
yeast extract.
L Broth Agar L Broth plus 1.5% w/v agar
Ampicillin, where appropriate, was added to L Broth or 
L Broth Agar at 50 ug/ml.
12 Commonly Used Solutions
EEB 10-mM NaAc, 2-mM EDTA, 80-mM Tris pH7.8
Fix methanol: H20:acetic acid, 50:50:7
5x gel loading buffer: 5x TBE, 50% glycerol,
bromophenol blue, xylene cyanol.
2x HeBs: 260-mM NaCl, 9.8-mM KC1, 1.6-mM Na2HP04, 11-
mM D-glucose, 42-mM HEPES.
PBS A : 170-mM NaCl, 3.4-mM KC1, 10-mM Na2HP04, 2-mM
KH2P04, (pH7.2).
PBS: PBS A plus CaCl2.H20 and MgCl2.6H20 both at
1 g/i.
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SDS-PAGE buffers: 
boiling mix
sample buffer 
4x RGB 
4x SGB 
tank buffer 
Solution 1 
Solution 2 
Solution 3 
TBE:
TE:
Trypsin:
Versene:
30% SGB, 30& glycerol, 15% 2ME, 6% 
SDS, 0.03% bromophenol blue, 
one-third dilution of boiling mix. 
1.5-M Tris pH8.9, 0.4% SDS.
0.488-M Tris pH6.7, 0.4% SDS.
52-mM Tris, 53-mM glycine, 0.1% SDS. 
50-mM glucose, 10-mM EDTA, 25-mM Tris pH8.0. 
0.2-M NaOH, 1% w/v SDS.
3-M KAc, 2-M acetic acid.
125-mM Tris, 40-mM Boric Acid, 2.7-mM EDTA, 
not pH'd.
10-mM Tris HC1, 1-mM EDTA, pH8.0.
0.25% w/v trypsin dissolved in tris-saline.
0.6-mM EDTA dissolved in PBSA containing 
0.0002% phenol red.
2B METHODS
2B.1 Construction and Preparation of Plasmids
1.1 Restriction Enzyme Digests
Diagnostic restriction enzyme digests were generally 
carried out in 20-ul volumes of the appropriate buffer as 
specified by the manufacturers. The number of units of 
enzyme added was dependent on the activity of the enzyme 
and the amount of DNA being digested. Reaction mixtures 
were generally incubated at 37°C for 1 h. Preparative 
restriction enzyme digestions used increased amounts of 
DNA and enzyme under similar conditions in 100-ul 
volumes.
1>2 Separation of DNA Fragments by Non-Denaturing Gel 
Electrophoresis
200-ml horizontal slab gels (260mm x 160mm x 5mm) 
containing 0.8% (w/v) agarose were electrophoresed
submerged in lx TBE plus 0.5 ug/ml ethidium bromide at up
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to 12 V/cm. Samples were loaded in 0.2 volumes of 5x gel 
loading buffer. DNA was examined and photographed with 
short-wave u.v. transillumination. Long wave u.v. was 
used to reduce DNA damage when preparative gels were 
being examined. 50-ml agarose gels (100mm x 70mm x 7mm) 
were used for analysis of mini-prep DNA. These gels were 
electrophoresed in TBE at 100 V for approximately 1 h.
1.3 Purification of DNA Fragments from Gels
An agarose slice containing the required DNA fragment was 
removed from the gel and placed in dialysis tubing. The 
DNA was electroeluted from the agarose in lx EEB at 50 V 
for 1 h. The EEB containing the DNA was removed from the 
dialysis tubing, extracted with phenol/chloroform and 
precipitated with 2 volumes of ethanol at -20°C for 1 h.
1.4 Purification of Synthetic Oligonucleotides
The 16-mer oligonucleotides A and B, used in the cloning 
of UL19, were purified using Oligonucleotide Purification 
Cartridges (Applied Biosystems), according to the 
manufacturer's instructions. The 60-mer oligonucleotides 
C and D, also used in the cloning of UL19, were purified 
in the following manner. The DNA was eluted from the 
synthesiser in 1 ml of ammonia. Following incubation at 
55°C for 5 h, the ammonia was removed by evaporation on a 
rotary drier. The DNA was resuspended in 50 ul of 1^0 and 
half removed to a fresh tube and stored at -20°C. The 
remainder was mixed with an equal volume of 90% formamide 
in lx TBE then boiled for 5 min and loaded onto a 
denaturing 15% polyacrylamide gel
(acrylamiderbisacrylamide, 24:1) containing 8-M urea 
(this concentration of gel was suitable for the 
purification of 15-100-mer oligonucleotides). Formamide 
dye mix (2 ul) was loaded into wells adjacent to those 
containing the oligonucleotide sample as a migration
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marker and the gel electrophoresed in lx TBE at 300 V for 
4 h, until the bromophenol blue had almost reached the 
bottom of the gel. The gel was then transferred onto 
clingfilm and the DNA viewed over a silica gel thin-layer 
chromatography plate with an angled short-wave u.v. lamp. 
The DNA in the gel absorbed u.v. light thus casting a 
shadow on the fluorescent chromatography plate. The 
required band was excised and the DNA eluted into 0.5 ml 
of elution buffer (0.5-M NH40Ac, 10-mM MgCl2, 0.1% SDS 
and 1-mM EDTA) overnight at 37°C with constant agitation. 
The DNA solution was sequentially extracted with 
phenol/chloroform (1:1) and and chloroform, then ethanol 
precipitated. The DNA was pellet-ed, dried, resuspended 
in H90, and its concentration measured by
^ n
(OD26o 1,0 = 20 u9 single-stranded
DNA/ml.
1.5 DNA Ligation
DNA ligations were performed in 20 ul lx ligase buffer, 
with 0.5-mM ATP, 50-500 ng DNA and 1 unit of T4 DNA 
ligase, at 15°C for 2 h. To prevent self-annealing of the 
vector, it was usually treated with calf intestinal 
phosphatase during the restriction enzyme digestion. 
Staggered-cut termini of DNA fragments which required to 
be converted to blunt ends were treated with T4 DNA 
polymerase. Reactions contained 0.5 to 1.0 ug DNA, 33-mM 
Tris HC1 (pH7.8), 66-mM potassium acetate, 10-mM
magnesium acetate, 100 ug/ml BSA, 222-uM dCTP, dGTP, 
dATP, dTTP plus 4 units of T4 polymerase, and were 
incubated at 15°C for 3 h. Phosphorylated oligonucleotide 
linkers were inserted into plasmids by ligation with 
linear molecules using the same procedure as for 
vector/fragment ligations. A 50-fold molar excess of 
linker over plasmid DNA was used.
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1.6 Transformation of Competent E.coli
1 ug of ligation mix was added to 20 ul of competent 
DH5<X cells and incubated on ice for 30 min. The mixture 
was then heat-shocked at 42°C for 40 s and added to 80 ul 
of SOC medium (2%bactopeptone, 0.5% yeast extract, 10-mM 
NaCl, 2.5-mM KC1, 10-mM MgCl2, 10-mM MgS04, 20-mM 
glucose). Cultures were agitated at 37°C for 1 h, and 
then spread on L Broth Agar plates containing ampicillin. 
Plates were incubated overnight.
1.7 Mini-Prep Analysis of Transformed E.coli Colonies
Mini-prep DNA was prepared by the alkaline lysis 
procedure. Colonies were picked from agar plates into 
10 ml of L Broth containing ampicillin and shaken at 37°C 
overnight. The following day, cells from 1.5 ml of the 
culture were pellet-ed at 5,000 r.p.m. for 1 min in a
benchtop microfuge. The pellet was resuspended in 100 ul 
of solution 1 containing lysozyme and incubated at RT for 
5 min. 200 ul of Solution 2 was added, and after
vortexing, the sample was incubated on ice for 10 min. 
150 ul of Solution 3 was added, and after vortexing, the 
sample was incubated on ice for a further 10 min. This 
mixture was centrifuged at 13,000 r.p.m. in an MSE Micro 
Centaur benchtop centrifuge for 5 min, and the pellet
discarded. The supernatant was precipitated with an equal 
volume of isopropanol at -20°C for 20 min. After
centrifugation at 13,000 r.p.m. for 5 min, the pellet was 
washed in ethanol, dried, and resuspended in 50 ul of 
H20. Mini-prep DNA was stored at -20°C and 5 ul was used 
for restriction enzyme analysis. 0.2 ul of 1 mg/ml RNase 
was added to digestions of mini-prep DNA.
1.8 Large-Scale Preparation of Plasmid DNA 
Transformed bacteria were picked and inoculated into
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10 ml of L Broth plus ampicillin and incubated at 37°C 
overnight. 0.5 ml of this culture was used to inoculate 
300 ml of L Broth plus ampicillin, and the culture was 
shaken at 37°C overnight. The culture was then pelleted 
by centrifugation at 7,000 r.p.m. for 10 min in a Sorvall 
RC-5B centrifuge (GS3 rotor). After decanting the 
supernatant, the pellet was resuspended in 7.5 ml of 
Solution 1 containing 1 mg/ml of lysozyme, and incubated 
at RT for 5 min. Then 14 ml of Solution 2 was added, and 
the sample was vortexed and incubated on ice for 10 min. 
15 ml of Solution 3 was added, and the sample was left on 
ice for a further 10 min. The sample was then centrifuged 
at 17,000 r.p.m. for 30 min in a Sorvall RC-5B centrifuge 
(SS34) rotor to pellet the cell debris and cellular DNA. 
The supernatant containing the plasmid DNA was 
precipitated with an equal volume of isopropanol at 
-20°C. DNA was pelleted by centrifugation at 3,000 r.p.m. 
for 15 min in a Sorvall RT6000B benchtop centrifuge, 
washed in ethanol, dried, and resuspended in a total 
volume of 1 ml of H20.
The DNA solution was prepared for caesium banding by 
dissolving 1.15 g of CsCl and adding 50 ul of 10 mg/ml 
EtBr per ml of DNA solution. This was transferred to a 
Beckman TLV-100 ultracentrifuge tube and topped up with 
stock solution containing similar amounts of CsCl and 
EtBr. The tube was heat-sealed and centrifuged for 4 h at
100,000 r.p.m. at 20°C in a Beckman TL100 ultra­
centrifuge. DNA was visualised by daylight or long-wave 
u.v. transilluminator and the lower supercoiled plasmid 
DNA recovered with a large bore needle and syringe. The 
DNA was extracted three times with isopropanol 
equilibrated with saturated CsCl solution to remove EtBr, 
diluted three fold with H20, and precipitated with 
ethanol. Once resuspended in TE, the DNA was treated with 
50 ug RNase (1 h at 65°C) before extraction with 
phenol/chloroform and ethanol precipitation. The DNA was 
lyophilised, resuspended in H20 and its concentration
0
determined by spectrophot^ietry (OD260 i #q = 50ug DNA/ml).
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pBJl96 DNA was sequenced by the dideoxy chain termination 
method (Sanger At— suL. , 1977), using the Pharmacia T7
sequencing kit consisting of dideoxy sequencing reactions 
using T7 DNA polymerase. This was carried out according 
to the manufacturer's instructions.
The products of sequencing of pBJ196 were resolved on a
TM
6% denaturing polyacrylamide gel prepared from Sequagel 
(National Diagnostics) sequencing gel solutions,
according to the manufacturer's instructions. This
solution was poured into a mould (230mm x 450mm x
0.35mm), and, after polymerisation, was prerun at 40 W
for 30 min prior to loading of samples. Electrophoresis
was performed in 0.5x TBE at 40 W for approximately 2 h.
2B.2 Growth and Titration of Virus Stocks
2.1 Tissue Culture
o
BHK cells were routinely passaged m  850-cm^ plastic 
roller bottles seeded with approximately 2 x 10' cells at 
37°C in 100 ml ETC-^ q and an atmosphere of 5% CO2 in air. 
Confluent monolayers were harvested in 20 ml ETC-^ q after 
two versene washes and brief trypsinisation with 
trypsin/versene (1:4). Cells were resuspended and 
remained viable for at least 5 days stored at 4°C.
9
CV-1 cells were routinely passaged in 150-cm plastic 
tissue culture flasks at 37°C in an atmosphere of 5% CO2 
in air. Monolayers could be maintained at 31 °C for up to 
one week. Confluent monolayers were harvested in 10 ml 
MEM after two versene washes and trypsinisation with 
trypsin/versene. Cells were resuspended and remained 
viable for at least 5 days stored at 4°C.
TK cells were routinely passaged every 2-3 days in 150-
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cm flasks at 37°C in an atmosphere of 5% C02 in air. 
These cells did not survive at 31°C. Confluent monolayers 
were harvested in 10 ml MEM after two versene washes and 
a very brief trypsinisation with trypsin/versene. Cells 
did not survive at 4°C.
S.frugiperda cells were routinely passaged every 2-3 days 
in 150-cm^ tissue culture flasks in TC100/5 at 28°C in 
air. Confluent monolayers were dislodged by vigorous 
shaking into 10 ml of TC100/5. When stored at 4°C cells 
remained viable for at least 24 h.
2.2 Preparation of Stocks of Infectious Virus
Stocks of wild-type and mutant HSV-1 were prepared using
80%-confluent monolayers of BHK cells. These were seeded 
4with 4 x 10 p.f.u. of virus per 850-cm^ roller bottle in 
40 ml ETC^q (a m.o.i. of 0.002 p.f.u./cell) and incubated 
for 4-5 days at 31°C until the cells exhibited obvious 
c.p.e. (31°C rather than 37°C was found to be better for 
growth of high-titre viral stocks). The cells were shaken 
into medium and pelleted at 1,000 r.p.m. for 5 min at 4°C 
using a Sorvall RT6000B benchtop centrifuge. Cell- 
associated virus (CAV) was prepared by sonicating the 
pellet in 2 ml ETC-^q . Cell-released virus (CRV) was
pelleted from the supernatant at 9,000 r.p.m. for 2 h at 
4°C using a Sorvall RC-5B centrifuge (GS-3 rotor), gently 
resuspended in 2 ml ETC-^ q and sonicated. Stocks were 
stored at -70°C.
Stocks of wild-type and recombinant vaccinia virus were 
prepared using confluent monolayers of CV-1 cells in 
150-cm^ flasks. These were seeded at a m.o.i. of 0.01 in 
50 ml of MEM. After approximately 5 days of incubation at 
37°C, the cells were shaken into the medium and
centrifuged at 1,000 r.p.m. for 5 min at 4°C. The pellet
was resuspended in 1 ml of MEM and stored at -20°C.
Stocks of vaccinia virus were sonicated before use.
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Stocks of wild-type and recombinant AcNPV were propagated 
in S.fruqiperda cells. Monolayers in 150-cm2 tissue 
culture flasks were infected at a m.o.i. of 4 p.f.u. per 
cell, incubated at RT for 1 h and then overlaid with 
30 ml of TC100/5 and incubated at 28°C for 2-4 days until 
the cells exhibited an obvious c.p.e. The cells were 
shaken into the medium and pelleted at 1,000 r.p.m. for 
10 min at 4°C. CRV in the supernatant was aliquoted and 
stored at -70°C.
2.3 Titration of Virus Stocks
Stocks of wild-type and mutant HSV-1 were titrated on BHK 
cell monolayers in 50-mm plates. Cells were infected with 
serial 10-fold dilutions of virus in 0.1 ml of PBS/10% 
newborn calf serum. After absorption for 1 h, plates were 
overlaid with 4 ml 0.6% Noble agar medium (100 ml 1.3x 
Eagle's A, 20 ml Eagle's B without phenol red, 30 ml 3.2% 
Noble agar, 5 ml newborn calf serum) to prevent secondary 
plaque formation, and incubated for 2-3 days at 37°C 
prior to fixing with Cidex (2.5% glutaraldehyde) and 
staining with Giemsa stain. The plates were washed after 
15 min and plaques counted using a plate microscope.
Stocks of wild-type and recombinant vaccinia virus were 
titrated on CV-1 cell monolayers in 35-mm plates. After 
removal of growth medium these were inoculated with 10- 
fold serial dilutions of virus in MEM and incubated at 
37°C for 1 h. The inoculum was removed and the cells 
overlaid with 2 ml of MEM-PR (MEM lacking phenol red and 
containing 1% (w/v) low-melting point agarose). After the 
agarose had set, the cells were incubated at 37°C for 2-3 
days and then fixed with Cidex and stained with Giemsa 
stain. Plaques were counted by eye.
Stocks of wild-type and recombinant AcNPV were titrated 
on S.frugiperda cell monolayers in 35-mm plates. After 
removal of growth medium these were inoculated with 10-
83
fold serial dilutions of virus in TC100/5 and incubated 
at RT for 1 h. The inoculum was removed and the cells 
overlaid with 2 ml of a warm (37°C) mixture containing 
equal volumes of 3% molten low-melting point agarose 
(Sea-Plaque) and TC100/5, followed (when set) by 1 ml of 
liquid TC100/5• The infected cells were incubated at 28°C 
for 3-4 days and then stained for 24 h with 0.5 ml of a 
solution of 1 part 0.4% Neutral Red plus 24 parts 
TC100/5. Plaques were counted by eye.
2B.3 Growth, Labelling and Purification of HSV Particles 
3.1 Virions
Virions were labelled and purified essentially by the 
method of Szilagyi & Cunningham (1991). Monolayers of BHK 
cells in roller bottles were infected with HSV-1 strain 
17 at a m.o.i. of 1 p.f.u./10^ cells and incubated at 
31°C for 3 days. The growth medium was replaced with 
40 ml of fresh medium, and incubation continued for a 
further 48 h. To label the viral proteins, 26 MBq of ^S- 
methionine was added per bottle 7 h after the medium was 
changed. Once the cells exhibited obvious c.p.e., they 
were shaken into the medium, and pelleted by low-speed 
centrifugation (1,000 g for 10 min at 4°C), and the virus 
particles in the clarified medium were pelleted by 
centrifugation at 23,000 g for 2 h at 4°C. The pellet was 
then gently resuspended in 1 ml of modified medium 
(culture medium without phenol red or calf serum) and 
layered onto a 35-ml preformed gradient of 5 to 15% 
Ficoll 400 (Sigma) suspended in this medium. After 
centrifugation in a swing-out rotor (26,000 g for 2 h at 
4°C in an AH627 cellulose nitrate tube), the lower 
particle band was withdrawn by side puncture. These 
virions were pelleted by centrifugation (80,000 r.p.m. 
for 2 h at 4°C in an AH627 tube), gently resuspended in 
200 ul of modified medium and either used immediately or 
stored at -70°C.
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3.2 Capsids
HSV-1 intranuclear capsids were purified essentially 
according to the method of Irmiere & Gibson (1985) and 
Rixon et al. (1990). Cells were infected and labelled as 
described above for virions. When cells exhibited obvious 
c.p.e., they were shaken into the medium and collected by 
low-speed centrifugation (1,000 r.p.m. for 10 min at 4°C 
in a Sorvall RT6000B centrifuge). This cell pellet was 
fractionated in 10 ml of 0.5% NP40 in PBS for 5 min at 
4°C. Nuclei were recovered by centrifugation at
1.000 r.p.m. for 10 min at 4°C. The nuclear pellet was 
subjected to three cycles of freezing on solid C02 and 
thawing at 37°C with vortexing. Nuclear debris was 
pelleted and the supernatant subjected to centrifugation 
through a 10 to 40% (w/w) sucrose gradient (Gibson & 
Roizman, 1972) in a Sorvall TST41 swing-out rotor at
38.000 r.p.m. for 20 min. This usually resolved two bands 
of capsids (see Figure 5). The gradient was then either 
separated into sequential fractions and samples of each 
fraction subjected to PAGE analysis (see Figure 7), or 
the two bands of capsids were removed by side puncture 
and pelleted by centrifugation at 70,000 r.p.m. for 
30 min in a TLA100 rotor. The pellet was resuspended in 
1 ml of PBS and recentrifuged. This pellet was 
resuspended in 0.5 ml PBS. Capsid preparations were 
stored at -20°C.
2B.4 PAGE Analysis of Viral Proteins
SDS-PAGE was performed essentially as described by 
Marsden et al. (1976). Stock solutions of 30% acrylamide 
with 5% or 2.5% bisacrylamide were prepared in H20. 1.5- 
nun thick gels were prepared in vertical glass plate 
sandwiches. For single concentration gels, a resolving 
9®1 of acrylamide with bisacrylamide cross-linker was 
prepared in lx RGB, having a ratio of acrylamiderbisacry- 
lamide of 39:1, on top of which was polymerised a
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stacking gel of 5% acrylamide in lx SGB. Some gels 
contained DATD as cross-linker, in a ratio of 
acrylamide:DATD of 57:1. The 5-12% gradient gel used to 
produce Figure 7 contained bisacrylamide as cross-linker, 
in a ratio of acrylamide:bisacrylamide of 19:1.
Protein samples were boiled for 5 min in sample buffer, 
immediately loaded onto the gel and electrophoresed in 
tank buffer at 10 mA overnight. Gels were fixed by 
shaking for 45 min in Fix, and dried at 80°C under vacuum 
onto Whatman filter paper. Dried gels were exposed to 
autoradiographic film at -70°C. The gel shown in Figure 
43 was stained with a solution of 0.2% Coomassie 
brilliant blue in methanol:water:acetic acid (50:50:7) 
for 1 h, washed for several hours in a solution of 
methanol:water:acetic acid (500:8800:140), and dried at 
80°C under vacuum onto Whatman filter paper.
2B.5 Generation of recombinant vaccinia viruses
This was performed essentially as described by Davison 
and Moss (1989). Approximately 1 ug of plasmid DNA was 
resuspended in 100 ul of Hepes-buffered saline (0.14-M 
NaCl, 5-mM KC1, 1-mM Na2HP0/|. 21^0, 0.1% w/v glucose,
20-mM Hepes pH 7.05). Carrier DNA was not used. 5 ul of 2 
M-CaCl2 were added, and the mixture was incubated at RT 
for 30 min. This suspension was added to a 17-mm well 
containing a drained confluent monolayer of CV-1 cells 
that had been infected 2 h previously with vaccinia virus 
at a multiplicity of 0.05. After 30 min at RT, the 
monolayer was overlaid with 1 ml of MEM, and was 
incubated at 37°C for 3.5 h. The medium was aspirated, 
overlaid with 0.5 ml of fresh MEM and incubated at 37°C 
for 2 days. Infected cells were scraped into the medium, 
placed in vials, and disrupted by sonication. Recombinant 
viruses, containing lacZ inserted into the TK gene, were 
plaque-purified thrice on 30-mm dishes containing 
confluent monolayers of TK cells as follows. After
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absorbing 0.1 ml of appropriate dilutions of virus for 
1 h, the inoculum was aspirated and monolayers were 
overlaid with 2 ml of MEM-PR (MEM lacking phenol red and 
containing 1% w/v low melting point agarose) containing 
25 ug BUdR/ml. After allowing the agarose to set at 4°C, 
the dishes were incubated at 37°C for 2 days. The dishes 
were then overlaid with 1 ml MEM-PR containing 0.3 mg X- 
gal/ml, and incubated overnight at 37°C. Well-separated 
blue plaques were picked and sonicated in 0.5 ml of 
medium before the next round of plaque purification. A 
purified plaque of each recombinant was used to infect a
o _
25-cm^ flask of TK cells in the presence of 25 ug 
BUdR/ml. After incubation at 37°C for 2 days, infected 
cells were scraped, pelleted and sonicated in 0.5 ml of 
MEM. A 150-cm^ flask of CV-1 cells was then infected with 
a 0.25-ml inoculum and incubated at 37°C for 3 days. The 
cells were scraped, pellet-ed and sonicated in 0.5 ml of 
MEM, and the resulting virus stock was stored at -20°C.
2B.6 Preparation of Infected-Cell Extracts
Whole-cell extracts of recombinant-vaccinia- and HSV-1- 
infected cells were prepared in the following manner. 
17-mm wells containing monolayers of CV-1 or BHK cells 
were infected with 5 p.f.u. per cell of virus in 100 ul 
of MEM. Following a 1 h period of adsorption at 37°C, the 
inoculum was removed and replaced with 1 ml of MEM. 
Following a further period of incubation of 2 h, the 
medium was removed and replaced with 0.5 ml of MEM 
containing 1/5 the normal level of methionine and 
supplemented with 20 uCi per ml of ^^S-methionine. The 
cells were incubated at 37°C for a further 21 h. At 24 h 
p.i. the medium was removed and replaced with 200 ul of 
extraction buffer (0.1-M Tris pH8, 10% v/v glycerol, 0.5% 
NP40, 0.5% sodium deoxycholate, 0.2-mM PMSF [Showalter et 
al., 1981]), and incubation was continued at 4°C for 1 h. 
The sample was then removed into a 1.5-ml reaction vial 
and stored at -20°C until use.
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2B.7 Immunoprecipitation
Infected-cell extracts were prepared as in section 2B.6. 
These were clarified by centrifugation at 7,000 r.p.m. 
for 5 min at 4°C. 50 ul of antibody (a 1/50 dilution of 
1060 or 5010, or a 1/100 dilution of ascitic fluid), 
20 ul of infected-cell extract and 10 ul of rabbit anti­
mouse Ig were incubated overnight at 4°C. Antigen-
antibody complexes were precipitated by the addition of 
100 ul of a 10% suspension of heat-killed formalin-fixed 
Staphylococcus aureus (gifted by Dr A.M.Cross) and
further incubated for 1 h at 4°C. After centrifugation of 
the mixture at 14,000 r.p.m. for 10 min, the pellet was 
resuspended and washed three times by centrifugation in 
buffer containing 0.15-M NaCl, 0.1-M Tris pH7.4, and 
0.25% NP40. Bound antigen was released by treatment with 
0.2-M glycine pH2.5 for 30 min at 4°C. The bacteria were 
removed by centrifugation at 1,400 r.p.m. and
supernatants were analysed by SDS-PAGE.
2B.8 Cell Fractionation
For the preparation of cytoplasmic and nuclear fractions 
a method based on that of Piette et al. (1985) was
employed. CV-1 cells grown in 30-mm dishes were infected 
at a m.o.i. of 5 p.f.u./cell and incubated from 1 - 18 h 
post-infection in one-tenth methionine MEM containing 
50 uCi ^^S-methionine/ml. Cells were washed in cold 
phoshate-buffered saline (PBS), scraped into 1 ml of 
fresh PBS, centrifuged at 2000 r.p.m. for 5 min at 4°C, 
and resuspended in 500 ul lysis buffer (10-mM Hepes pH8, 
50-mM NaCl, 0.5-M sucrose, 1-mM EDTA, 0.5% Triton X-100,
1-mM PMSF and 7-mM 2ME) • Following 10 strokes with a 
Dounce homogeniser, on ice, the nuclear fraction was 
collected by centrifugation at 3000 rpm for 10 min at 4°C 
and resuspended in 25 ul of lysis buffer; the supernatant 
was retained as the cytoplasmic fraction.
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2B.9 Immunofluorescence
Cells grown on 13-mm cover slips were infected with virus 
or transfected with plasmid DNA. Following fixation in 
cold methanol at -20°C for 10 min, they were washed in 
staining solution (Hank's balanced salts solution plus 
4.76 g/1 HEPES, Sigma H-3375, 5.2g/l HEPES, Sigma H-7006, 
4% v/v newborn calf serum and 0.05% Sodium Azide). 
Antibody (50 ul), diluted in staining solution, was 
placed on each cover slip, and incubated at room 
temperature for 30 min. The cover slip was then rinsed 
three times in fresh staining solution before incubation 
with the FITC-conjugated goat anti-mouse secondary 
antibody for 30 min at room temperature. The cells were 
again fixed in cold methanol and examined under UV 
illumination.
2B.10 Transfection of plasmid DNA
The method followed was essentially that of Shen et al. 
(1982). DNAs to be transfected (1 ug each of pill, pl75 
and pBJ182 or pGDCAT) were resuspended in 57 ul H20 and 
66 ul 2X HEBS (N-2-hydroxyethylpiperazine-N1 -2-
ethanesulphonic acid, 35-mM; NaCl, 273-mM; KC1, 10-mM; 
Na2HPC>4 , 1.4-mM; D-glucose,> 11-mM; pH 7.05); 9 ul 2-M
CaCl2 was added, and the DNA was allowed to precipitate 
for 30 min at room temperature. 30-mm dishes containing 
75%-confluent monolayers of BHK cells growing on 13-mm 
glass coverslips were aspirated,' the Calcium-DNA 
coprecipitate was added to the monolayer, and incubated 
with occasional rocking at 37°C. After 45 min, 2 ml of 
plating medium (20 ml of medium from the original cell 
cultures to be transfected plus 17.75 ml of fresh growth 
medium, 2.0 ml of 2X HEBS, and 0.25 ml of 2-M CaCl2) was 
added to the monolayers, and incubation continued at 
37°C. At 3 to 4 h after plating, the medium was 
aspirated, and the cells were washed with 2 ml of fresh 
plating medium. 1 ml of 25% DMSO in IX HEBS was added,
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and the plates incubated for 4 min with occasional 
rocking. The DMSO was removed, and the cells were washed 
twice with 2 ml of plating medium and incubated in 2 ml 
of plating medium at 38.5°C, for a further 68h.
2B.11 Electron Microscopy
Cells were harvested by scraping into PBS. Duplicate 
samples were pelleted into BEEM capsules (Agar Aids) and 
fixed for 1 h with 2.5% glutaraldehyde in PBS. Samples 
were then embedded in either Epon 812 resin (Agar Aids) 
for morphological examination, or in Lowicryl K4M (TAAB 
Laboratories) for immunolocalisation studies. Samples for 
Epon embedding were post-fixed for 1 h with 1% OsO^ and 
washed in PBS before being dehydrated through a series of 
increasing ethanol concentrations (30%, 50%, 70%, 90% v/v 
in PBS, then two changes in 100% ethanol). The pellets 
were then infiltrated with 50% v/v Epon resin in ethanol, 
followed by two changes of Epon resin alone. The pellet, 
embedded in the final change of Epon resin, was incubated 
at 65°C for three days to polymerise the resin.
Samples for Lowicryl embedding were dehydrated through a 
graded ethanol series without OsO^ post-fixation. The 
samples were placed in 30% ethanol at 4°C for 30 min,' 
then in 50% ethanol for 60 min, and shifted to -20°C. All 
subsequent dehydration and infiltration steps were 
performed at -20°C. The samples were placed sequentially 
in 70%, 90% and 100% ethanol for 1-h periods and
infiltrated with Lowicryl K4M resin by 1-h exposures to a 
1:1 mixture of resin and ethanol followed by two changes 
of pure resin. Polymerisation was performed using a 360- 
nm wavelength u.v. lamp (Taab Laboratories) for 24 h at - 
20°C and a further two days at RT.
Pelleted and embedded cells were cut with a diamond knife 
on an ultra-microtome (Ultracut E, Reichart-Jung), and 
thin sections were collected on parlodion—coated copper
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grids (Epon sections) or uncoated nickel grids (Lowicryl 
sections). Epon-embedded sections were stained with 
saturated uranyl acetate in 50% v/v ethanol for 1 h, 
rinsed with deionised H2 O and counter-stained with lead 
citrate for 1 h. Sections were examined using a JEOL 100S 
electron microscope.
2B.12 Electron Microscopic Immunolocalisation
All procedures were carried out at RT. Grids containing 
sections of Lowicryl-embedded cells were submerged 
briefly in PBS containing 0.05% Tween 20. This solution 
was also used for all antibody dilutions and for washing 
the sections after treatment with antibody. The sections 
were transferred into a 1/50 dilution of 5010 for 45 min, 
then jet-washed and placed into a 1/50 dilution of a goat 
anti-mouse antibody tagged with 10-nm gold particles 
(Janssen Life Sciences). After a further 45 min, they 
were jet-washed, rinsed in distilled H20 and dried. 
Contrast was enhanced by exposing sections to 0s04 vapour 
for 1 h.
2B.13 Western Blotting
Western blotting was essentially by the method described 
by Towbin et al. (1979). Proteins were separated on a 9%
SDS-polyacrylamide gel and transferred to a 
nitrocellulose filter using a Bio-Rad Trans-Blot 
apparatus. VP23 immobilised on the nitrocellulose was 
detected by incubating the filter for 1 h at 37°C in a 
1/100 dilution of 1060. Bound antibody was detected using 
the Promega Protoblot horseradish peroxidase system. This 
employs an anti-mouse immunoglobulin-horseradish 
peroxidase conjugate and a 4 chloro-1 napthol substrate 
to develop a deep purple colour where bound antibody is 
detected. The manufacturer's instructions were followed 
closely.
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2B.14 Labelling of DNA by Nick Translation
This was performed using 32P as described by Rigby et al. 
(1977). 1.0 ug of pG35a DNA was incubated in a reaction
mix containing 40-mM dATP, 40-mM dTTP, 2.5 ul of lOx nick 
translation buffer (5-M Tris HC1 pH7.5, 1-M MgCl2, 1-M
DTT, 5 mg/ml BSA) and 2 x 10“^ ug DNase at RT for 3 min.
The mix was placed on ice and diluted to 25 ul by the 
addition of 30 uCi of both alpha-32P-dCTP and alpha-32P- 
dGTP, 3 units of E.coli DNA polymerase I plus distilled 
water. The reaction was incubated at 15°C for 1 h. 32p- 
labelled DNA was then separated from unincorporated 
triphosphates by running through a 10-ml medium Sephadex 
G50 column in a 10-ml pipette plugged with siliconised 
glass wool. Columns were loaded with the sample with 
bromophenol blue dye, and the fastest-eluting fractions 
taken as purified DNA.
2B.15 Southwestern Assay of DNA-binding
Samples containing proteins to be analysed for DNA- 
binding ability were separated by SDS-PAGE on a 10.5% 
polyacrylamide slab gel cross-linked with DATD. These 
proteins were electrophoretically transferred to a 
nitrocellulose filter using a Bio-Rad Trans-Blot 
apparatus. The nitrocellulose filter was then processed 
for binding potential by pretreating in binding buffer 
(10-mM Tris pH7.2, 50-mM NaCl, 1-mM EDTA, 0.2%
polyvinylpyrrolidone, 0.2% Ficoll, 0.2% BSA [Russell & 
Precious, 1982]) containing 2.5% NP40 detergent, by 
shaking for 1 h on a moving stage in a closed plastic 
box. The detergent was removed by washing the sheet in 
several changes of binding buffer followed by overnight 
incubation at RT. The filter was then immersed in 10 ml 
of binding buffer containing nick-translated pG35a DNA at 
a level of 100,000 c.p.m./ml, and was incubated at RT for 
2 h with shaking. Excess label was removed by washing 
twice for 30 min in binding buffer. The filter was then
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dried and exposed to film for autoradiography.
2B.16 Electrophoresis Under Nonreducing and Reducing 
Conditions
16.1 Electrophoresis in Cylindrical Gels
Samples of CV-1 cells coinfected with VMJ535 and vMJ534 
were electrophoresed in cylindrical gels under non­
reducing conditions, according to the method of Zweig et 
al. (1979a). The gel medium consisted of 2.5% acrylamide, 
0.938% bisacrylamide, 0.5% agarose, 0.2% SDS, 40-mM Tris 
pH7.4,' 20-mM sodium acetate and 2-mM EDTA. Gels were cast 
in 6-cm glass tubes with a 2-mm bore, using solutions 
prewarmed to 40°C (Liu et al.,’ 1977). Electrophoresis was 
conducted in an apparatus specially constructed for this 
purpose, in electrolyte buffer consisting of 0.2% SDS, 
40-mM Tris pH7.4, 20-mM sodium acetate and 2-mM EDTA. The 
sample buffer consisted of 2% SDS, 10% glycerol, 40-mM 
Tris pH7.4, 20-mM sodium acetate, 2-mM EDTA and 0.005%
bromophenol blue. The sample buffer contained no reducing 
agent, and samples were not boiled before 
electrophoresis.
16.2 Two-Dimensional Electrophoresis
Electrophoresis was conducted in a cylindrical gel as 
described above. The gel was then incubated in an 
equilibration buffer containing 0.1% SDS, 0.0625-M Tris 
pH6.8, 2-mM EDTA, 10% glycerol, 0.005% bromophenol blue 
and 40-mM 2ME for 10 min at 100°C. The gel was then laid 
across the top of the stacking gel of a 9% polyacrylamide 
slab gel. The slab gel was between two glass plates, one 
having a bevelled edge to accomodate the cylindrical gel. 
The cylindrical gel was sealed in place using a melted 
agarose solution. Following electrophoresis, the slab gel 
was prepared for autoradiography as described previously.
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2B.17 Expression of VP5 in a Recombinant Baculovirus
In order to assess the expression of VP 5 by AcUL19, 
S.frugiperda monolayers in 17-mm wells were infected with 
wild-type AcNPV, AcUL19, or AcRP231acZ at a multiplicity 
of 10 p.f.u./cell, and incubated for 48 h at 28°C. Cells 
were harvested in 200 ul of extraction buffer (0.1-M Tris 
pH8, 10% v/v glycerol, 0.5% NP40, 0.5% sodium
deoxycholate,' 0.2-mM PMSF [Showalter et al., 1981]), and 
samples were analysed on a 7.5% SDS polyacrylamide gel. 
Proteins were visualised by staining with Coomassie 
brilliant blue. For electron microscopy, AcUL19- and 
AcNPV-infected cells were harvested and embedded in Epon 
812 resin as described previously.
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RESULTS
A Capsids 
B Capsids
Figure 5. Velocity gradient centrifugation of HSV-1 
intranuclear capsids* Centrifugation of 0.5 ml of nuclear 
extract at 38,000 r.p.m. for 20 minutes through a 12-ml 
10 to 40% sucrose gradient separated the A and the B 
capsids as indicated.
1 AIMS OF PROJECT
The aim of this research was to investigate aspects of 
capsid structure and assembly in HSV-1. To this end four 
capsid protein genes were successfully cloned and 
expressed in a recombinant vaccinia system, and several 
properties of the products of these genes were 
investigated. Ultimately it is hoped that all the capsid 
protein genes can be cloned and expressed in a system 
which will allow assembly of capsids from cloned gene 
products. This would enable experiments which would yield 
valuable information on the pathway of assembly and on 
capsid architecture. Preliminary studies focussed on the 
capsid protein composition of HSV-1 capsids.
2 CAPSID PROTEIN PROFILES
Capsid protein profiles have been reported for several 
herpesviruses. A consensus exists as to the number and 
identities of the proteins comprising the HSV-1 capsid 
(Gibson & Roizman, 1972; Zweig et al., 1979a; Cohen £t 
al., 1980; Rixon et al., 1990). The experiments reported 
in this section confirm these findings, and analyse the 
distribution of capsid proteins in sucrose velocity 
gradients. The method of capsid purification used in 
these experiments was that of Irmiere & Gibson (1985) and 
Rixon et al. (1990), and is detailed in the Materials and 
Methods.
BHK C13 cells infected with HSV-1 strain 17 were 
harvested, and intranuclear capsids were purified. 
Samples of nuclear extract were centrifuged through 10 to 
40% sucrose velocity gradients, yielding two light- 
scattering bands containing A and B capsids (Figure 5).
Separate bands could be withdrawn from the centrifuge 
tube by side puncture and aspiration. The upper band, 
containing A capsids, was always much less dense than the
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Figure 6. Graph of scintillation counts of fractions of 
a sucrose gradient of intranuclear capsids. Forty-seven 
successive 225-ul fractions were collected from a 12.5-ml 
sucrose gradient containing visibly separate bands of 
^S-labelled B and A capsids. 40-ul aliquots of each 
fraction were spotted onto filter paper discs and the 
amount of S (expressed here as counts per minute) 
contained in each sample was measured by scintillation 
counting. The results are represented here in graphical 
form. The proportion of 35S-methionine present in each 
fraction of the gradient is represented by the height of 
the line. Fraction number 1 represents the lower region
of the gradient/ below the band of B capsids/ and
fraction number 47 represents the upper region of the 
gradient/ above the band of A capsids. Two peaks can be
seen on the graph; the higher peak represents the B
capsids/ and the lower peak the A capsids.
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Figure 7. PAGE analysis of fractions of a sucrose 
gradient of intranuclear capsids. 30-ul aliquots of 
fraction numbers 15 to 43 (details given in Table 2,< 
Figure 6, and text) were analysed in successive lanes 
over two 5 to 12% SDS-polyacrylamide slab gels. The 
cross-linker was bis-acrylamide. Samples were labelled 
with 5S-methionine,' and were visualised by
autoradiography. The lanes are numbered according to the 
number of the gradient fraction run in that lane. 
Fractions 27 to 31 contain peak levels of B capsid 
proteins,' and correspond to the region of the gradient 
which contained the light-scattering band of B capsids. 
Fractions 35 to 39 contain peak levels of A capsid 
proteins,* and correspond to the region of the gradient 
which contained the light-scattering band of A capsids. 
Each of the seven capsid proteins is indicated. Three 
dots at the right hand side of the figure indicate the 
positions of other proteins which cosediment with the 
peak at the position of A capsids.
lower band/ and often did not contain sufficient amounts 
of protein to be useful for analysis by PAGE. The lower 
band, containing B capsids, did more often contain 
sufficient yield of protein. This difference in band 
density has also been reported by other workers (Gibson & 
Roizman, 1972; Allen & Bryans, 1976).
The distribution of capsids throughout the sucrose 
gradients was investigated by puncturing the base of a 
centrifuge tube containing a suitable gradient, and 
collecting successive fractions as the gradient dripped 
out of the tube. A 0.8 x 40 mm needle (21G) was used, and 
each fraction consisted of 3 successive drops 
(approximate volume 75 ul per drop) from a total gradient 
volume of 12.5 ml. In one such experiment, 47 successive 
fractions were obtained from a gradient containing 
capsids labelled with ^S-methionine. The amount of label 
present in each fraction was determined by scintillation 
counting of 40-ul aliquots, and the results are presented 
in graphical form in Figure 6. Two peaks of radioactivity 
can be seen, which correspond to the lower (B capsid) 
band and the upper (A capsid) band.
30-ul aliquots of fractions 15 to 43 were analysed by 
PAGE over two 5 to 12% gradient gels (Figure 7). The 
intensity of each protein varies across the gels, and 
peaks can be seen which correspond to the B and A capsid 
bands. In lane 29, representing the peak of the B capsid 
band, all seven capsid proteins can be seen. In lane 36, 
representing the peak of the A capsid band, VP21 is 
absent, although a small amount of VP22a is present. It 
is interesting to note that most of the capsid proteins 
are present throughout the entire gradient. VP5, VP23 and 
VP26 each show two peaks corresponding to the B and A 
capsid bands. VP19C, VP21, VP22a and VP24 each peak at 
the position of B capsids. VP19C does not show a distinct 
peak at the position of A capsids in this experiment. 
VP24 is a minor capsid protein and is very faint on these 
gels. The fact that small amounts of VP22a can be seen in
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Figure 8. The locus of UL18 and UL19
the A capsid band probably indicates the presence of 
contaminating B capsids in the A capsid band. Presumably 
some A capsids separate at the position of B capsids, and 
vice versa.
Three further proteins are of interest. The positions of 
these proteins are marked with a dot at the right hand 
side of the autoradiograph. These are not known capsid 
proteins, yet each shows a peak of concentration at the 
position of A capsids. This would not be expected of a 
contaminating protein. The first of these proteins lies 
between VP5 and VP19C. In preparations of HSV-1 virions, 
a protein of this size accumulates on storage (personal 
communication, Dr F.J.Rixon), and it is possible that 
this protein is a breakdown product of VP5. The second of 
these proteins lies between VP21 and VP22a, and the third 
lies between VP22a and VP23. The identities of these two 
proteins are not known. However,- they might also 
represent breakdown products of VP5, or of another capsid 
protein.
3 CLONING OF CAPSID GENES 
3.1 The locus of UL18 and UL19
The two capsid protein genes UL18 and UL19 are contained 
within the HSV-1 Kpnl _i fragment ( fWsden et al., 1978) 
which extends from position 34188 to position 43620 
according to the numbering of the HSV-1 sequence (McGeoch 
et al., 1988a). This corresponds to a map location of 
approximately 0.224-0.286 map units (Figure 8). The UL18 
and UL19 reading frames are transcribed from right to 
left on the prototype arrangement of HSV-1 DNA. The 
translation initiation codon of UL18 is at position 36051 
and the TAA stop codon is at 35097 (McGeoch et al., 
1988a). The UL18 mRNA is unspliced and is 1.5 kb in 
length (Costa et al., 1984). It initiates at 
approximately position 36250 (Costa et al., 1984) and
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terminates at one of two AATAAA polyadenylation sequences 
which begin at 35032 and 35028 respectively (Costa et 
a_l • f* 1984; McGeoch et al., 1988a). The sequence reported 
by McGeoch et al. (1988a) contains a potential regulatory 
element of sequence CATAAAA commencing at 36268. The 
initiation codon of UL19 is at position 40528 and the TAA 
stop codon is at 36406 (McGeoch et al., 1988a). The major 
UL19 mRNA is unspliced and is 6 kb in length (Costa et 
al., 1984). The 51 terminus is at position 40768, and
promoter elements which are recognisable upstream are a 
TATATAA sequence beginning at 40796, and two potential 
CAAT sequences,' beginning at 40850 (GGCCATCTT), and at
40870 (GGCCAATCTT) (Costa et al., 1984; Dennis & Smiley, 
1984; McGeoch et al.,' 1988a). Although there is an
AATAAA sequence beginning at position 36405, mapping data 
indicate that the UL19 mRNA is 3' coterminal with that of 
UL18, and therefore that it must make use of one or both 
of the polyadenylation sites at 35032 and 35028. However, 
it has not been ruled out that a minor proportion of UL19 
transcripts terminates close to the stop codon. Two minor 
UL19 mRNAs originate upstream of the major species at 
positions 40798 and 40858 respectively (Costa et al.,' 
1984). A rightward-transcribed 3.1-kb mRNA of unknown 
function initiates from the region of the leader 
sequences of the 6-kb transcript, but this has not been 
mapped precisely (Costa et al., 1981; Costa et al., 
1984) . UL20 also lies within Kpnl i^. The C-terminal 
coding sequences of UL20 partially overlap the promoter 
region of UL19. There is no polyadenylation site close 
downstream from the UL20 coding region and it seems that 
the mRNA may be 31 coterminal with UL19 and UL18. If this 
is so,' the transcript would be expected to be about 6.8 
kb in size,' and Costa et al. (1981) detected a 7-kb mRNA
of undetermined orientation which at least partially 
overlapped the 6-kb transcript as well as the region of 
UL20. The C-terminal portion of exon 2 of UL15 lies at 
the left-hand end of Kpnl i^, and the N-terminal 96% of 
UL21 lies at the right-hand end. Kpnl i. is contained on 
the plasmid pGX128.
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Figure 9. The structures of PMJ601 and pMJ521
3.2 Vaccinia transfer vectors
In order to express the capsid genes in vaccinia the 
coding sequences first had to be placed under the control 
of vaccinia transcriptional promoter and terminator 
signals. To do this use was made of the vaccinia 
expression plasmids pMJ601 and pMJ602 (Davison & Moss/ 
1990), which contain a synthetic vaccinia late promoter 
and a vaccinia polyadenylation signal, optimised to give 
maximal expression, separated by a multiple cloning 
sequence. This cassette is flanked by vaccinia thymidine 
kinase (TK) sequences to allow recombination into the 
viral TK gene. These two vectors also contain 
the p)-galactosidase gene under the control of the 
vaccinia 7.5-kDa early promoter to assist in easy 
identification of recombinant viruses by their blue 
plaque colour.
3.3 Cloning of UL18 into the vaccinia transfer vector
Narl cuts twelve times within Kpnl i_. Two of these sites 
flank the UL18 ORF. Narl cuts two residues upstream from 
the UL18 initiation codon, within the sequences encoding 
the untranslated leader of UL18 mRNA, at 36053, and 381 
residues downstream from the stop codon, at 34713 (see 
Figure 8), releasing the UL18 coding sequences on a 1340- 
base-pair fragment. This fragment was purified from
pGX128 and ligated into the Narl site in the multiple 
cloning sequence of pMJ601, and a clone (pMJ521) was
selected having the UL18 ORF under the control of the
synthetic vaccinia late promoter. The structures of
pMJ521 and the parental plasmid pMJ601 are illustrated in 
Figure 9.
3.4 Cloning of UL19 into the vaccinia transfer vector 
Unlike UL18, there were no convenient restriction enzyme
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figure 10 A. The cloning of UL19.
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Figure 10 A (continued). The cloning of UL19.
, EcoRV Ncol   Bgl II
oligonucleotide A CATGGATATCAGATCT
oligonucleotide B CTATAGTCTAGATTAA
EcoRI compatible, but 
site not regenerated
Ncol
oligonucleotide C CATGGCCGCGGCATACCGGTATCCCGGAGG.
oligonucleotide D CGGCGCCGTATGGCCATAGGGCCTCC.
.GTCGCGGTTGGGAGCGGCCATATGATATCA 
.CAGCGCCAACCCT CGCCGGT AT ACT ATAGTCTAG
Ndel   Bgl II
EcoRV
Figure 10 B. Synthetic oligonucleotides 
used in the cloning of UL19.
sites flanking the UL19 ORF. There— fore a much more 
complicated cloning strategy had to be adopted. The steps 
taken in the cloning of UL19 are illustrated in Figure 
10A. Hpal cuts within Kpnl d. at 35755 and at 41132 (see 
Figure 8), releasing a 5377-base-pair fragment which 
contains the UL19 coding sequences. The 5377-base-pair 
Hpal fragment of pGX128 containing UL19 was ligated into 
the BamHI site (which had been rendered blunt-ended by 
treatment with T4 polymerase) of pUC19 to give pBJ191. 
pBJ191 was then digested with Mlul which makes a single 
cut 45 residues downstream from the TAA stop codon of 
UL19, and a Bglll linker was inserted by ligation to 
generate pBJ192. A Hindlll site 676 residues downstream 
from the initiation codon of UL19, and another in the 
pUC19 multiple cloning sequence,' enabled the separation 
of this construct into two fragments, of 3941 and 4126 
base-pairs. This step was necessary because the 4126- 
base-pair fragment contained two Ncol sites which would 
have interfered with subsequent stages of the procedure. 
The 4126-base-pair fragment was retained for subsequent 
use in reconstructing the gene. The 3941-base-pair 
fragment was self-ligated to form a plasmid containing 
the 5' 679 nucleotides of UL19 as well as the pUC19
sequences (pBJ193). pBJ193 was digested with Ncol (which 
makes two cuts, one overlapping the UL19 ATG initiation 
codon and the other 48 base-pairs downstream), and with 
EcoRI which cuts 630 residues upstream of the ATG in the 
pUC19 multiple cloning sequence. This generated three 
fragments,' of 3263, 630 and 48 residues. The 3263-base-
pair fragment was purified and ligated with a 16-base- 
pair fragment prepared from two 16-mer partially 
complementary synthetic oligonucleotides (A and B, Figure 
10B), to give pBJ194. The oligonucleotides were designed 
such that the synthetic fragment generated an Ncol site,' 
introducing immediately upstream two further cloning 
sites, EcoRV and Bglll. The EcoRI site of the pUC19 
multiple cloning sequence was not regenerated. This 
plasmid now had unique Ncol, EcoRV and Bglll restriction 
sites. It had been intended to reconstruct the UL19 ORF
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Figure 11. Dideoxy sequencing of pBJ196. The
reconstructed portion of UL19 in pBJ196 was checked to 
confirm the fidelity of the sequence. The position of the 
ATG initiation codon of UL19 is indicated (as CAT)/ 
corresponding to position 4805 on pBJ196. The position of 
the Ncol site at position 4754 on pBJ196 is indicated. 
Two dots indicate the positions of two C-C compressions. 
The region extending from the ATG to the Ncol site 
represents the reconstructed portion of UL19. Taking the 
compressions into account/ the sequence of this region 
reads TAC CGG CGA GGG TTG GCG CTG GGA GGC CCT ATG GCC ATA 
CGG CGC CGG TAC C. This corresponds exactly to the 
sequence of this portion of UL19 published by McGeoch et 
al. (1988a).
by inserting the 48-base-pair Ncol-Ncol fragment of 
pBJ193 into the Ncol site of pBJ194. However/ at this 
point it was deemed desirable to introduce an Ndel site 
into the UL19 ORF at the initiation codon, and new 
oligonucleotides were designed for this purpose. This was 
to facilitate cloning of the UL19 ORF into the T7 RNA 
polymerase expression vector pET3a (Studier et al./ 
1990). Accordingly, pBJ194 was digested with Ncol and 
Bglll and religated using a 60-base-pair fragment 
prepared from two 60-mer partially complementary 
synthetic oligonucleotides C and D (Figure 10B), to give 
pBJ195. This synthetic fragment regenerated the 48-base- 
pair 51 coding portion of UL19, converting the initiation 
codon Ncol site to an Ndel site, and retaining the EcoRV 
and Bglll cloning sites previously introduced. To 
reconstruct the intact UL19 open reading frame, pBJ195 
was linearised at the single Hindlll site and the 4126- 
base-pair Hindlll fragment containing the remainder of 
the UL19 coding sequence was inserted to generate pBJ196. 
Digestion of pBJ196 with Bglll released the UL19 ORF on a 
4184-base-pair fragment, which was then cloned into the 
BamHI site in the multiple cloning sequence of pMJ601. A 
clone (pMJ535) was selected having the UL19 ORF under the 
control of the synthetic vaccinia late promoter.
3.5 Sequencing of UL19
Due to the complexity of this cloning procedure it was 
felt important to check the fidelity of the sequence at 
the 51 end of the UL19 ORF. The sequence of the 
reconstucted 51 portion of UL19 was checked in pBJ196 by 
the dideoxy chain termination method. Figure 11 shows an 
autoradiograph from which may be deduced the sequence of 
the relevant part of pBJ196. Reading from the bottom of 
the autoradiograph the sequence TAC is indicated, which 
corresponds to the ATG initiation codon of UL19 on the 
opposite strand. The sequence GGTACC is indicated, which 
represents the Ncol restriction site at position 4754 of
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Figure 12. The locus of UL38
pMJ196 (Figure 10A). Two dots indicate the positions of 
two bands in the C track which are of increased density 
and appear to represent C-C compressions. Taking these 
compressions into account, the sequence of the section 
from the ATG to the Ncol site corresponds exactly to the 
sequence of this portion of UL19 published by McGeoch et 
al. (1988a).
3.6 The locus of UL38
The capsid protein gene UL38 is contained within the 
HSV-1 Hindlll k fragment (Wilkie, 1976; Skare & Summers, 
1977) which extends from position 80707 to position 90145 
according to the numbering of the sequence as determined 
by McGeoch et al. (1988a). This corresponds to a map
location of approximately 0.530-0.592 map units (Figure 
12). The UL38 reading frame is transcribed from left to 
right on the prototype arrangement of HSV-1 DNA, and is 
unspliced. The translation initiation codon of UL38 is at 
position 84531, and the TGA termination codon is at 
position 85926 (McGeoch et al., 1988a). Two mRNAs of
1.9 kb and 7 kb have been mapped to the region of UL38 
(Anderson et al., 1981). The UL38 promoter has recently 
been characterised. The mRNAs initiate at position 84382, 
and only 45 bases of DNA sequence 51 of the UL38 mRNA cap 
site is required to direct reporter gene expression in 
recombinant virus. Recogniseable promoter and regulatory 
elements are a TATA box beginning at position 84373, a 
potential CAAT box at 843 51 and a potential Spl-binding 
site of sequence GGGCGG at 84343 (Flanagan et al.,- 1991). 
There is a probable polyadenylation site of sequence 
AATAAA which begins at position 86016, and another, also 
of sequence AATAAA,' which begins outwith Hindlll k after 
the 31 terminus of UL40 at 90983 (McGeoch et al., 1988a). 
These sites appear to represent the 31 termini of the 
1.9- and 7- kb mRNAs respectively. The polyadenylation 
site at 90983 marks the 3' termini of UL39 and UL40 
(McLauchlan & Clements, 1983). Also contained in
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Figure 13. The cloning of UL38
Hindlll k are UL37,- UL39, and the N-terminal portion of 
UL40. Hindlll k is contained on the plasmid pGX79.
3.7 Cloning of UL38 into vaccinia transfer vector
The procedure followed for cloning UL38 is shown in 
Figure 13. HincII cuts eight times within Hindlll k. A 
2888-base-pair HincII fragment extending from 83110 to 
85998 contains the UL38 coding sequences (see Figure 12). 
This fragment was isolated and purified from pGX79, and 
was ligated into the HincII site of pUC18, to give 
pBJ381. pBJ381 was then digested with Nrul and HincII. 
Nrul cuts once within the 2888-base-pair HincII fragment, 
at 84515. Thus the NruI-HincII double digest released a 
1482-base-pair fragment containing UL38. Nrul cuts 15 
residues upstream from the UL38 initiation codon in the 
untranslated leader sequences, and HincII cuts 70 
residues downstream from the stop codon. The 1482-base- 
pair fragment was ligated into the HincII site of pUCl8. 
A clone, pBJ382, was selected in which the UL38 ATG was 
adjacent to the BamHI site of the pUCl8 multiple cloning 
sequence. UL38 was then cloned as a 1513-base-pair BamHI- 
Hindlll fragment into BamHI-Hindlll-digested pMJ601, to 
give pMJ534.
3.8 The locus of UL26 and UL26.5
The UL26 and UL26.5 genes are contained within the HSV-1 
Kpnl jt fragment (Preston et al., 1978), which extends 
from position 49345 to position 52732 according to the 
numbering of the sequence as determined by McGeoch et al. 
(1988a). This corresponds to a map location of 
approximately 0.324-0.346 map units (Figure 14). The UL26 
and UL26.5 genes are both transcribed from left to right 
on the prototype arrangement of the HSV-1 genome and are 
unspliced. The UL26.5 ORF is entirely contained within 
and is in frame with that of UL26,' and the two ORFs are
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3' coterminal (Liu & Roizman, 1991a; Preston et al., 
1992). Two 31-coterminal mRNAs of 2.4 kb and 1.4 kb were 
mapped to this region by Holland et al. (1984) which
appear to be the transcripts of UL26 and UL26.5 
respectively (Liu & Roizman, 1991a). The preferred 
translation initiation codon of UL26 is at position 50809 
(Preston et al., 1992), and the TGA termination codon is 
at 52714. A second in-frame ATG codon is located 27 
nucleotides downstream from the first initiation codon at 
position 50836 (McGeoch et al., 1988a), which is 
functional as an initiation codon in the absence of the 
first ATG (Preston et al., 1992). The transcription 
initiation site is approximately 180 nucleotides upstream 
of the ATG; however, no sequences corresponding to a TATA 
box or other regulatory elements are discernable in the 
vicinity (Liu & Roizman, 1991a). The 3' terminus of the 
UL26 mRNA lies outwith Kpnl t, at a polyadenylation site 
of sequence AATAAA/ beginning at position 52756 (McGeoch 
et al., 1988a; Liu & Roizman, 1991a). The translation 
initiation codon of UL26.5 is at position 51727, and the 
termination codon is common with UL26, at position 52714 
(Liu & Roizman, 1991a; Preston et al., 1992). The UL26.5 
mRNA initiates approximately 99 nucleotides upstream of 
the ATG. A region consisting of 168 nucleotides upstream 
of the transcription initiation site, delineated by a 
Hpal restriction site at position 51463, contains all the 
promoter and regulatory elements necessary for efficient 
expression of the UL26.5 protein in transfected cells 
superinfected with HSV-1 or HSV-2 (Liu & Roizman, 1991a). 
The sequence reported by McGeoch et al. (1988a) contains
potential regulatory elements in this region at positions 
51604 (TATAA), 51572 (GGGCGG) and 51561 (CAAAAT). The 3'
terminus of the UL26.5 mRNA is common with that of UL26 
(Liu & Roizman, 1991a). Kpnl t also contains the C- 
terminal 70% of UL25. Three other mRNAs were detected by 
Holland et al. (1984) which were 31-coterminal with those 
of UL26 and UL26.5. These were of 5.6 and 5.2 kb, and of
4.4 kb, and they appear to be transcripts of UL24 and 
UL25 respectively. Kpnl Jt is contained within pGX142.
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Figure 15. The cloning of UL26
3.9 Cloning of UL26 into vaccinia transfer vector
The steps followed in the cloning of UL26 are summarised 
in Figure 15. Apal cuts within Kpnl t at positions 50291,. 
51618, 52626 and 52710. The 1327-base-pair fragment
extending from 50291 to 51618 which contains the N- 
terminal region of UL26 was isolated and purified from 
pGX142• This fragment was digested with Nlalll, which 
cuts within this fragment at 50504,. 50811 and 51471,
releasing fragments of 213,. 307, 660 and 147 base-pairs. 
The 660 base-pair fragment was isolated and purified.
This consisted of nucleotides 4 to 664 of the UL26 ORF,
corresponding to positions 50812 to 51471. The Nlalll 
site cutting at position 50811 removed the first three 
bases of the UL26 ORF, ie the ATG initiation codon. The 
single Hpal site of the UL26 ORF at position 51463 was 
located near the 3' end of the 660-base-pair fragment. 
The 660-base-pair Nlalll fragment was cloned into the
compatible SphI site in the multiple cloning sequence of 
pUC19. Thus the Nlalll sites were regenerated, and the 
ATG of UL26 was restored. The SphI sites were not
regenerated. A clone was selected having the initiation 
codon adjacent to the Hindlll site in the pUC19 multiple 
cloning sequence. This clone, pBJ261, contains the first 
663 base-pairs of the UL26 ORF. The Hpal site which cuts 
within UL26 at position 51463 and the Kpnl site at 52732 
enabled separation from pGX142 of a 1269-base-pair Hpal- 
Kpnl fragment. This fragment contained the 3'-terminal 
1253 residues of the UL26 ORF and extended to include the 
16 residues immediately following the end of the TGA 
termination codon. pBJ261 was digested with Hpal and Kpnl 
which removed 8 bases of UL26 sequence, from the Hpal 
site to the Nlalll site,, and a further 32 bases of the 
pUC multiple cloning sequence, up to the Kpnl site. The 
1269-base-pair fragment was ligated into the Hpal-Kpnl- 
digested pBJ261. The resultant plasmid, pBJ262, contained 
the entire UL26 ORF, beginning with the initiation codon 
and ending at the Kpnl site 16 bases 3' of the end of the 
termination codon, and corresponding to positions 50809
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to 52732. The Kpnl site was regenerated and was unique, 
and a unique Hindlll site in pBJ262 8 base-pairs upstream 
of the UL26 ATG enabled removal of the UL26 coding 
sequences on a Hindlll-Kpnl fragment of 1931 base-pairs. 
This was ligated into the multiple cloning sequence of 
Hindlll-KpnI-digested pMJ602 to give pMJ540.
3.10 Cloning of UL26 lacking the initial ATG into 
vaccinia transfer vector
The plasmid pGX237 contains a 1956-base-pair Hindlll 
fragment inserted into pFJIO (Preston et al., 1992). This 
insert includes a 1911-base-pair section of the UL26 ORF,' 
which extends from position 50826, upstream of the 
second ATG at position 50836 to the Kpnl site 20 bases 3' 
of the termination codon, at 52736. Thus the UL26 
initiation codon at position 50809 is absent. This clone 
was used by Preston et al. (1992) and was referred to by
them as containing the UL26 ORF, although it actually 
contains an N-terminal truncated version. It was included 
in this study in an attempt to repeat in the recombinant 
vaccinia system the results obtained by these workers by 
expressing this clone under IE gene regulation. This 
clone was of further interest in that it presented an 
opportunity to investigate the respective roles of the 
first and second ATG initiation codons of the UL26 ORF. 
Digestion of pGX237 with Hindlll and Kpnl yielded the 
UL26 sequences on a fragment of 1917 base-pairs. This was 
ligated into the multiple cloning sequence of Hindlll- 
Kpnl-digested pMJ602 to give pMJ541. However, since 
attempts at obtaining recombinant vaccinia viruses using 
pMJ541 were unsuccessful, further details of this plasmid 
are not presented.
3.11 Cloning of UL26.5 into vaccinia transfer vector
The plasmid pGX239 contains a 1110-base-pair Hindlll
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Figure 16. The structure of PMJ542
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Figure 17. Restriction enzyme digests demonstrating the 
structures of vaccinia transfer vectors containing HSV-1 
capsid genes. Plasmid DNA was digested with the enzymes 
indicated and analysed on a 1% agarose gel. Lane Is 
pMJ521 digested with Narl, (A dot at the left hand side 
of the photograph indicates the position of the 1340-bp 
Narl fragment of pMJ521.) Lane 2: pMJ535 digested with
Hindlll. Lane 3: pBJ196 digested with Bglll, Lane 4:
pMJ534 digested with BamHI and Hindlll. Lane 5: pMJ540
digested with Hindlll and Kpnl. Lane 6: pMJ541 digested 
with Hindlll and Kpnl. Lane 7: pMJ542 digested with
Hindlll and Kpnl. Lane 8 contains a ladder of size 
markers. The size (in base pairs) of each fragment in 
lane 8 is indicated at the right hand side of the 
photograph•
fragment inserted into pFJIO (Preston et al., 1992). This 
insert includes a 1006-base-pair section which contains 
the entire UL26.5 reading frame extending from the 
initiation codon at position 51727 to the Kpnl site 16 
bases 3' of the termination codon, at 52732. This 1006- 
base-pair section is bounded by a Hindlll site 65 base- 
pairs upstream of the UL26.5 initiation codon. Digestion 
of pGX239 with Hindlll and Kpnl yielded the UL26.5 
sequences on a fragment of 1071 base-pairs. This was 
ligated into the multiple cloning sequence of pMJ602 to 
give pMJ542. The structure of pMJ542 is shown in Figure 
16.
3.12 Restriction digests demonstrating the structures of 
vaccinia transfer vectors containing HSV-1 capsid genes
In order to confirm the structures of the plasmids to be 
used as transfer vectors in the construction of 
recombinant vaccinia viruses, each plasmid was analysed 
by restriction enzyme digestion. Fragments produced by 
these digestions were separated on an agarose gel and 
visualised under UV illumination following staining with 
ethidium bromide (Figure 17). pMJ521 was digested with 
Narl, which released the UL18 ORF contained on a 1340- 
base-pair fragment from the parental transfer vector 
pMJ601 (7167 bp) (see Figure 9). pMJ535 was digested with 
Hindlll, which released two fragments, of 7825 bp and 
3526 bp. In order to demonstrate the Bglll fragment which 
was used to transfer the UL19 ORF into pMJ535, pBJ196 was 
digested with Bglll, which released the UL19 ORF 
contained on a 4184-bp fragment, and a second fragment of 
3281 bp (see Figure 10A) . pMJ534 was digested with BamHI 
and Hindlll, which released the UL38 ORF contained on a 
1513-bp fragment from the parental transfer vector pMJ601 
(7137 bp) (see Figure 13). pMJ540 was digested with 
Hindlll and Kpnl, which released the UL26 ORF contained 
on a 1931-bp fragment from the parental transfer vector 
PMJ602 (7163 bp) (see Figure 15). pMJ541 was digested
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Recombinant
Virus HSV-1 Gene
VMJ521 UL18
VMJ535 UL19
VMJ534 UL38
VMJ542 UL26.5
Table 2. Recombinant vaccinia viruses 
containing HSV-1 capsid protein genes
with Hindlll and Kpnl, which released the truncated UL26 
ORF contained on a 1917—bp fragment from the parental 
transfer vector pMJ602 (7163 bp). pMJ542 was digested 
with Hindlll and Kpnl,- which released the UL26.5 ORF 
contained on a 1071-bp fragment from the parental 
transfer vector pMJ602 (7163 bp) (see Figure 16).
4 INTRODUCTION OF CAPSID GENES INTO VACCINIA
Following transfection of pMJ521 (UL18),' pMJ535 (UL19), 
pMJ534 (UL38), pMJ540 (UL26), pMJ541 (truncated UL26) and 
pMJ542 (UL26.5), and superinfection with wild-type 
vaccinia virus, progeny viruses were selected for TK
minus phenotype. Blue plaques were isolated and purified 
to homogeneity through at least two cycles of plaque 
purification. The efficiency of recombination appeared to 
be very low, in that very few blue plaques were ever 
obtained. In the cases of pMJ535 and pMJ542, the blue
plaques formed were obscured by high levels of wild-type 
vaccinia virus which had survived the BUdR selection. 
These blue plaques were very small, consisting of only 
one or two cells, and could only be seen using a 
microscope. After several rounds of purification in the 
presence of BUdR, these tiny plaques yielded blue plaques 
which were visible to the naked eye. Despite repeated
attempts,' blue plaques could not be obtained following
transfection with pMJ540 or pMJ541. This may be due 
simply to the low efficiency of recombination or because 
in these cases the HSV proteins expressed were toxic to 
vaccinia virus. Several plaque isolates of each 
recombinant were selected and grown to high titre. One of 
each was selected for further study; these were 
designated VMJ521 (UL18), vMJ535 (UL19), vMJ534 (UL38) 
and vMJ542 (UL26.5). These viruses are listed in Table 2 
for ease of reference whilst reading this thesis.
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Figure 18, Expression of HSV-1 capsid proteins by 
recombinant vaccinia viruses. CV-1 cells were infected 
with 5 p.f.u. per cell of WR strain vaccinia virus (lane 
2),' VMJ521 (lane 3)/ VMJ535 (lane 4) or VMJ534 (lane 5),' 
and labelled from 3 to 24 hours p.i. with 35S-methionine. 
Mock-infected cells (lane 1) were similarly labelled. 
Cells were harvested and 30 ul of whole cell extract was 
analysed on a 10.5% SDS-polyacrylamide slab gel. The 
cross-linker was DATD. Lane 6 contains purified HSV-1 B 
capsids. Arrows indicate the positions of the named 
capsid proteins.
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Figure 19. Expression of HSV-1 capsid proteins by 
recombinant vaccinia viruses. CV-1 cells were infected 
with 5 p.f.u. per cell of VMJ542 (lane 1), vMJ521 (lane 
2), VMJ535 (lane 3) or VMJ534 (lane 4),' and labelled from 
3 to 24 hours p.i. with 35S-methionine. Cells were 
harvested and 30 ul of whole cell extract was analysed on 
a 9% SDS-polyacrylamide slab gel. The cross-linker was 
bis-acrylamide. Proteins of interest are marked at the 
left hand side of each lane with a dot ( ■ ) . Arrows 
indicate the positions of protein bands which correspond 
to the named capsid proteins.
5 EXPRESSION OF CAPSID PROTEINS
To examine whether the recombinant vaccinia viruses 
expressed the HSV-1 proteins, confluent monolayers of 
CV-1 cells were infected with 5 pfu per cell of vMJ521,. 
VMJ535, VMJ534 or VMJ542 and labelled with 35S-methionine 
from 3 to 24 hours after infection. The cells were 
harvested at 24 h p.i., and whole—cell extracts were 
analysed by PAGE. Figure 18 shows an analysis of cells 
infected with vMJ521, VMJ535 and vMJ534 (lanes 3, 4 and 5 
respectively). Control lanes show protein profiles of 
mock-infected cells, WR vaccinia-infected cells and 
purified HSV-1 B capsids (lanes 1, 2 and 6 respectively). 
The four capsid proteins visible in lane 6 are indicated. 
In each case the recombinant virus expresses large 
amounts of a novel protein not present in the parental 
vaccinia-infected cells. Each protein appears to 
comigrate with the appropriate capsid protein, being of 
apparent Mr 33 kDa (VP23), 155 kDa (VP5) and 53 kDa
(VP19C).
Figure 19 shows the results of a similar experiment which 
includes a protein profile of vMJ542-infected cells. 
Lanes 2, 3 and 4 again each contain an abundant novel
protein. Each novel protein is labelled with the name of 
the capsid protein with which it was shown to migrate in 
Figure 17, and which is known to be the product of the 
capsid gene used to construct the respective vaccinia 
virus. The sample in lane 1 consisted of cells infected 
with vMJ542. In this lane two novel bands can be seen,- of 
approximate size 40 kDa. These are labelled as VP22a 
inasmuch as they are products of UL26.5.
The products of UL26.5 are known to be a highly processed 
family of proteins. In order to examine whether the 
products of UL26.5 expressed by vMJ542 were similarly 
processed and also to confirm that the novel products of 
VMJ542 are forms of VP22a, an immunoprecipitation 
experiment was carried out using the monoclonal antibody
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Figure 20. Immunoprecipitation of the products of UL26.5 
expressed from HSV-1 and from VMJ542 by monoclonal 
antibody 5010. Autoradiograph of the immunoprecipitation 
of unprocessed and processed forms of VP22a from cells 
infected with HSV-1 (lanes 2/ 5 and 6),' vMJ542 (lane 4),- 
WR vaccinia (lane 3), or mock-infected cells (lane 1) . 
Cells were CV-1 (lanes 1 to 4),> or BHK (lanes 5 and 6). 
Cells were labelled from 1 to 18 h p.i. with ^S-
methionine. The cells in lanes 5 and 6 were pulse 
labelled at 5 h p.i. After 30 minutesthe medium was
removed/ and the cells were harvested either immediately
(lane 5) or after a chase of 5 h (lane 6). Following
immunoprecipitation/ samples were analysed on a 9% SDS- 
polyacrylamide slab gel. The cross-linker was bis- 
acrylamide. Arrows indicate the positions of three forms 
of VP22a•
5010, which recognises the unprocessed and the processed 
forms of VP22a (Rixon et al., 1988). The results of this 
experiment are shown in Figure 20. CV-1 or BHK cells were 
infected at a multiplicity of 20 p.f.u. per cell with 
HSV-1 (lanes 2, 5 and 6), WR vaccinia (lane 3), VMJ542
(lane 4), or were mock-infected (lane 1). The proteins 
present in lane 2 were precipitated from CV-1 cells 
infected with HSV-1 and harvested at 18 h p.i. Both 
unprocessed (position A) and processed (position C) forms 
of VP22a can be seen in lane 2. Lanes 5 and 6 show the 
immunoprecipitates from BHK cells infected with HSV-1,' 
pulse-labelled at 5 h p.i. for 30 minutes,' and then 
harvested immediately (lane 5) or after a chase of 5 h 
(lane 6). The transition during the period of chase from 
unprocessed forms of VP22a (positions A and B, lane 5) to 
the processed forms (position C, track 6) can be seen, as 
was previously demonstrated in a similar experiment by 
Rixon et al. (1988). In this experiment the processed
forms of VP22a are seen as a single band (position C),' 
whereas other reports have shown them to consist of a 
closely comigrating doublet (Rixon et al., 1988; Preston 
et al., 1992). Lane 4 contains the immunoprecipitates 
from CV-1 cells infected with vMJ542 and harvested after 
18 h. It can be seen that VMJ542 synthesises abundant 
amounts of the higher molecular weight unprocessed form 
of VP22a (position A) and smaller amounts of the lower 
molecular weight form (position B). Thus vMJ542 expresses 
unprocessed forms of VP22a.
6A CHARACTERISATION OF MONOCLONAL ANTIBODY 1060
Monoclonal antibody 1060 was originally produced in this 
Institute by Dr J.Palfreyman and was shown to react with 
an HSV-1 protein of apparent Mr 33 kDa on SDS-PAGE. The 
antibody reacted also with HSV-2 precipitating a protein 
that migrated slightly faster on SDS-PAGE than the HSV-1 
protein. The difference in mobility allowed the gene to 
be mapped using a series of intertypic recombinants.
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Figure 21. Immunopr ec ipi t at ion of the product of UL18 
expressed "by HSV— 1 and by VNJ521 using monoclonal 
antibody 1060. Autoradiogram of the immunoprecipitation 
of the product of UL18 from CV-1 cells infected with 
5 p.f.u. per cell of HSV-1 (lanes 1 and 4) or VMJ521 
(lanes 2 and 3). Virus-infected cells were labelled with 
^5S-methionine from 3 to 24 h p.i./ when cells were 
harvested. Immunoprecipitation was carried out using 1060 
(lanes 3 and 4) or control ascites (lanes 1 and 2). 1060 
precipitated a band of approximate molecular weight of 
33 kDa (arrowed) from both VMJ521- and HSV-1- infected 
cells (lanes 3 and 4 respectively). Lane 18E is a whole­
cell extract of vMJ521-infected CV-1 cells/ and contains 
a strong band migrating at the position of the protein 
precipitated by 1060. Lane IE contains a whole-cell 
extract of HSV-l-infected CV-1 cells. Following 
immunoprecipitation/ samples were analysed on a 9% SDS- 
polyacryl amide slab gel. The cross-linker was bis- 
acrylamide•
Mapping localised the gene to the long unique region of 
the HSV-1 genome between 0.195 and 0.276 map units 
(personal communication/ Dr A.M.Cross). This region
contains the genes UL16 to UL20 and parts of the genes 
UL15 and UL21. Of these genes UL16 and UL18 are predicted 
to encode proteins of similar sizes to that recognised by 
1060 (McGeoch et al., 1988a).
To determine whether 1060 was recognising the product of 
UL18, it was tested in immunoprecipitation experiments 
against an extract from vMJ521-infected CV-1 cells. 1060 
specifically precipitated a strong protein band that 
comigrated with the vMJ521 Mr 33-kDa band. The protein 
precipitated from vMJ521-infected cells also comigrated 
with that precipitated from HSV-l-infected cells, thereby 
confirming that 1060 recognised the product of UL18 
(Figure 21).
UL18 encodes an abundant capsid protein, and 1060 
antibody reacted on Western blots with a preparation of 
purified virions. However,- 1060 repeatedly failed to 
react with purified virions by immunoprecipitation, 
although an antibody to glycoprotein B reacted with the 
same virion preparations. Prior to immunoprecipitation 
the virions were solubilised in a buffer containing 0.5% 
nonidet P40 and 0.5% deoxycholate. This removes the 
virion envelope and much of the tegument, but does not 
disrupt the capsid. In these conditions the epitope 
recognised by 1060 appears to be inaccessible to antibody 
(personal communication, Dr A.M.Cross).
6B MARKER RESCUE OF tsG8
As described in the Introduction ts mutants belonging to 
two complementation groups which fail to assemble capsids 
at NPTs are believed to map to capsid protein genes. Ts2 
has been mapped definitively to UL38 (Pertuiset et al., 
1989). However, the group of mutants exemplified by tsG8
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DNA
rescue
fragment
tit re
31 C 39 C
marker
rescue
efficiency
+ - 1.2 x 107 <1 X 102 8.3 x 10'5
+ UL19 1 x 107 1.6 X 105 16
+ UL18 2 x 107 1 x 102 5 x 10-5
Table 3 Marker rescue of fsG8
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Figure 22. Separation of cells infected with vaccinia 
recombinants into cytoplasmic and nuclear fractions.
Samples were prepared from CV-1 cells infected with 
5 p.f.u. per cell of the following viruses: sample 1 - 
mock-infected; sample 2 - HSV-1; sample 3 - WR vaccinia; 
sample 4 - vMJ521; sample 5 - VMJ535; sample 6 - vMJ534; 
sample 7 - VMJ521; sample 8 - yMJ535; sample 9 - VMJ534. 
Cells were labelled with 35S-methionine from 3 to 
18 h p.i.,> and then harvested. Samples 1 to 6 were 
separated into cytoplasmic (C) and nuclear (N) fractions,' 
while samples 7 to 9 were used as whole-cell extracts. 
Aliquots were analysed on a 9% SDS-polyacrylamide slab 
gel. The cross-linker was bis-acrylamide. Samples 1 to 6 
were analysed in lanes 1 to 6 respectively,' and 30 ul 
(from a total sample volume of 500 ul) of each 
cytoplasmic fraction was used (lanes ’ C'), and 12 ul 
(from a total sample volume of 25 ul) of nuclear fraction 
(lanes *N'). Samples 7 to 9 were analysed in lanes 7 to 9 
respectively,' and 20 ul (from a total sample volume of 
200 ul) of whole-cell extract was used. Arrows indicate 
the positions of proteins which are the products of the 
HSV-1 capsid genes under investigation. These proteins 
are also marked at the left hand side of each lane with a 
dot ( ■ ).
and tsG3 were mapped using a DNA fragment which included 
both the UL18 and UL19 ORFs (Weller et al., 1987). It was 
concluded from the phenotype of these mutants that the 
lesion was in UL19, since UL18 was not recognised as a 
capsid protein gene at that time.
To address this question the lesion in tsG8 was mapped 
using the cloned UL19 and UL18 ORFs contained in pBJ196 
and pBJ183 respectively (pBJ183 was generated by 
subcloning the Sall/BamHI fragment of pMJ521 into 
Sall/BamHI-digested pUC19). Table 3 shows the results 
obtained following cotransfection of tsG8 DNA (provided 
by Dr F.J.Rixon) with either pBJ196 or pBJ183. The 
resultant titres (in p.f.u./ml) of infectious virus at 
the permissive (31°C) and non-permissive (39°C) 
temperatures are shown. The results are also expressed as 
marker rescue efficiencies, which were calculated using 
the formula [(p.f.u./ml 39°C)/(p.f.u./ml 31°C)] x 10^ .
TsG8 was rescued efficiently by pBJ196 thereby confirming 
that the lesion maps to UL19.
7 SUBCELLULAR LOCALISATION OF THE CAPSID PROTEINS
7.1 Cell Fractionation
HSV-1 capsids are assembled in the nucleus of infected 
cells. To examine whether the HSV-1 capsid proteins 
expressed from the vaccinia vectors were efficiently 
transported to the nucleus,' cells infected with vMJ521, 
vMJ535 and vMJ534 were separated into cytoplasmic and 
nuclear fractions. VP5 has previously been shown in cell 
fractionation experiments to locate to the nucleus of 
HSV-l-infected cells (Fenwick et al., 1978). Figure 22
shows that 18 h after infection with HSV-1 VP5, VP19C and 
VP23 are abundant in the nucleus. All three proteins are 
also present in the cytoplasmic fraction. This probably 
reflects the presence of mature virions which are found 
in the cytoplasm and on the cell surface at this time
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Figure 23 • Fractionation of cells infected with vMJ534/ 
showing nuclear localisation of VP19C. Samples were 
prepared from CV-1 cells infected with 5 p.f.u. per cell 
of the following viruses: sample 1 - VMJ534; sample 2 -
WR vaccinia; sample 3 - vMJ521; sample 4 - VMJ534. Cells 
were labelled with S-methionine from 3 to 18 h p.i./ 
and then harvested. Sample 1 was separated into 
cytoplasmic (C) and nuclear (N) fractions,' and samples 
were analysed on a 9% SDS-polyacrylamide slab gel. The 
cross-linker was bis-acrylamide. Sample 1 was analysed in 
lane 1/ and 30 ul (from a total sample volume of 500 ul) 
of the cytoplasmic fraction was used (lane 1C') / and 
12 ul (from a total sample volume of 25 ul) of nuclear 
fraction (lane ’N 1). Samples 2 to 4 were analysed in 
lanes 2 to 4 respectively/ and 20 ul (from a total sample 
volume of 200 ul) of whole-cell extract (lanes 2/ 3 and 
4) was used. Lane 5 contains a sample of HSV-1 B capsids. 
(This sample contains a number of contaminating/ non- 
capsid proteins. Arrows indicate the positions of HSV-1 
capsid proteins}

Figure 24. Separation of cells infected with VMJ542 into 
cytoplasmic and nuclear fractions. The samples used in 
lanes 1 and 2 were prepared from CV-1 cells infected with 
5 p.f.u. per cell of VMJ542. Cells were labelled with 
S-methionine from 3 to 18 h p.i./ and then harvested. 
The sample used in lane 1 was separated into cytoplasmic 
(C) and nuclear (N) fractions. The sample used in lane 2 
was a whole-cell extract. Aliquots were analysed on a 9% 
SDS-polyacrylamide slab gel. The cross-linker was bis- 
acrylamide. 30 ul (from a total sample volume of 500 ul) 
of the cytoplasmic fraction was used (lane ' C'), and 
12 ul (from a total sample volume of 25 ul) of nuclear 
fraction (lane 'N'). 20 ul (from a total sample volume of 
200 ul) of whole-cell extract (lane 2) was used. Arrows 
indicate the positions of proteins which are the products 
of UL26.5. These proteins are also marked at the left 
hand side of lane 1C with a dot ( ■ ).
after infection. By contrast, in recombinant-vaccinia- 
infected cells VP23 and VP5 are almost exclusively 
cytoplasmic. VP19C, however, remains predominantly 
nuclear. This is interesting in that VP19C appears to 
possess intrinsic ability to localise to the nucleus, 
whereas VP5 and VP23 do not. These results were 
consistently obtained over several experiments. Another 
experiment,' shown in Figure 23, confirms the finding for 
VP19C. VP19C expressed by VMJ534 is again found 
predominantly in the nuclear fraction.
Figure 24 shows the results of a fractionation experiment 
carried out on cells infected with vMJ542. Here the two 
bands labelled as VP22a appear to be fairly equally 
divided between the tracks containing the cytoplasmic and 
the nuclear fractions. However, it must be noted that a 
greater proportion of the nuclear sample is used in these 
experiments than of the cytoplasmic sample. This is 
because the fractionation procedure results in a 
cytoplasmic sample of 500 ul, and a nuclear sample of 
25 ul. On these gels, in order to achieve comparable 
amounts of radiolabel in each lane,' 30 ul of cytoplasmic 
sample was used, and 12 ul of nuclear sample, i.e. an 8 
times greater proportion of nuclear sample is present on 
this gel than cytoplasmic sample. Thus it would appear 
from this experiment that in cells infected with vMJ542, 
the products of UL26.5 are located primarily in the 
cytoplasm. However, it does appear that these proteins do 
possess intrinsic ability to locate to the nucleus.
7.2 Cell fractionation in infections with more than one 
recombinant
To determine whether nuclear transport of VP5 and VP23 
required the presence of more than one capsid protein, 
coinfection experiments were performed. Simultaneous 
infection of cells with any pair of the recombinants 
VMJ521, VMJ535 and vMJ534, or a triple infection using
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Figure 25. Fractionation of cells infected with more 
than one recombinant vaccinia virus. Samples were 
prepared from CV-1 cells infected with 5 p.f.u. per cell 
of each of the following viruses: sample 1 - mock-
infected; sample 2 - HSV-1; sample 3 - WR vaccinia;
sample 4 - VMJ521 and VMJ535; sample 5 - VMJ521 and
VMJ534; sample 6 - VMJ535 and VMJ534; sample 7 - vMJ521,< 
VMJ535 and vMJ534; sample 8 - VMJ521; sample 9 - vMJ535; 
sample 10 - VMJ534. Cells were labelled with ^S-
methionine from 3 to 18 h p.i.,« and then harvested. 
Samples 1 to 7 were separated into cytoplasmic (C) and 
nuclear (N) fractions,' and aliquots were analysed on a 9% 
SDS-polyacrylamide slab gel. The cross-linker was bis- 
acrylamide. Samples 1 to 7 were analysed in lanes 1 to 7 
respectively,' and 30 ul (from a total sample volume of 
500 ul) of each cytoplasmic fraction was used (lanes 
’C 1 ),' and 12 ul (from a total sample volume of 25 ul) of 
nuclear fraction (lanes 1N 1). Samples 8 to 10 were 
analysed in lanes 8 to 10 respectively,' and 20 ul (from a 
total sample volume of 200 ul) of whole-cell extract was 
used. Arrows indicate the positions of proteins which are 
the products of the HSV-1 capsid genes under 
investigation. These proteins are also marked at the left 
hand side of each lane with a dot ( ■ ) • VP19C is not 
well-resolved in lanes 5,> 6 or 7.
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Figure 26. Fractionation of cells infected with all four 
vaccinia recombinants. Samples were prepared from CV-1 
cells infected with 5 p.f.u. per cell of each of the 
following viruses: sample 1 - vMJ521,« vMJ535,' VMJ534 and 
VMJ542; sample 2 - VMJ542; sample 3 - vMJ521; sample 4 -
VMJ535; sample 5 - VMJ534. Cells were labelled with ^S-
methionine from 3 to 18 h p.i./ and then harvested. 
Sample 1 was separated into cytoplasmic (C) and nuclear 
(N) fractions/ and aliquots were analysed on a 9% SDS- 
polyacrylamide slab gel. The cross-linker was bis- 
acrylamide. Sample 1 was analysed in lane 1/ and 30 ul
(from a total sample volume of 500 ul) of the cytoplasmic 
fraction was used (lane 'C1 ),' and 12 ul (from a total 
sample volume of 25 ul) of nuclear fraction (lane 'N'). 
Samples 2 to 5 were analysed in lanes 2 to 5
respectively/ and 20 ul (from a total sample volume of 
200 ul) of whole-cell extract was used. Arrows indicate 
the positions of proteins which are the products of the 
HSV-1 capsid genes under investigation. These proteins 
are also marked at the left hand side of each lane with a 
dot ( ■ ). VP19C is not visible in lanes 1C or IN.
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Figure 27. Down-regulation of VP19C in the presence of 
VP5 in a recombinant vaccinia expression system. Samples 
were prepared from CV-1 cells infected with 5 p.f.u. per 
cell of each of the following viruses: lane 1 - VMJ534; 
lane 2 - vMJ535: lane 3 - VMJ534 and vMJ535. Cells were
labelled with 35S-methionine from 3 to 18 h p.i., and 
then harvested. Samples were analysed on a 9% SDS- 
polyacrylamide slab gel. The cross-linker was bis- 
acrylamide. Arrows indicate the positions of proteins 
which are the products of the HSV-1 capsid genes under 
investigation. Both VP19C (lane 1) and VP5 (lane 2) are 
expressed in abundant amounts from the respective 
vaccinia virus in a single infection. In cells infected 
with both viruses (lane 3)/ the level of VP 5 is 
unaffected,' but the level of VP19C is greatly reduced.
all three recombinants, did not affect distribution of 
VP5 or VP23. Figure 25 shows that the location of VP5 and 
VP23 in dual or triple coinfections remained almost 
exclusively cytoplasmic. However, in these experiments, 
VP19C was not visible in lanes where cells coinfected 
with vMJ534 and with any other recombinant were used 
(tracks 5, 6 and 7 in Figure 25). VP19C was, however,
always well resolved on these gels in control tracks of 
whole-cell extracts of vMJ534-infected cells.
Figure 26 shows the result of a fractionation experiment 
performed on cells infected with all four recombinants. 
The distribution of VP22a appears to be unaltered, when 
compared to its distribution in cells infected only with 
VMJ542 (compare with Figure 24). Similarly, the 
distribution of VP23 appears to be unaltered, being
almost exclusively cytoplasmic. However, although VP5 is 
still predominantly cytoplasmic, some VP 5 is clearly 
present in the nuclear fraction. This presence of VP5 in 
the nucleus was not a reproducible feature of these
experiments and may be due to a weakness in the
fractionation procedure. Again, VP19C is not visible on 
this gel.
7.3 Downregulation of VP19C expressed by vMJ534 in dual 
infections with a second recombinant virus
In the experiments reported in section 7.2, VP19C could 
not be detected in cells coinfected with vMJ534 and any 
other of the recombinant viruses. In order to assess this 
more accurately, whole-cell extracts of cells infected
with VMJ534, with vMJ535, and with both viruses,- were 
analysed by electrophoresis. This experiment is shown in 
Figure 27. Lane 1 contains an extract of cells infected 
with VMJ534, and VP19C can be seen at the position 
marked. Lane 2 contains an extract of cells infected with 
VMJ535, and VP5 is clearly visible. Lane 3 contains cells 
infected with equal amounts of both viruses. VP5 is
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Figure 28. Immunofluorescent staining of HSV-l-infected 
cells using the anti-VP23 monoclonal antibody 1060. CV-1 
cells were infected with 5 p.f.u. per cell of HSV-1 and 
were incubated at 37°C for 18 h. Cells were then stained 
with a 1/100 dilution of 1060 (A) or a 1/100 dilution of 
control ascites (B) / followed by a 1/200 dilution of 
FITC-conjugated goat anti-mouse immunoglobulin G, to 
detect VP23•
A
Figure 29. Immunofluorescent: staining of vMJ521-infected 
cells using 1060. CV-1 cells were infected with 5 p.f.u. 
per cell of VMJ521 and were incubated at 37°C for 18 h. 
Cells were then stained with a 1/100 dilution of 1060 (A) 
or a 1/100 dilution of control ascites (B),' followed by a 
1/200 dilution of FITC-conjugated goat anti-mouse 
immunoglobulin G, to detect VP23.
present in amounts similar to those found with vMJ535 
alone, but VP19C is present only in greatly reduced 
amounts. The reason for this is not known.
7.4 The intracellular distribution of capsid proteins 
determined by immunofluorescence
To further investigate the intracellular distribution of 
the capsid proteins, and in particular to confirm that 
the cytoplasmic distribution of the products of UL18 and 
UL19 was a true reflection of their intracellular 
distributions and not a result of the fractionation 
procedure, the subcellular localisation of individual 
capsid proteins was determined by immunofluorescence. The 
method used was one of indirect immunofluorescent 
staining, using either a mouse monoclonal or a rabbit 
polyclonal antibody as the primary antibody, and a goat 
FITC-conjugated anti-mouse or anti-rabbit secondary 
antibody.
7.4.1 Immunofluorescent localisation of VP23
This was performed using monoclonal antibody 1060 as 
primary antibody. Cohen et al. (1980) have previously
shown by immunofluorescent techniques that VP23 is 
localised to the nucleus of HSV-l-infected cells. These 
results, and the results of the fractionation of HSV-l- 
inf ected cells presented above (section 7.1), led to the 
expectation that use of 1060 to stain HSV-l-inf ected 
cells would show a nuclear location of VP23. As expected,- 
VP23 was found to be predominantly nuclear in HSV-1- 
infected cells (Figure 28). In marked contrast, in cells 
infected with vMJ521, VP23 was predominantly cytoplasmic 
in agreement with the cell fractionation experiments 
(Figure 29). vMJ521-infected cells do show a slight 
nuclear fluorescence, as evidenced by the presence of 
unstained nucleoli.
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Figure 30. The structures of pqDCAT and pBJ182
The proportions of this diagram are approximately to scale and are based on 
the details of pgDCAT given by Everett (1986) and by Gaffnev et al. (1985).
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Figure 31. Immunofluorescence of cells transfected with 
pBJ182,i showing cytoplasmic distribution of VP23.
Confluent monolayers of BHK cells were transfected with 
1 ug each of pBJ182,' pl75/ and pill DNA,' and incubated at 
38.5°C for 72 h. Cells were then stained with a 1/100 
dilution of 1060 (A and B) or a 1/100 dilution of control 
ascites (C),' followed by a 1/200 dilution of FITC- 
conjugated goat anti-mouse immunoglobulin G,> to detect 
VP23 •

7.4.2 Expression of VP23 from a plasmid vector
There are two possible reasons why VP23 adopts a 
cytoplasmic localisation in these experiments. The first 
is that VP23 lacks a nuclear targetting signal and is 
dependent on some other protein (presumably HSV- 
specified) to transport it to or to retain it in the 
nucleus. The second is that the normal transport 
mechanism is disrupted by the vaccinia host. It was 
thought unlikely that the failure of VP23 to accumulate 
in the nucleus was a consequence of the vaccinia vector 
interfering with the normal transport mechanisms since 
VP22a when expressed by VMJ542 (see below, sections 
7.4.5, 7.4.6 and 7.4.7) and other herpesvirus proteins
expressed from the same vector (personal communication, 
Dr A.J.Davison) were known to enter and to accumulate in 
the nucleus. However, to eliminate this possibility the 
distribution of VP23 expressed from a plasmid vector was 
examined. The plasmid pBJ182 was constructed by cloning 
the UL18 coding sequences contained on a 1370-base-pair 
Sall-BamHI fragment from pMJ521 (refer to Figure 9) into 
the Sail and BamHI sites of pgDCAT, such that UL18 was 
under the control of the HSV-1 gD promoter. The 
structures of pgDCAT and of pBJ182 are shown in Figure 
30. The gD promoter is a strong early promoter exhibiting 
very high levels of activation in the presence of two 
HSV-1 immediate early transactivating proteins VmwllO and 
Vmwl75,' which were expressed from the plasmids pill and 
pl75 respectively (Everett, 1986). 1 ug of each of
pBJ182, pill and pl75 was cotransfected into BHK cells, 
which were then incubated for 72 hours at 38.5°C. When 
the distribution of VP23 in these cells was examined by 
fluorescent staining with 1060, a very small proportion 
of cells was found to be fluorescing. Presumably the
efficiency of transfection was very low,- and very few
cells received sufficient amounts of all three plasmids 
necessary for expression of VP23. When fluorescence was
detected, it was similar to that in vMJ521-infected
cells, ie predominantly cytoplasmic (Figure 31).
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Figure 32. Immunofluorescence of cells infected with 
vMJ521,> VMJ535 and vMJ534,< showing predominantly 
cytoplasmic distribution of VP23. CV-1 cells were 
infected with 5 p.f.u. per cell each of vMJ521f> vMJ535 
and vMJ534 and were incubated at 37°C for 18 h. Cells 
were then stained with a 1/100 dilution of 1060 (A) or a 
1/100 dilution of control ascites (B), followed by a 
1/200 dilution of FITC-conjugated goat anti-mouse 
immunoglobulin Gf' to detect VP23.

Figure 33, Immunofluorescence of vMJ535-infected cells. 
CV-1 cells were infected with 0.05 p.f.u. per cell of 
vMJ535 (A) or 5 p.f.u. per cell of WR vaccinia (B) and 
were incubated at 37°C for 18 h. Cells were then stained 
with a 1/200 dilution of 10555, followed by a 1/200 
dilution of FITC-conjugated goat anti-rabbit 
immunoglobulin G.
7.4.3_____Immuno fluorescent localisation of VP23 in
coinfection experiments
The intracellular distribution of VP23 in cells infected 
with VMJ521 was further examined by coinfecting cells 
with VMJ521 and either or both of vMJ535 and vMJ534. The 
results showed that neither of the other two capsid 
proteins,- VP5 nor VP19C, when expressed in the 
recombinant vaccinia system,’ had any effect on the 
distribution of VP23. Figure 32 shows that in CV-1 cells 
infected with vMJ521, VMJ535 and VMJ534, VP23 still has a 
predominantly cytoplasmic location, similar to that in 
Figure 29A.
7.4.4 Immunofluorescent localisation of VP5
The intracellular distribution of VP5 was also examined 
using immunofluorescent techniques. Powell & Watson 
(1975) and Cohen et al. (1980) have previously
demonstrated that VP5 adopts a nuclear location in HSV-1- 
infected cells. The antibody used in the present 
experiments,’ 10555, was a rabbit anti-HSV-1 antibody, and 
as such,’ was not specifically raised against VP5. It was 
therefore unsuitable for use in HSV-l-infected cells. 
However, in studies of human HSV-l-immune sera, VP5 has 
been shown to be a dominant antigen (Eberle & Mou, 1983),> 
and it was felt likely that 10555 would recognise VP5. In 
practice it was found that either 10555 or the anti­
rabbit secondary antibody produced a level of background 
fluorescence which sometimes made the results difficult 
to interpret. The most effective way to control these 
experiments was by using a low m.o.i. which resulted in 
fields of view showing only a few infected cells against 
a background of uninfected cells. Figure 33A shows a CV-1 
cell monolayer infected with vMJ535 at an m.o.i. of 
0.05 p.f.u. per cell, and stained using 10555 as primary 
antibody. Two cells show levels of fluorescence higher 
than background. The fluorescence is stronger in the
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Figure 34. Immunofluorescence of HSV-l-inf ected cells 
using monoclonal antibody 5010 ^ showing nuclear 
localisation of VP22a. CV-1 cells were infected with 
5 p.f.u. per cell of HSV-1 and were incubated at 37°C for 
18 h. Cells were then stained with a 1/50 dilution of 
5010 (A) or a 1/50 dilution of control ascites (B),>
followed by a 1/200 dilution of FITC-conjugated goat 
anti-mouse immunoglobulin G,- to detect VP22a.

Figure 35, Immunofluorescence of vMJ542-infected cells 
showing nuclear localisation of the products of UL26.5.
CV-1 cells were infected with 5 p.f.u. per cell of VMJ542 
and were incubated at 37°C for 18 h. Cells were then 
stained with a 1/50 dilution of 5010 (A) or a 1/50
dilution of control ascites (B),> followed by a 1/200 
dilution of FITC-conjugated goat anti-mouse
immunoglobulin G,> to detect VP22a.
cytoplasm,' although there is apparent nuclear 
fluorescence also. This suggests a predominantly 
cytoplasmic location for VP5. Figure 33B shows CV-1 cells 
infected with WR vaccinia at an m.o.i. of 5 p.f.u. per 
cell, and stained with 10555. The relatively high 
background fluorescence obtained with this antibody is 
again illustrated.
Antibody 10555 was also used in similar experiments on 
cells infected with VMJ534. However, this antibody did 
not show a detectable response to VP19C in these 
experiments.
7.4.5 Immunofluorescent localisation of the products of 
UL26.5 expressed from VMJ542
The nuclear localisation of VP22a in HSV-l-infected cells 
has been demonstrated by immunofluorescent techniques by 
Heilman et al. (1979), Cohen et al. (1980) and Rixon et
al. (1988). In the latter report, the anti-VP22a antibody 
employed was the monoclonal antibody 5010, which was also 
the antibody used in the experiments reported here. 
HSV-l-infected CV-1 cells showed strong nuclear 
fluorescence when stained with 5010 as primary antibody
(Figure 34). In cells infected with vMJ542, the
fluorescence was again strongly nuclear (Figure 35). This 
is in contrast to the results obtained for VP23 and for 
VP5. This result does, however, conflict with the result 
obtained for the distribution of the products of UL26.5 
in the cell fractionation studies reported above in
sections 7.1 and 7.2. This anomaly will be treated 
further in the Discussion.
7.4.6 The effect of the products of UL26.5 on the
location of VP23 determined by immunofluorescence
The coinfection experiments reported in section 7.4.3
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Figure 36, The effect of the presence of the products of 
UL26.5 on the intracellular distribution of VP23 in a 
recombinant vaccinia expression system. CV-1 cells were 
infected with 5 p.f.u. per cell each of vMJ521 and vMJ542 
and were incubated at 37°C for 18 h. Cells were then 
stained with a 1/50 dilution of 5010 (A) or a 1/100
dilution of 1060 (B), followed by a 1/200 dilution of
FITC-conjugated goat anti-mouse immunoglobulin G,> to 
detect VP22a and VP23 respectively.
were extended by coinfecting cells with VMJ521 and 
VMJ542• Figure 36A shows that in cells infected with both 
viruses,' the location of the products of UL26.5 is the 
same as in cells infected only with vMJ542 (see Figure 
35). However, Figure 36B shows that when vMJ521 is 
coinfected with VMJ542, there is a change in the 
distribution of VP23. In infections with both viruses, a 
majority of cells exhibit nuclear fluorescence when 1060 
is used as primary antibody. Most of the cells in Figure 
36B show strong nuclear fluorescence as well as 
cytoplasmic fluorescence. This is in marked contrast to 
the distribution of VP23 shown in Figure 29. This result 
suggests that the products of UL26.5 not only have 
intrinsic ability to localise to the nucleus, but that 
they can also effect nuclear localisation of VP23. This 
result contrasts with the results obtained by 
fractionation of coinfected cells (section 7.2),> where 
the products of UL26.5 did not appear to affect the 
location of VP23. In the experiments reported in this 
section a minority of cells were seen in which VP23 was 
retained in the cytoplasm. These may represent cells 
which were not infected with both viruses.
7.4.7 The intracellular location of the products of 
UL26.5 determined by immunoelectron microscopy
The anti-VP22a monoclonal antibody 5010 has been 
successfully used for identifying the sites of 
subcellular location of unprocessed and processed forms 
of VP22a in HSV-l-infected cells by electron microscopy 
using immunogold localisation procedures (Rixon et al., 
1988)• In order further to examine the intracellular 
distribution of the products of UL26.5 when expressed by 
the recombinant vaccinia virus vMJ542, CV-1 cells 
infected for 18 h with 5 p.f.u. per cell of vMJ542 were 
embedded in Lowicryl K4M resin. Sections were incubated 
with monoclonal antibody 5010 and this was visualised 
using a goat anti-mouse antibody tagged with 10-nm gold
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Figure 37. The intracellular distribution of the 
products of UL26.5 demonstrated by immune electron-
microscopy. Monolayers of CV-1 cells on 30-mm plates were 
infected with VMJ542 (A)/ HSV-1 (B) / or WR vaccinia (C)/ 
at a multiplicity of 5 p.f.u. per cell/ and incubated at 
37°C for 18 h. The cells were harvested, fixed/ then 
embedded in Lowicryl K4M resin. Sections were incubated 
with a 1/50 dilution of 5010/ followed by a 1/50 dilution 
of goat anti-mouse antibody tagged with 10-nm gold
particles/ and then exposed to OsO^ vapour to enhance
contrast. Symbols: C/ cytoplasm; N/ nucleus? Nl/
nucleolus? ^ / HSV capsid? ► / vaccinia particle. Bar 
marker represents 0.5 um.

particles. The results shown in Figure 37 indicate that 
when expressed by VMJ542, the products of UL26.5 are 
located in the nucleus. vMJ542-infected cells did not 
show significant binding of gold particles in the 
cytoplasm. Figure 37A shows that the products of UL26.5 
are specifically localised in the nucleus but are 
excluded from the nucleolus. This result conflicts with 
those presented in sections 7.1 and 7.2, but is in 
agreement with the result presented in section 7.4.5; 
these results will be treated further in the Discussion. 
HSV-1-infected cells (Figure 37B) also showed nuclear 
binding of gold particles, to intranuclear capsids, as 
was previously demonstrated by Rixon et al. (1988). In WR 
vaccinia-infected cells (Figure 37C) there was a low 
background level of gold particles over the whole section 
but no specific binding to any region of the cell was 
observed.
8 ATTEMPTS TO ASSEMBLE CAPSID SUB-STRUCTURES IN VIVO 
WITH CAPSID PROTEINS EXPRESSED FROM RECOMBINANT VIRUSES
In a variety of viruses,' purified capsid proteins have 
been shown to self-assemble into capsids, capsid-like 
particles or subunits of capsids. Assembly of structural 
entities has also been achieved by expression of capsid 
genes using in vivo expression systems, including 
recombinant vaccinia viruses. Details of these results 
are given in the Discussion. Thus the results of other 
workers suggested that some form of particle self- 
assembly might be achieved using individual capsid 
protein genes expressed from recombinant vaccinia 
viruses. Of particular interest was VMJ535, because VP5 
as the structural component of capsomers might be able to 
self-assemble to form capsomers, as is the case with the 
polyomavirus major capsid protein VP1 (Salunke et al., 
1986). VMJ542 was also of interest, in view of the 
proposed role of VP22a as a scaffolding protein, and the 
finding of Newcomb & Brown (1991) that VP22a can exist in
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Figure 38. Electron microscopy of cells infected with 
vaccinia recombinants / showing no evidence of HSV-1 
structural intermediates. Monolayers of CV-1 cells on 30- 
mm plates were infected with 5 p.f.u. per cell each of 
vMJ521,< vMJ535,< VMJ534 and VMJ542 (A)/ HSV-1 (B), or WR 
vaccinia (C)/ and incubated at 37°C for 18 h. The cells 
were harvested/ fixed/ then embedded in Epon 812 resin. 
Sections were stained with uranyl acetate and lead 
citrate. Symbols: C/ cytoplasm; N/ nucleus; |> / HSV
capsid ;• ►  / vaccinia factory/particle. Bar marker 
represents 0.5 um.
c
a free form as discrete condensations.
Monolayers of CV-1 cells infected with 5 p.f.u. per cell 
of HSV-1/ WR vaccinia,- vMJ521, vMJ535,> vMJ534 or vMJ542 
for 18 h were embedded in Epon 812 resin for examination 
by electron microscopy. Although formation of vaccinia 
particles occurred apparently normally in infections with 
recombinant viruses, no novel structural element could be 
seen in sections of these cells. As it was possible that 
more than one capsid protein is necessary for any kind of 
assembly to be formed, further experiments were attempted 
by coinfecting cells with all four recombinants. Again,' 
no novel structural element was observed (Figure 38) . The 
products of the four capsid genes UL18, UL19,' UL38 and
UL26.5 are not sufficient for assembly of capsid-like 
particles in this expression system.
9 TIME COURSE OF SYNTHESIS OF VP23
As part of the study of the properties of VP23, the 
availability of the newly characterised antibody 1060 
made possible an investigation of the kinetics of 
synthesis of VP23 by HSV-1. The UL18 mRNA was reported to 
be regulated with early-late kinetics in lytic infections 
by Costa et al. (1985). In the present experiments the
kinetics of synthesis of VP23 were examined in 
collaboration with Dr A.M.Cross. HSV-1 was allowed to 
adsorb onto BHK cells for 1 hour at 37°C and then 
replicate plates were labelled with ^ S  methionine in 
succcessive 1 hour pulses. By immunoprecipitation of 1 h 
pulses Dr A.M.Cross showed that VP23 was already 
precipitable by 1060 in cells pulsed 2 to 3 hours post­
infection. Longer exposures of the autoradiographs failed 
to show any VP23 in the 1-2 hour pulse. Amounts of VP23 
steadily increased in later samples.
To examine this in more detail,' a further experiment 
tested whether the DNA synthesis inhibitor
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Figure 39. The time course of expression of VP23. 
Western blot of HSV-l-infecte<* cell extracts. BHK
monolayers on 50-mm plates were infected with 20 p.f.u. 
per cell of HSV-1 strain 17 (lanes 1 to 10)/ PAAR-1 
(lanes 11 to 15)/ or were mock-infected (lane 16). These 
cells were incubated at 37°C in the absence (lanes 1 to 
5/ and 16) or the presence (lanes 6 to 10/ and 11 to 15) 
of PAA (300 ug/ml)/ and were harvested at 0 h (lanes 
1/6/11)/ 3 h (lanes 2/7/12)/ 6 h (lanes 3/8/13)/ 9 h
(lanes 4/9/14)/ and 12 h (lanes 5/10/15/16) post 
infection. Samples were separated on a 9% SDS- 
polyacrylamide slab gel and transferred to a 
nitrocellulose membrane filter by transverse 
electroblotting. The membrane was probed with 1060 to 
detect VP23. Bound 1060 was visualised using the Promega 
Protoblot horseradish peroxidase system.
phosphonoacetic acid (PAA) would affect the production of 
VP23 • PAA was used at a concentration of 300 ug per ml, 
which reduces virus replication to a level of less than 
5% of the no PAA control in cells infected with HSV-1 
strain 17 (Johnson et al., 1986). The PAA-resistant
mutant,' PAAr-l (Hay & Subak-Sharpe,' 1976), which induces 
wild-type levels of DNA synthesis in the presence of 
300 ug per ml of PAA, was included in the experiment as a 
control. This control would have been important had VP23 
been a true-late protein. A second control, demonstrating 
the efficient inhibition of DNA synthesis by PAA at the 
concentration used, is discussed below. The results of 
this experiment are shown in Figure 39. BHK monolayers on 
50-mm plates were infected with HSV-1 strain 17 (lanes 1 
to 10)/ PAAr-l (lanes 11 to 15),- or were mock-infected 
(lane 16). These cells were incubated in the absence 
(lanes 1 to 5 and lane 16) or presence (lanes 6 to 10 and 
11 to 15) of PAA,- and were harvested at 0 hours (lanes 
1,6,11),- 3 h (lanes 2,7,12), 6 h (lanes 3,8,13), 9 h
(lanes 4,9,14) or 12 h (lanes 5,19,15,16) post infection. 
Cells incubated in the presence of PAA had been 
maintained in PAA for 1 h prior to infection. Samples 
were separated on a 9% SDS-polyacrylamide gel and 
transferred to a nitrocellulose membrane filter by 
transverse electroblotting. The membrane was probed with 
1060 to detect VP23. Bound 1060 was visualised using the 
Promega Protoblot horseradish peroxidase system. Figure 
39 shows that VP23 was first detectable in this system at 
3 h p.i. (lane 2), and that levels of VP23 steadily 
increased in later samples (lanes 3 to 5). Similar 
amounts of VP23 were produced by strain 17-infected cells 
in the presence of PAA, and by PAAr-l-infected cells in 
the presence of PAA, at corresponding times post 
infection. A second control experiment was carried out,' 
using a second gel, identical to the one used for Figure 
39. This gel was blotted,- and probed with antibody 14327,' 
which recognises the true-late products of gene US11 
(MacLean et al., 1987). Bound antibody was visualised 
using 125I-labelled Protein A. In this experiment, the
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products of US11 were not detected in HSV-l-infected 
cells in the presence of PAA,- but they were detected in 
HSV-l-infected cells in the absence of PAA and in PAAr-l- 
infected cells in the presence of PAA. Thus the levels of 
PAA used in these experiments were successful in 
inhibiting synthesis of DNA (result not shown). VP23 is 
produced early in infection, steadily increases in later 
samples and is not dependent on viral DNA synthesis. This 
is in agreement with the finding of Costa et al. (1985).
10 THE DNA-BINDING PROPERTIES OF VP19C
Several of the capsid proteins of HSV have been reported 
to be DNA-binding. Bayliss et al. (1975) identified an
HSV-l-infected cell protein of 43 kDa which bound DNA in 
affinity chromatography experiments. They identified this 
protein as the capsid protein VP21, because during PAGE 
it comigrated with the VP21 present in purified virions. 
In similar experiments, Powell & Purifoy (1976) and 
Purifoy & Powell (1976) identified 155-kDa infected-cell 
proteins in HSV types 1 and 2 which were DNA-binding. 
These were identified as the capsid protein VP5 because 
they comigrated with the VP5 present in purified virions. 
Binding was very inefficient, when compared to the 
binding activities of other infected-cell proteins. The 
study of Bayliss et al. (1975) did not identify VP5 as
being DNA-binding. Blair & Honess (1983) reported a study 
of the DNA-binding structural proteins of herpesvirus 
saimiri which also included some observations on HSV-1. 
Proteins of interest were identified by binding of 
labelled DNA to nitrocellulose filters containing 
electrophoretically separated proteins of purified 
virions. They did not detect DNA-binding activity in VP5 
or VP19C. They did detect an HSV-1 DNA-binding protein of 
38 kDa, which they identified as the virion protein VP22. 
The study of Pinard et al. (1987) also identified the 
HSV-1 VP22 as a DNA-binding protein, using the same 
technique. They also identified the virion proteins VP13
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and VP14 as being DNA-binding. Blair & Honess (1983),
although they did not name the candidate proteins, also 
found strong DNA-binding activity in a protein or 
proteins of this size (approximately 82 kDa) in virions 
of HSV-1.
A 38-kDa HSV-2 protein was found by Burdett & Docherty 
(1987) and Burdett et al. (1990) to be DNA-binding in
affinity chromatography experiments. This protein was 
claimed by these workers to be a component of the capsid. 
However, in an attempt to identify this protein, they 
specifically eliminated VP22a, and mapped the protein to 
a region on the HSV-2 genome spanning 0.605 to 0.720 map 
units. This region is not known to encode any capsid
protein. In view of the lack of a candidate capsid
component of this size, it would seem that the 38-kDa
protein is not a capsid protein.
Another recent investigation of HSV DNA-binding
structural proteins is that of Braun et al. (1984a).
Again, proteins of interest were located on
nitrocellulose filters, which this time contained 
electrophoretically separated proteins of purified B and 
C capsids. They did not detect any DNA-binding activity 
associated with VP5 or any protein of approximately 
40 kDa. However, they did detect in HSV -1 and -2 an 
efficient DNA-binding protein which they identified as 
VP19C•
The availability of a recombinant vaccinia virus 
expressing VP19C enabled repetition of the work of Braun 
et al. (1984a) in an attempt to investigate the DNA-
binding properties of this protein. vMJ534 expresses
VP19C in abundant amounts and represents a more 
convenient source of VP19C than do purified capsids. The 
reported DNA-binding activity of VP19C is of special 
interest because its proposed location in the capsid 
floor suggests that it may have a role in anchoring DNA 
within the capsid.
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Figure 40A. Investigation of the DNA-binding properties
of VP19C. CV-1 cells were infected with 5 p.f.u. per cell 
of vMJ534 and were labelled with 35S-methionine from 3 to 
24 h p.i. Whole-cell extract (lane l)f' and unlabelled 
HSV-1 virions (lane 2),' were electrophoretically 
separated on a 10.5% SDS-polyacrylamide slab gel. The 
cross-linker was DATD. The proteins were then transferred 
by transverse electrophoresis onto a nitrocellulose 
filter. The filter was then probed for DNA-binding 
activity using nick-translated 32P-labelled pG35a DNA. 
Figure 40A shows an autoradiograph developed following a 
2-hour exposure of the filter. There is no detectable 
DNA-binding activity in the VMJ534 lane (lane 1). In lane 
2, there is a protein (arrowed) exhibiting strong DNA- 
binding activity. This protein is not VP19C, as can be 
seen by a comparison with Figure 40B.
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Figure 40B. Identification of a DNA-binding protein 
present in HSV—1 virions. Figure 40B shows an 
autoradiograph developed following a 2-day exposure of 
the same filter which was used in the production of 
Figure 40A,- and shows the positions of 3^S-labelled 
proteins in lane 1. Lanes 3 to 7 is an autoradiograph of 
an SDS-polyasrylamide gel containing electrophoretically 
separated 35S-labelled proteins which can be used to 
identify the proteins of interest in lanes 1 and 2. Lane 
3 contains HSV-1 virions. Lane 4 contains HSV-1 capsids. 
Lanes 5 to 7 contain samples of CV-1 cells infected with 
5 p.f.u. per cell of VMJ534 (lane vMJ535 (lane 6) or
VMJ521 (lane 7) and labelled with S-methionine from 1 
to 24 h p.i. Several vaccinia or cellular proteins are 
common to lanes 1/ 5/ 6 and 7/ and have been used to
align the two parts of Figure 40B. The positions of 
several HSV-1 structural proteins are indicated with a 
dot ( ■ ) between lanes 2 and 3 and with arrows at the 
right hand side of the figure.
Figure 40A shows the result of an experiment in which a 
sample of CV-1 cells infected with 5 p.f.u. per cell of 
VMJ534 and labelled with 3~*S-methionine from 1 to 
24 h p.i. was electrophoresed (Figure 40A lane 1) 
alongside a preparation of HSV-1 virions (Figure 40A lane 
2). The virions were not radiolabelled. The proteins were 
transferred by transverse electroblotting onto a 
nitrocellulose filter and incubated in the presence of 
nick-translated 32P-labelled pG35a DNA. Figure 40A shows 
an autoradiograph developed following a 2-hour exposure 
of this filter. There is no detectable DNA-binding 
activity in the VMJ534 sample (40A lane 1). In the virion 
sample (40A lane 2) there is a protein present (arrowed) 
exhibiting strong DNA-binding activity. This protein is 
not VP19C, as can be seen by a comparison with Figure 
40B.
Figure 40B lanes 1 and 2 show an autoradiograph developed
following a 2-day exposure of the same filter which was
used in the production of Figure 40A, and shows the
positions of JS-labelled vMJ534-infected-cell proteins
in lane 1. Figure 40B lanes 3 to 7 is an autoradiograph
of an SDS-polyacrylamide gel containing
3 5electrophoretically separated J S-labelled proteins which 
can be used to identify the proteins of interest in lanes 
1 and 2. Lane 3 contains HSV-1 virions. Lane 4 contains 
HSV-1 capsids. Lanes 5 to 7 contain samples of CV-1 cells 
infected with 5 p.f.u. per cell of vMJ534 (lane 5),
vMJ535 (lane 6) or VMJ521 (lane 7) and labelled from 1 to
24 h p.i. Several vaccinia or cellular proteins are
common to lanes 1, 5, 6 and 7, and have been used to
align the two parts of Figure 40B. The positions of
several HSV-1 structural proteins are indicated with dots 
between lanes 2 and 3 and with arrows at the right hand 
side of the figure. The capsid proteins VP19C, VP5 and 
VP23 can be seen in lanes 5, 6 and 7 respectively. These 
capsid proteins, and the capsid protein VP22a, can be
seen in lane 4. VP5 and VP19C are also visible in lane 3.
The position of VP19C in lane 1 is easily identifiable by
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a comparison with lanes 3, 4 and 5. It is clear that the 
strong DNA-binding protein in lane 2 is not VP19C.
A minor band is present in Figure 40B lane 2 at the 
position of VP19C. A comparison with Figure 40A lane 2 
reveals that several minor bands have appeared during the 
2-day exposure of the filter. During the 2-day exposure, 
a second sheet of film was placed immediately behind the 
one shown as Figure 40B lanes 1 and 2. This sheet was 
activated only by emissions due to bound P, and 
revealed several minor bands in lane 1 of similar 
intensity to those in Figure 40B lane 2, including a 
minor band at the position of VP19C. The low intensity of 
these bands, and the fact that several minor bands were 
detected, suggests that this does not represent 
significant DNA-binding activity by VP19C.
The identities of the four most intense bands in Figure 
40B lane 2 are of interest and can be determined by a 
comparison with lanes 3 and 4 and by comparison with 
published HSV-1 virion protein profiles (Heine et al., 
1974; Marsden et al., 1976; Dargan, 1986; McLean et al., 
1990). The band immediately above VP19C is probably VP16. 
VP16 is visible in lane 3; the protein immediately below 
is probably gD. The doublet above VP16 in lane 2 is 
probably VP13 and VP14. The strong DNA-binding protein 
which migrates at a position just above the position of 
VP23 is probably VP22, which is the only virion protein 
of this size. Thus, although this experiment has failed 
to demonstrate significant DNA-binding activity in VP19C, 
it has confirmed the finding of Blair & Honess (1983) and 
of Pinard et al. (1987) that VP13, VP14 and VP22 are DNA- 
binding .
No DNA-binding activity due to VP5 is detectable in 
Figure 40B lane 2. vMJ535 was also used in similar 
experiments to assess the DNA-binding properties of VP5. 
Again, no DNA-binding activity was found to be associated 
with VP5 in this system.
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11 THE DISULPHIDE LINKAGE OF VP5 AND VP19C
VP5 and VP19C were reported to be covalently linked by 
disulphide bonds in capsids of HSV-2 (Zweig et al.,
1979a) . In their experiments, B capsids were investigated 
using a two-dimensional PAGE system. Samples were run in 
the first dimension in a cylindrical gel under non­
reducing conditions. The cylindrical gel was then treated 
with a reducing agent (dithiothreitol), in order to 
disaggregate proteins bound by disulphide bonds. The gel 
was then placed across the top of a slab gel and
electrophoresis was conducted at right angles to the 
first dimension. In this system, a diagonal line of
protein spots results from proteins which in both
directions migrate according to their molecular weights. 
Proteins which were linked under non-reducing conditions 
migrate as higher molecular weight complexes in the first 
dimension. Under reducing conditions, these complexes are 
disaggregated, and in the second dimension these proteins 
show up as spots lying to the left of the diagonal.
Prior to the report of Zweig et al. (1979a), McCombs &
Williams (1973) found that HSV-1 nucleocapsids underwent 
collapse if treated with the reducing agent 
2-mercaptoethanol at 80°C. Capsids did not collapse at 
this temperature in the absence of the reducing agent. 
Electron microscopy, which revealed the collapse of 
capsids, showed that the intercapsomeric bonding had not 
been disrupted. They concluded that some disulphide 
linkages were involved in structural integrity. Given the 
proposed location of VP19C in the capsid floor, some form 
of interaction with capsomers would seem likely. This 
could be a crucial feature of structural integrity. 
Capsids of polyomavirus have been shown to be resistant 
to mild treatment with SDS, due to the presence of 
disulphide bonds (Walter & Deppert, 1974).
Repetition of the experiments of Zweig et al. (1979a)
using cells co-infected with VMJ535 and VMJ534 was
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Figure 41 • Two-dimensional electrophoresis of VP5 and 
VP19C* CV-1 cells were infected with 5 p.f.u, per cell of 
VMJ534 (lane 1)/ VMJ535 (lane 2), or with 5 p.f.u. per 
cell of both viruses. Cells were labelled with 35S- 
methionine from 1 to 24 h p.i./ and were harvested. A 
sample of infected-cell extract from the dual infection 
was electrophoresed through a cylindrical gel (described 
in Materials and Methods) under non-reducing conditions. 
The cylindrical gel was then cemented along the top of a 
9% SDS-polyacrylamide slab gel (the cross-linker was bis- 
acrylamide) and electrophoresis was conducted at right 
angles t’o that of the first direction/ under reducing 
conditions. Control lanes 1 and 2 were also run in the 
second dimension. Lane 1 shows the position at which 
VP19C (arrowed) migrates in the second dimension. Lane 2 
shows the position at which VP5 (arrowed) migrates in the 
second dimension. Lane 1 also contains some VP5/ due to 
spill-over of sample during loading of the gel. A 
diagonal line can be seen which consists of proteins 
which migrate according to their molecular weights in 
both dimensions. To the left of this diagonal can be seen 
a smear of VP5 (marked at the left hand side with a dot).
undertaken in an attempt to determine whether disulphide 
linkages would form under these circumstances. One such 
experiment is represented in Figure 41. Control lanes 
show the positions of VP5 (lane 2) and VP19C (lane 1) in 
the second dimension. On the two-dimensional gel of 
coinfected cells, a number of protein species lie to the 
left of the diagonal, representing cellular or vaccinia 
polypeptides which were disulphide-linked under non­
reducing conditions (in these experiments the reducing 
agent used was 2-mercaptoethanol). A smear migrating in 
the second dimension at the position of VP5 can be seen 
to the left of the diagonal, indicating that under non­
reducing conditions it migrated with a molecular weight 
higher than 155 kDa. This is interesting because it shows 
that VP5 had formed disulphide bonds with some other 
protein. Such smearing of VP5 also occurred during the 
two-dimensional electrophoresis of purified capsids 
carried out by Zweig et al. (1979a), when VP5 was shown
to form disulphide bonds with VP19C. In Figure 41, if 
VP19C had formed part of a higher molecular weight 
complex with VP5 in the first dimension, a spot migrating 
in the second dimension at the position of VP19C 
(indicated by the position of VP19C in lane 1) would be 
expected lying vertically below one point of the smear of 
VP5. No such spot could be detected in these experiments. 
Thus, these experiments did not confirm that the HSV-1 
VP5 and VP19C can form disulphide-linked complexes. 
However, in view of the results presented in section 7.3, 
the existence of disulphide linkages between VP5 and 
VP19C can not be discounted. A further weakness is the 
lack of other factors. Zweig et al. (1979a) used
preformed capsids. In the present experiments, free 
protein was used; formation of correct bonding 
arrangements may require another protein such as VP22a, 
or may require capsid assembly. Also, VP5 expressed by 
VMJ535 remains in the cytoplasm. Physiological conditions 
in the cytoplasm are not suitable for assembly of capsid 
proteins of polyomavirus (Montross et al., 1991). 
However, similar two-dimensional electrophoresis
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experiments using HSV-1 virions have failed to 
demonstrate disulphide linking between VP5 and VP19C 
(personal communication, Dr F.J.Rixon).
12 EXPRESSION OF UL19 IN A RECOMBINANT BACULOVIRUS
12.1 Cloning of UL19 into a baculovirus transfer vector
Many recent studies on the properties of a variety of 
proteins have been greatly facilitated by the use of the 
baculovirus Autographa californica nuclear polyhedrosis 
virus (AcNPV) as an expression vector. These studies 
include several on a number of virus structural systems, 
and have enabled elucidation of aspects of structure and 
assembly in these viruses. Further details of these 
studies are given in the Discussion. Other studies have 
shown that a subset of HSV-1 proteins, when expressed by 
recombinant baculoviruses,« are able to associate normally 
as in HSV-1 infections, retaining full biochemical 
activity (Dodson et al., 1989; Calder & Stow, 1990; Stow, 
1992). Study of aspects of HSV-1 capsid structure and 
assembly using recombinant baculoviruses may prove to be 
a useful alternative to the vaccinia expression system 
used in this thesis. Recombinant baculoviruses may also 
prove useful for the production and purification of large 
amounts of capsid proteins. It would be of particular 
interest to be able to crystallise VP5 and analyse it by 
X-ray crystallography.
As an initial step in developing a recombinant 
baculovirus system, a virus was constructed which 
contained the UL19 gene. The transfer vector used for 
this purpose was pAcYMl (Matsuura et al., 1987), which 
contains sequences from AcNPV which flank the polyhedrin 
gene. The polyhedrin gene has been deleted, and a BamHI 
restriction site allows insertion of foreign DNA between 
the polyhedrin gene promoter and polyadenylation 
sequences.
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Figure 42. The structures of pAcYMI and pBJ199
The proportions of this diagram are approximately to scale and are 
based on the details of pAcYMI given by Matsuura et al. (1987).
VP5
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Figure 43, Expression of VP5 by a recombinant 
baculovirus. Spodoptera fruqiperda cells were harvested 
48 h after infection with 10 p.f.u. per cell of AcNPV 
(lane l)f> AcUL19 (lane 2),< or AcRP231acZ (lane 3). 
Samples of total cellular proteins were analysed on a 
7.5% SDS-polyacrylamide slab gel. The cross-linker was 
bis-acrylamide. After electrophoresis the gel was stained 
with Coomassie brilliant blue,- destained/ dried/ and 
photographed. The positions of VP 5 (155 kDa) and
jj -galactosidase (135 kDa) are indicated.
The UL19 coding sequences on a 4184-base-pair Bglll 
fragment from pBJ196 were ligated into the BamHI site of 
pAcYMI. A clone, pBJ199, was selected having the UL19 
ORF under the control of the baculovirus polyhedrin gene
promoter. A diagram of the structures of pAcYMI and
pBJ199 is given in Figure 42.
12.2 Construction of a recombinant baculovirus
A recombinant baculovirus containing UL19 was 
constructed J essentially as described by Elliott &
McGregor (1989). pBJ199 DNA was cotransfected with AcNPV 
DNA into Spodoptera fruqiperda cells by calcium phosphate 
precipitation. After incubation at 28°C for 48 h, serial 
dilutions of the supernatant fluid were used to infect
S.fruqiperda cells in 9§-well microtitre plates which 
were then incubated at 28°C for 48 h. Supernatants from 
these cultures were used to produce plaques on 
S.fruqiperda monolayers, and polyhedrin-minus plaques 
were identified by microscopic examination. Several such 
plaques were picked, and purified by two further rounds 
of plaque purification. One plaque was grown up to 
produce a high-titre stock, and this virus was designated 
AcULl9.
12.3 Expression of VP5 by AcUL19
S.fruqiperda cells were infected with 10 p.f.u. per cell 
of wild-type AcNPV, AcUL19 and AcRP231acZ, and incubated 
at 28°C for 48 h. AcRP231acZ contains the lacZ gene 
(Possee & Howard, 1987). Samples containing total 
cellular proteins were analysed by SDS-PAGE. Figure 43 
shows the separated proteins visualised by Coomassie 
brilliant blue staining. Lane 1 contains the sample 
prepared from AcNPV, lane 2 that prepared from AcUL19, 
and lane 3 that from AcRP231acZ. The products of UL19 and 
of lacZ are readily apparent in lane 2 (VP5, 155 kDa) and
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lane 3 ( ji-galactosidase, 135 kDa) and are arrowed. This 
indicates efficient expression of VP5 by AcUL19. In some 
samples VP5 was estimated to form over 10% of total cell 
protein (personal communication, Dr F.J.Rixon).
12.4 Electron microscopy of AcUL19-infected cells
In view of the large amounts of VP5 made by AcUL19, 
electron microscopy of AcUL19-infected cells was 
undertaken in order further to assess the expression of 
VP5. S.fruqiperda cells infected with 10 p.f.u. per cell 
of AcUL19 were incubated at 28°C for 48 h. The cells were 
harvested, fixed, then embedded in Epon 812 resin prior 
to electron microscopic examination of thin sections. 
However, as was the case with vMJ535-infected cells 
(section 8), no novel structural element or inclusion 
body could be detected in AcUL19-infected cells.
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DISCUSSION
1 CAPSID PROTEIN PROFILES
General agreement exists as to the protein components of 
HSV-1 capsids (Gibson & Roizman, 1972; Zweig et al., 
1979a; Cohen et al., 1980; Rixon et al., 1990). These 
proteins are: VP 5, VP19C, VP21,> VP22a, VP23,’ VP24 and
VP26 (refer to Table 1). However, not all of these 
proteins are present in all capsid types. The genes which 
encode six of the seven known capsid proteins have now 
been identified: VP5 - UL19; VP19C - UL38;
VP22a - UL26.5; VP23 - UL18; VP24 - UL26; VP26 - UL35. 
The seventh capsid protein, VP21, is also believed to be 
a product of UL26. However, direct demonstration of the 
exact regions of UL26 which encode VP21 and VP24 is 
lacking, and this problem will be discussed in a later 
section.
The protein profiles shown in Figure 7 afford an 
interesting demonstration of the HSV-1 capsid proteins 
and their distributions through a sucrose velocity 
gradient. The capsid proteins described by previous 
workers are all present. Three additional proteins were 
also detected in A capsids in Figure 7. The protein of 
approximate molecular weight of 110 kDa, running at a 
position between VP5 and VP19C, is previously undescribed 
in HSV-1 capsids, and some evidence suggests that it is a 
breakdown product of VP5 (personal communication,' 
Dr F.J.Rixon). It is interesting to note that the capsid 
protein profiles of two other herpesviruses contain 
proteins which are possible counterparts of this protein. 
Stevely (1975) reported a protein profile for capsids of 
PRV which included a major capsid protein of 150 kDa and 
a protein running immediately below the MCP at a position 
of 120 kDa. Similarly, Dolyniuk et al. (1976) reported a
protein profile for capsids of EBV which included a MCP 
of 160 kDa and a protein running immediately below this 
at a position of 144 kDa, which was not present in EBV 
virions. It is not clear why this novel protein in the 
present study is strongly associated with A capsids. The
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two other novel proteins highlighted in Figure 7 are also 
strongly associated with A capsids. It is possible that 
they also are breakdown products of VP5.
The herpesvirus capsid is a highly defined structure 
which presumably means that architectural constraints 
select against gross variations in the conformations of 
constituent proteins (Heine et al., 1974; Dargan, 1986). 
It seems unlikely that an essential structural component 
in one type of herpesvirus would be dispensible in 
another. Capsid protein profiles published for a variety 
of herpesviruses indicate that this is probably the case, 
with the notable exceptions of human and simian CMV, 
which apparently lack a VP19C homologue,- and CCV, which 
has only three capsid proteins. Sequencing studies have 
recently raised the possibility that CCV may not be a 
herpesvirus, and it will be interesting to see if further 
structural analyses of the capsid support this 
suggestion.
Many investigations of herpesvirus capsid composition 
have reported more than seven proteins. Thus, in the 
study of Grose et al. (1983), the capsids of VZV were 
found to contain approximately 15 proteins, but electron 
microscopy of the capsid samples showed that they 
contained virions in a ratio of unenveloped:enveloped 
particles of 10:1. The study of Kemp et al. (1974) on
EHV-1 also isolated capsids on a gradient containing 
whole-cell extracts. Electron microscopy did not detect 
the presence of contaminating virions in the capsid 
samples, but the possibilty exists that these samples did 
contain capsids originating from the cytoplasm which had 
been enveloped but which had lost the envelope during the 
disruptive preparative procedures. Such capsids usually 
retain some tegument material, which would not easily be 
detected by electron microscopy, but which would account 
for the experimental finding of 11 capsid proteins. A 
related problem is that some workers have prepared 
capsids by chemical stripping of the envelope and
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tegument from virions. Since the stripping process does 
not normally achieve removal of all tegument material, 
the resultant capsids might still possess several 
tegument species. Thus in the study of Shiraki et al. 
(1989) on HHV-6, virions were stripped of envelope and 
tegument by treatment with NP40, and the resultant 
capsids were found to contain approximately 10 proteins. 
Using a similar procedure, Dolyniuk et al. (1976) found a 
275-kDa protein in the capsids of EBV. It is probable 
that this protein is in fact a homologue of the 273-kDa 
HSV-1 tegument protein VP1, which is known to be closely 
associated with capsids (Gibson & Roizman, 1972). The 
possibility also exists of there being contaminating 
cellular proteins in any preparation of capsids. Even 
when apparently 'clean' preparations of intranuclear 
capsids are used, anomalies can result. Sanchez-Pinel £t 
al. (1989) reported a monoclonal antibody which
specifically reacted with a 75-kDa component of EBV 
capsids. The study of Dolyniuk et al. (1976) did not
detect a capsid protein of this size in EBV. It is 
possible that the capsids used by Sanchez-Pinel et al. 
(1989) to prepare the monoclonal antibody, and in 
subsequent investigations of that antibody, were 
contaminated with a non-capsid protein. Thus in these 
studies the large numbers of 'capsid' proteins observed 
probably reflect deficiencies in the purification 
protocols resulting in incomplete separation of 
intranuclear (unenveloped) from cytoplasmic (enveloped) 
particles. Some workers have not used isolated nuclei, 
but instead have used whole-cell extracts, and the 
gradient systems employed have not been able to achieve 
good resolution of capsids from virions.
Thus it would appear that all the constituent proteins of 
the HSV-1 nucleocapsid are known, and that the genes 
which encode them have been identified. That a relatively 
small number of genes is directly involved in capsid 
assembly is suggested by the fact that despite the large 
number of mutants available for study, those in only two
134
complementation groups (mapping in UL19 and UL38) are 
known to have a direct effect on capsid assembly. This 
knowledge enables more detailed study of capsid structure 
and assembly than has hitherto been possible.
2 CLONING OF GENES
This thesis reports the cloning of four capsid protein 
genes of HSV-1: UL18, UL19,- UL26 and UL38. Three of these 
genes,- UL18, UL19 and UL38, were successfully expressed 
in a recombinant vaccinia virus system. The capsid 
protein gene UL26.5, cloned by other workers (Preston et 
al.,' 1992),' was also expressed in a recombinant vaccinia 
virus.
UL35 was not cloned because it had not been identified as 
a capsid gene at the time of this work. It has recently 
been cloned successfully using the polymerase chain 
reaction (personal communication, Dr F.J.Rixon).
The cloning of UL35 brings the number of HSV-1 capsid 
protein genes which have been cloned to six: UL18,' UL19,' 
UL26, UL26.5, UL35 and UL38. This being the case, the
genes encoding all seven HSV-1 capsid proteins have now 
been cloned. With the cloning of all the capsid protein 
genes,' there is now much potential for further work to 
investigate HSV-1 capsid structure and assembly.
3 CHOICE OF EXPRESSION SYSTEM
High-level transient expression of heterologous DNA has 
been achieved in mammalian cells by a variety of methods,- 
which fall into two general classes. Direct 
administration of DNA usually requires less effort than 
is involved in construction of a recombinant viral 
vector, but the efficiency of DNA transfer by 
conventional methods is poor. The experiment in which
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VP23 was expressed from UL18 under the control of the 
HSV-1 gD promoter is an example of this problem. The 
experiment was useful in that it confirmed that the 
failure of VP23 to accumulate in the nucleus of VMJ521- 
infected cells was not a consequence of the vaccinia 
vector interfering with the normal transport mechanisms. 
However, introduction of pBJ182 into BHK cells by calcium 
phosphate coprecipitation was clearly an inefficient 
process,- in that only a very small proportion 
(approximately 1%) of cells exhibited any fluorescence, 
and this severely limits the potential for further 
experiments using this technique. It has been reported 
that efficiency of transfection can be significantly 
increased by using unilamellar phospholipid vesicles 
(liposomes) to mediate DNA transfection, and in 
particular the synthetic cationic lipid DOTMA may prove 
useful in extending these experiments (Keown et al., 
1990; Karger & Komro, 1990). If high levels of 
transfection could be achieved by this means, it might 
prove possible to use plasmids expressing capsid genes to 
examine capsid assembly.
By contrast, the ability of viruses to infect cells 
efficiently means that effectively 100% targeting of 
cells can be achieved using a recombinant virus. HSV-1 is 
itself suitable for use as an expression vector in that 
its large genome size allows for accomodation of 
additional DNA sequences without adversely affecting 
virus replication. Foreign DNA is usually introduced by 
homologous recombination. An HSV-1 vector has been
engineered which is based on the t_s mutant tsk, which
expresses only immediate early genes at the NPT. This 
vector allows the insertion of heterologous DNA sequences 
under the control of an HSV IE promoter into a unique 
Xbal site in an intergenic position in the short unique
genome region (Rixon & McLauchlan, 1990). The HSV-1
capsid genes UL26 and UL26.5 have been expressed using 
this vector (Preston et al., 1992), which would also have 
potential for expression of other capsid proteins.
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The project reported in this thesis began with the 
intention of expressing capsid proteins in recombinant 
vaccinia viruses. Vaccinia virus is now widely used as an 
expression vector (reviewed by Mackett et al., 1985; 
Mackett & Smith, 1986; Piccini et al., 1987). In common 
with HSV the large genome (approximately 185 kb) of 
vaccinia has many non-essential sites suitable for 
insertion of DNA sequences. Other proteins which have 
been expressed in recombinant vaccinia viruses have shown 
correct synthesis, processing and transport (eg Ansardi 
et al., 1991; Hong & Engler, 1991).
The insertion plasmids (Davison & Moss, 1990) used in 
this project for introduction of capsid genes into 
vaccinia aim to improve the ease of isolation of 
recombinants by two means. The first is that the foreign 
DNA is inserted into and disrupts the vaccinia TK gene. 
Thus TK- recombinants can be selected by the 
incorporation into the culture medium of BUdR,' which 
inhibits TK+ virus. Incorporation of the (5-galactosidase 
gene into the insertion plasmid further enhances 
selection of recombinants,' which are easily recognisable 
by the resultant blue plaque colour, not possessed by 
plaques arising from spontaneous TK” mutants. However, 
considerable difficulty was encountered during the course 
of this project in attempts to isolate recombinant 
vaccinia viruses. The chief problem was the low 
efficiency of recombination, resulting in formation of
very few blue plaques. A second problem was the poor 
selection by BUdR. Poor inhibition of growth of TK+ virus 
meant that plates were infected at relatively high m.o.i. 
resulting in microscopic plaques following recombination 
reactions using pMJ535 (UL19) and pMJ542 (UL26.5). The 
recombinant viruses only yielded plaques visible to the 
naked eye following several passages in BUdR. Recombinant 
viruses could not be obtained using pMJ540 and pMJ541 
(full-length and truncated versions respectively of
UL26). The UL26 protein which would be expressed by such
viruses is a protease, and it may be that it is toxic to
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vaccinia virus, thus preventing replication and plaque 
formation. However, the UL26 protease has since been
successfully cloned into baculovirus (personal
communication, Dr V.G.Preston).
High-level expression of heterologous DNA has also been 
achieved successfully using the baculovirus Autographa 
californica nuclear polyhedrosis virus as a vector 
(Doerfler,- 1986; Emery,' 1991). The viral genome of
approximately 126 kbp can, like that of vaccinia virus 
accon^)date relatively large segments of additional
foreign DNA. Also, as is the case with the vaccinia 
expression system, the insect cells used in the
propagation of baculoviruses appear capable of 
accomplishing most post-translational modifications that 
are required to render a foreign gene product
biologically active (eg Urakawa et al., 1989). A number
of herpesvirus proteins have been expressed from
baculovirus vectors. Of particular interest is the recent 
work showing that a subset of HSV-1 proteins, when
expressed by recombinant baculoviruses, are able to 
associate normally as in HSV-1 infections, retaining full 
biochemical activity (Dodson et al., 1989; Calder & Stow, 
1990; Stow,' 1992). It would be of great interest to be 
able to express HSV-1 capsid proteins in such a system in 
order to study aspects of capsid structure and assembly. 
The large amounts of foreign protein which can be 
synthesised by placing the gene of interest under the 
control of the polyhedrin gene promoter make this a 
potentially useful system for purifying proteins for 
structural studies. This thesis reports the expression of 
VP5 by a recombinant baculovirus.
4 EXPRESSED PROTEINS
This thesis reports the construction of four recombinant 
vaccinia viruses each of which contains an HSV-1 capsid 
protein gene. These viruses, and the HSV-1 genes they
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contain, are VMJ521 (UL18), vMJ535 (UL19), vMJ542 
(UL26.5) and VMJ534 (UL38). In three cases, the capsid 
protein expressed by the recombinant vaccinia virus was 
shown to migrate at the position of the equivalent 
protein in a profile of purified HSV-1 capsids. Thus 
VMJ535 produced a protein migrating at the position of 
VP5, VMJ534 one which migrated at the position of VP19C, 
and VMJ521 one migrating at the position of VP23 (Figure 
18) . The apparent similarity of size between the native 
HSV-1 proteins and those expressed by the recombinant 
viruses supports the view that there is little or no 
post-translational modification of VP5, VP19C or VP23.
The products of UL26.5 do undergo significant post- 
translational processing (Liu & Roizman, 1991b; Preston 
et al., 1992), and the size of the processed product 
present in capsids would not necessarily be the same as 
that of the protein expressed by the recombinant. In the 
case of VMJ542, containing UL26.5,' two proteins of 
approximate size 40 kDa were expressed (Figure 19), which 
were characterised using a monoclonal antibody (5010) 
known to react specifically with processed and 
unprocessed forms of VP22a. Immunoprecipitations 
performed using this antibody showed that the proteins 
expressed by VMJ542 are the unprocessed forms of VP22a 
(Figure 20). This was predictable, in that the processing 
event is a cleavage accomplished by the product of UL26,' 
which is not present during infections with VMJ542. UL26 
was cloned during this project, but attempts to introduce 
this gene into vaccinia virus were unsuccessful. Such a 
recombinant could be used in a coinfection experiment 
with VMJ542, to determine whether the protease product of 
UL26 is able to accomplish the cleavage of the products 
of UL26.5 in a vaccinia system, as it is able to do in a 
transient expression assay (Liu & Roizman, 1991b) and 
when expressed under IE conditions in an HSV-1 vector 
(Preston et al.,' 1992). It is not known why vMJ542
produced two novel protein bands. The UL26.5 sequences 
used to construct vMJ542, when expressed in an HSV vector
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under IE control, also produced two protein bands 
(Preston et al., 1992).
5 ANTIBODIES
Several aspects of this project were hampered by a lack 
of suitable antibodies against VP5 and VP19C. The 
antibody 10555 was a rabbit anti-HSV antibody which was 
able in an immunofluorescence assay to recognise VP5 when 
expressed by VMJ535. However, it did not recognise VP19C 
when expressed by vMJ534. Presumably VP19C is not such a 
prominent antigen as is VP5. Two rabbit antibodies raised 
against HSV-1 virions and kindly supplied by 
Dr J.C.M.MacNab were also used in these IF experiments. 
However, neither recognised VP5 or VP19C. Attempts have 
been made in this department to produce monoclonal 
antibodies against capsid proteins following immunising 
mice with purified capsids (personal communication, 
Dr A.M.Cross),' but these have so far been unsuccessful. 
An attempt was made during the course of this project to 
raise an antibody against VP19C by immunising rabbits 
with a synthetic branching peptide. The sequence of the 
branches was designed to be identical to that of the N- 
terminal 15 amino acids of VP19C. Sera from two rabbits 
thus immunised were both found to have very high titres 
to the synthetic peptide,' when tested by ELISA. However,' 
neither showed any detectable response to VP19C when 
tested in immunofluorescence or Western blot assays. 
Antibodies against VP19C were successfully prepared by 
Yei et al. (1990) by two methods. Three synthetic
peptides, of lengths of 15, 15 and 13 amino acids
respectively were prepared and each was conjugated with a 
carrier protein. The sequences of the synthetic peptides 
were those of three different internal regions of the 
VP19C of HSV-2. The conjugates were used to immunise 
rabbits. A fourth antibody was prepared by immunising 
rabbits with a 59-kDa fusion protein containing 197 amino 
acids of an internal region of the HSV-2 VP19C. All four
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antibodies showed cross-reactivity with the type 1 
protein.
6 SUBCELLULAR LOCALISATION OF CAPSID PROTEINS
6.1 Cell Fractionation
Whilst some newly synthesised herpesvirus proteins remain 
in the cytoplasm,' the structural proteins are amongst 
those which migrate to the nucleus of infected cells 
(Spear & Roizman, 1968; Mark & Kaplan,' 1971), the site of 
nucleocapsid assembly (Morgan et al., 1954). In 
experiments similar to those reported in this thesis, 
Fenwick et al. (1978) demonstrated the transferral of VP5 
from cytoplasm to nucleus during the first 6 h of 
infection with HSV-1. This process was found to be 
inhibited by the arginine analogue canavanine and by the 
proline analogue azetidine, although the mechanism of 
this inhibition was not known. That nuclear localisation 
of VP5 in HSV-infected cells is an efficient process was 
demonstrated by Bibor-Hardy et al. (1985a), who showed
that 80% was tightly bound to the nuclear matrix as early 
as 4 h after infection. In a study of the kinetics of the 
intracellular transport of the HCMV MCP,- Yamauchi et al. 
(1985) found that 90% of the newly synthesised protein 
localised to the nucleus during the 3 h period from 72 to 
75 h post infection.
The results of experiments reported in this thesis show 
that VP 5, VP19C and VP23 are able to locate to the 
nucleus in HSV-1 infections (Figure 22). In recombinant 
vaccinia infections, VP5 and VP23 are almost exclusively 
cytoplasmic, indicating lack of an endogenous nuclear 
localisation signal (NLS). VP19C and VP22a did partially 
localise to the nucleus in recombinant vaccinia 
infections (Figures 22, 23 and 24) . VP22a appeared to
have the ability to affect the location of VP5 (Figure 
26), although this effect was limited and was not
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reproducible. This effect may have been due to a possible 
weakness of the fractionation procedure,- in that nuclear- 
bound proteins could leach into the cytoplasmic fraction 
during fractionation. A proportion of capsid proteins did 
fractionate with the cytoplasm in HSV-infected cells - 
this may represent leakage but probably also represents 
the true state of affairs. Capsid proteins are 
synthesised in the cytoplasm so must be expected to be 
present there. Capsid proteins present in the cytoplasm 
late in infection may also represent the presence of 
progeny virions.
6.2 Immunofluorescence
Immunofluorescent staining techniques have been used to 
demonstrate that VP5 adopts a nuclear location in 
HSV-l-inf ected cells (Powell & Watson,- 1975; Cohen £t 
al.,- 1980). The intracellular distributions of other
herpesvirus MCPs have also been investigated using this 
technique,- and have also shown strong nuclear 
localisation: VZV (Vafai et al., 1990), PRV (Yamada et
al., 1991),- HCMV (Rudolph et al., 1990a), HHV-6 (Littler 
et al.,- 1990) and EBV (Vroman et al., 1985). The HSV-1
capsid proteins VP19C, VP23 and VP26 were also shown to 
adopt a nuclear location in IF experiments by Cohen et 
al. (1980). Using an antibody raised against VP21/VP22a,>
Cohen et al. (1980) also demonstrated a nuclear location
for VP21/VP22a in HSV-infected cells. Heilman et al. 
(1979) and Rixon et al. (1988) have also used IF to
demonstrate a nuclear location of VP22a. The VP22a 
homologue in HCMV has been shown by IF to be distributed 
roughly evenly between the cytoplasm and the nucleus of 
infected cells (Landini et al., 1991b). Experiments 
reported in this thesis confirm the nuclear locations of 
VP22a and VP23 in HSV-l-inf ected cells by IF using the 
monoclonal antibodies 5010 and 1060 respectively.
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The cytoplasmic locations of VP23 when expressed by a 
vaccinia vector (Figure 29) and by a plasmid vector 
(Figure 31), and of VP5 when expressed by a vaccinia 
vector (Figure 33), are of interest as a demonstration 
that these proteins do not have intrinsic ability to 
localise to the nucleus of infected cells. These results 
are in accordance with the result obtained by cell 
fractionation.
IF experiments using 5010 demonstrated that, when 
expressed by a vaccinia vector, VP22a adopts a nuclear 
location (Figure 35) in a similar fashion to the 
situation in HSV-infected cells (Figure 34). VP22a was 
also shown to be specifically located to the nucleus of 
vMJ542-infected cells in immunoelectron microscopy 
experiments (Figure 37). This distribution differs from 
that obtained by cell fractionation,' and as described 
above, probably reflects weaknesses in the fractionation 
approach. It is worth noting that, using cell 
fractionation, Braun et al. (1984b) found that some
unprocessed forms of VP22a were specifically restricted 
to the cytoplasm. However, Rixon et al. (1988) using IF
and immune EM showed that the unprocessed forms of VP22a 
made by ts^ l201 are specifically located in the nucleus. 
This suggests that cell fractionation can generate 
misleading conclusions. The unprocessed forms of VP22a 
made by t£l201 probably correspond to those made by 
VMJ542.
The ability of VP22a to affect the intracellular location 
of VP23, as demonstrated by IF (Figure 36),' conflicts 
with the fractionation result. This again is difficult to 
explain. The potential inherent in the fractionation 
procedure for degradation of proteins and for leaching of 
nuclear-bound proteins into the cytoplasmic fraction 
suggests that this is the least reliable method of the 
two. Further work is necessary to analyse in more detail 
the effect of VP22a on the intracellular transport of 
VP23.
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An interesting example of a capsid protein which affects 
the intracellular location of another capsid protein is 
the 42-kDa polyomavirus MCP VP1. This protein contains an 
endogenous NLS (Moreland & Garcea, 1991) which is 
sufficient for nuclear localisation (Stamatos et al.,’ 
1987; Montross et al., 1991). The polyomavirus capsid 
contains two other proteins, VP2 (35 kDa) and VP3 (23
kDa), and it has been shown by cell fractionation studies 
that VP1 directs the nuclear localisation of VP3, whereas 
VP2 is able to locate to the nucleus independently 
(Stamatos et al., 1987).
7 KINETICS OF SYNTHESIS OF CAPSID PROTEINS
Results presented in this thesis are in agreement with 
the designation of VP23 as an early-late protein. VP5 and 
VP22a have also been defined as early-late proteins, as 
would be expected for capsid proteins given the temporal 
appearance of capsids. The status of VP19C is less clear; 
UL38 has been described as a true late gene. However, 
some capsid assembly does occur under conditions of 
inhibition of synthesis of DNA, indicating that 
sufficient VP19C must be available since this protein is 
essential for capsid formation. The different properties 
of VP19C and the other capsid proteins is intriguing in 
view of the finding that the levels of VP19C found in 
cells coinfected with VMJ534 and VMJ535 are greatly 
reduced compared to the levels present in cells infected 
only with VMJ534. If expression of VP 5 in some way 
interferes with expression of VP19C,' it may be necessary 
for these two proteins to be synthesised at different 
stages of the HSV lytic cycle. It has recently been shown 
that VP26 is also regulated as a true-late protein 
(McNabb & Courtney,- 1992). However, it has not been 
established that VP26 is essential for capsid assembly. 
No mutant in UL35 has been isolated. Stable capsids can 
exist without VP26 (Newcomb & Brown,- 1991), which might 
indicate that VP26 is not essential for capsid assembly.
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8 DNA-BINDING PROPERTIES OF CAPSID PROTEINS
Experiments carried out as part of this thesis have 
failed to demonstrate the DNA-binding ability of VP19C 
reported by Braun et al. (1984a). VP19C expressed by a 
recombinant vaccinia virus did not bind DNA in a 
Southwestern assay, nor did VP19C present in virions bind 
DNA in this assay even though other known virion DNA- 
binding proteins (Blair & Honess, 1983; Pinard et al., 
1987) showed DNA-binding activity.
It is interesting that another research group has been 
unable to demonstrate DNA-binding activity in intact 
VP19C. They do however have some evidence to suggest that 
in some virus stocks a DNA-binding protein is released by 
cleavage of approximately 100 amino acids from the 
N-terminus of VP19C (personal communication,' 
Dr P.Sheldrick). They are continuing investigation of 
this phenomenon using VMJ534.
The polyomavirus MCP VP1 is a high-aff inity, non- 
sequence-specific DNA-binding protein. DNA inhibits the 
self-assembly of VP1 into capsid-like structures in vitro 
(Salunke et al.,- 1986). The binding activity is localised 
at the amino terminus (Moreland et al., 1991),' and a 
recent study of SV40 virion structure shows that the N- 
terminal 15 amino acids of VP1 are oriented towards the 
interior of the virion (Liddington et al.,' 1991). The
proposed location of VP19C in the capsid floor (Newcomb & 
Brown, 1989) would be an ideal site for interaction with 
DNA. If VP19C does have significant DNA-binding activity,* 
it may be that it,' rather than the now-discounted core 
'plug1,* is the means of anchorage of DNA within the 
capsid.
9 ARTIFICIAL CAPSID ASSEMBLY
During the course of the work presented in this thesis,
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assembly of capsids or structural intermediates of a 
number of viruses has been achieved by expression of 
viral structural proteins in heterologous vectors. For 
example/ a recombinant vaccinia virus which expresses the 
gag and pol genes of HIV-1 and which produces HIV-like 
particles has been constructed by two research groups 
(Karacostas et al./ 1989; Shioda & Shibuta, 1990). Other 
workers have assembled HIV-like particles during dual 
infections using two recombinant vaccinia viruses which 
express the gag and env genes (Haffar et al.,» 1990;
Vzorov et al.,’ 1991). Ansardi et al. (1991) constructed
two recombinant vaccinia viruses,' one expressing the 
poliovirus PI capsid precursor polyprotein,' and the other 
expressing the poliovirus protease 3CD. Dual infections 
using these viruses resulted in the correct cleavage of 
the PI protein to yield the three capsid proteins VP0,< 
VP3 and VP1,’ which assembled correctly to form empty,’ 
immature poliovirus virions. A further interesting 
example is that of the vaccinia virus constructed by Hong 
& Engler (1991) which expresses the adenovirus fibre 
protein. The protein expressed was correctly assembled 
into trimers,' glycosylated,' and transported to the 
nucleus. A NLS was identified in this protein.
Baculovirus vectors have also been used in studies of 
virus assembly. The complete coding region of a 
poliovirus,’ when expressed in a recombinant baculovirus,- 
resulted in synthesis of empty,- immature poliovirus 
particles comprising VPO, VP3 and VP1 (Urakawa et al.,- 
1989). The major core protein of bovine rotavirus, VP2,- 
assembles into core-like particles when expressed by a 
recombinant baculovirus. In dual infections with another 
baculovirus expressing the component of the bovine 
rotavirus inner shell (VP6),- single-shelled capsids were 
formed which contained cores of VP2 (Labbe et al.,- 1991). 
Sabara et al. (1991) assembled double-shelled rotavirus­
like particles by expressing bovine rotavirus proteins in 
two recombinant baculoviruses. One recombinant expressed 
VP6,' and the other expressed the major component of the
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outer shell,' VP7. A baculovirus vector expressing the two 
major core proteins VP3 and VP7 of the reovirus 
bluetongue virus (BTV) assembled core-like particles 
(French & Roy, 1990)• A second baculovirus recombinant 
expressing the two outer capsid proteins VP2 and VP5 of 
BTV, when used in dual infections with the core protein 
recombinant,' led to the synthesis of double-shelled BTV 
particles (French et al., 1990).
In the above-cited examples,' assembly was an intrinsic 
feature of the capsid proteins involved. Thus it was 
hoped that the same would be true for HSV,- and that by 
simultaneous expression of HSV-1 capsid proteins using 
recombinant vaccinia viruses, assembly of capsids or 
capsid-like structures might occur. However,' electron 
microscopy failed to detect any capsids,' suggesting that 
the four capsid proteins VP5, VP19C,' VP22a and VP23 are 
not sufficient for the assembly of capsids in the 
vaccinia system. It is not known whether VP24 and/or VP26 
are essential for assembly of structural units,' or 
whether another non-capsid protein or proteins is 
necessary to achieve assembly. Capsid assembly may not 
have occurred because expression from a recombinant 
vaccinia virus might have altered transport or 
localisation of capsid proteins preventing them from 
coming together in the appropriate circumstances. This 
was thought a possible reason for the cytoplasmic 
locations of VP5 and VP23 and was the reason for the 
experiment expressing VP23 from a plasmid,' which ruled 
out this possibility. It is also possible that 
considerations of stoichiometry or features of temporal 
regulation of expression of capsid proteins might be 
important. These factors are not regulated in the 
vaccinia system. The observation that VP5 suppresses 
levels of VP19C in vaccinia suggests that they might need 
to be expressed at different times as in wild-type HSV 
infections. However,' the most likely reason for the lack 
of capsid assembly in vaccinia is simply that not all the 
HSV capsid proteins were present in these experiments,-
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and that some of these are essential for assembly. Minor 
capsid proteins can be essential for capsid stability. An 
example of such a protein is found in the 15-kDa 
adenovirus protein known as polypeptide IX (van Oostrum & 
Burnett, 1985). Particles of adenovirus,' when 
disassembled,' consistently yield groups-of-nine (GON) 
hexons,- which are the major shell component (Burnett,' 
1985; van Oostrum et al.,' 1987). Polypeptide IX acts as a 
capsid cement,' bonding hexons into the highly stable GON 
assemblies (Furcinitti et al.,- 1989; Stewart et al.,'
1991). Thus the role of polypeptide IX appears to be 
similar to that proposed for VP23 (Schrag et al.,' 1989). 
The role of VP26 is not known. It may be that VP26 plays 
an essential role in capsid stability during assembly. 
The fact that VP26 can be removed from capsids without 
disruption (Newcomb & Brown, 1991) does not necessarily 
militate against this suggestion,' since VP22a which is 
essential during capsid assembly is not essential for 
stability of mature capsids.
A further experiment carried out as part of the studies 
reported in this thesis was an attempt made to complement 
ts2 at the NPT in a coinfection with VMJ534. However,' 
electron microscopy did not detect formation of HSV 
capsids under these circumstances. This is interesting in 
that the only known mutation in ts2 is in the essential 
capsid gene UL38. Apparently,' VP19C,' the product of UL38,< 
does not direct the assembly of capsids by ts2 when 
supplied by a recombinant vaccinia virus. Infection with 
vaccinia interferes with HSV capsid assembly. However,' 
control experiments using sequentially staggered 
coinfections of wild-type vaccinia and wild-type HSV-1 
showed that HSV capsids can be formed under these 
circumstances•
Now that all the recognised HSV-1 capsid protein genes 
have been identified and cloned, they can be included in 
future experiments. It may be possible to achieve the 
project aim of assembly of capsids in a heterologous
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system. As A and B capsids are the only known immature 
capsid forms/ it would be interesting to be able to 
assemble other structural units/ which might yield 
valuable information on the pathway of assembly and 
maturation. The work of Newcomb & Brown (1991) showing 
that capsids lacking VP26 are stable suggests that it may 
be possible to construct capsids without VP26. Artificial 
assembly of capsids may prove a useful method for mass 
production of capsids for cryoelectron microscopy. If 
capsids can be assembled with this system/ it might also 
be possible to construct chimeric capsids using capsid 
proteins of other herpesviruses. This has been done with 
rotavirus (Labbe et al., 1991), with BTV (Loudon et al. /
1991) and with poliovirus (Rombaut et al. / 1991).
Experiments with assembly of capsids could be extended by 
the use of truncated forms of capsid proteins. This and 
other techniques such as the use of site-directed 
mutagenesis can be useful in identification of NLSs and 
other interactive sites, and regions of structural 
significance.
Although all known capsid genes are now available for
study it is still possible that there may be other/ non- 
capsid/ proteins essential for assembly. Cellular 
proteins necessary for capsid assembly would be supplied 
in the vaccinia system/ but other HSV-encoded proteins 
which might have a transient role in structure or
assembly would not. Capsid assembly may not be possible 
in the vaccinia (or baculovirus) system using only the 
recognised capsid proteins.
10 SCAFFOLDING PROTEINS and CHAPERONES
The potential role of VP22a as a scaffolding protein 
during HSV-1 capsid assembly is of great interest. The
precedents for such a function of VP22a are the 
scaffolding proteins of the double-stranded DNA
bacteriophages (reviewed in Casjens & Hendrix/ 1988). A
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good example of this is in the assembly of heads of the 
Salmonella typhimurium lambdoid phage P22 (reviewed by 
Georgopoulos et al., 1983), A double-shelled prohead is 
assembled consisting of a shell of about 420 55-kDa coat 
protein molecules around an inner shell of about 250 
molecules of the 42-kDa scaffolding protein. DNA is 
encapsidated and as a concomitant the scaffolding protein 
molecules are removed from the prohead,' to take part in 
further rounds of the process (King & Casjens, 1974). 
Mutants in either protein gene prevent this process. 
Using proteins purified from proheads,' the assembly 
process can be repeated and studied in vitro. When both 
proteins are present together, self-assembly of normal 
proheads occurs. However, the scaffolding protein does 
not form any structural units when present alone,' and in 
the absence of scaffolding protein the coat protein only 
forms aberrant shell structures when present in 
concentrations much higher than are necessary to form 
normal proheads in conjunction with a scaffold. These 
results suggest that assembly of P22 proheads in vivo 
occurs by a process of copolymerisation (Fuller & King,'
1980)• VP22a can be removed from HSV-1 capsids using 
GuHCl leaving a stable outer capsid shell (Newcomb & 
Brown,' 1991), and the P22 scaffolding protein can be 
removed from proheads in a similar way (Fuller & King,'
1981). Thus although the P22 coat protein is capable of a 
degree of self-assembly,' the scaffold is required for 
correct assembly; but once assembled the prohead shell of 
coat protein remains stable when the scaffold is removed.
Another interesting example of capsid assembly using a 
scaffold is found in the assembly of heads of the 
Es-cherichia coli bacteriophage T4 (reviewed by Black & 
Showe,' 1983). In T4 infections a scaffolding core is 
formed which comprises one major and seven minor proteins 
(Traub et al., 1984). Proheads are formed by the addition 
of two major coat proteins. Use of mutants defective in 
the coat proteins has shown that the scaffold core can 
form in vivo without the coat proteins (Traub et al.,'
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(However, in view of the discovery of the UL26 protease it 
no longer be certain that there is a single core protein 
HSV: Davison et al., 1992).
1984; Traub & Maeder, 1984), and that these cores can act 
as intermediates in the T4 head assembly pathway (Kuhn et 
al«/ 1987). Assembly of T4 is therefore not a
copolymerisation event. A further significant difference 
from the P22 assembly pathway is that after prohead 
assembly is complete/ the scaffolding core structure is 
proteolytically removed. In this process the core 
proteins are either totally or partially degraded/ and 
the degradation products of some core proteins remain 
inside the mature head (Onorato & Showe/ 1975; Onorato et 
al./ 1978).
Thus many similarities can be seen bdlween these 
bacteriophages and the assembly of HSV capsids. Like P22/ 
HSV capsids have a single known core proteii^ VP22a/ 
which is present during assembly but which is afterwards 
removed. The fact that intermediate structures in the 
herpesvirus assembly pathway are not known/ and the lack 
of assembly of cloned capsid gene products reported in 
this thesis suggest that HSV capsid assembly occurs by a 
process of copolymerisation as in P22. VP22a is lost from 
capsids at or near the time that viral DNA is packaged 
(Sherman & Bachenheimer/ 1988; Rixon et al., 1988)/ and
DNA packaging appears to be a concomitant of exit of
scaffold in the dsDNA bacteriophages also (Earnshaw &
Casjens/ 1980). Both VP22a and the P22 scaffolding
protein can be removed with GuHCl to leave basically 
intact capsid shells. The mechanism by which VP22a exits 
the HSV capsid is not clear. However/ it is known that 
VP22a does undergo proteolytic modification (Liu & 
Roizman/ 1991b; Preston et al./ 1992)/ but the full roles 
of the UL26 protease and of VP24 have yet to be
elucidated. These will be discussed in a later section. 
The precise roles of scaffolding proteins in virus 
assembly have not been fully elucidated/ but Georgopoulos 
et al. (1983) summarise three possibilities. These are 
that the role of the scaffolding proteins may be (1) to 
help guide the coat protein into a proper assembly/ (2) 
to exclude host macromolecules from the interior of the
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coat protein shell/ or (3) to allow coassembly of the 
coat protein with other/ minor capsid proteins. None of 
these possibilities has been rigourously excluded but 
neither are they/ in general/ mutually exclusive.
A broader class of proteins which are involved in the 
self-assembly of protein structures are the molecular 
chaperones. These have been defined by Ellis & van der 
Vies (1991) as proteins which are transiently associated 
with one or more proteins to prevent improper 
interactions between potentially complementary surfaces. 
Chaperones can be involved in preventing incorrect 
folding during synthesis or transport of a protein. Even 
where chaperones are involved in the assembly of protein 
structures they do not convey steric information. They 
merely act to prevent an incorrect folding or 
interaction/ allowing correct folding and interaction to 
predominate.
Certain stages in the assembly pathways of some viruses 
are known to depend upon proteins which clearly act as 
molecular chaperones but which are not scaffolding 
proteins. An example of a molecular chaperone involved in 
virus assembly is found in the papovavirus SV40. The SV40 
MCP VP1 has an endogenous nuclear localisation signal 
(Wychowski et al./ 1986). However/ nuclear localisation 
of VP1 is enhanced by a 61-amino-acid/ highly basic/ 
SV40-specified polypeptide known as the agnoprotein 
(Carswell & Alwine/ 1986? Resnick & Shenk/ 1986). The 
agnoprotein may facilitate formation of infectious 
particles by inhibiting polymerisation of VP1 molecules 
until the time they interact with viral minichromosomes 
(Barkan et al./ 1987). This is a recognised function of 
one type of molecular chaperone (Ellis & van der Vies/ 
1991). The ability of VP22a to effect nuclear 
localisation of VP23 as shown by IF experiments might be 
due to a similar phenomenon. Thus VP23 may adopt an 
incorrect conformation or form aggregations which prevent 
its translocation through nuclear pores. Association with
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VP22a could maintain VP23 molecules in a form which can 
be translocated into the nucleus.
The adenovirus capsomer/ the hexon/ is composed of three/ 
identical 110-kDa molecules (Burnett et - al. / 1985;
Roberts et al./ 1986). Assembly of this trimer is 
mediated by an essential 100-kDa virus-encoded non-virion 
protein. The 100-kDa protein complexes with nascent hexon 
monomer/ and trimerisation is concomitant with separation 
of the complex (Cepko & Sharp/ 1982; Cepko & Sharp/ 
1983). These authors suggest that the 100-kDa protein may 
serve actively to fold the hexon monomers into the 
trimer/ or to transport monomers to a site where 
trimerisation can occur. The function of one class of 
chaperones is to prevent incorrect folding during 
transport. Another class of chaperones prevents incorrect 
folding of the aminoterminal region of a protein while 
the carboxyterminal region is still being synthesised 
(Ellis & van der Vies, 1991)/ and the association of the 
100-kDa protein with hexon monomers while still attached 
to polyribosomes suggests that it may be acting in this 
way. In any case/ it is possible that proteins of similar 
function to the 100-kDa protein might be essential for 
HSV capsid assembly. If such a protein does exist, it 
remains unidentified, but this would explain why HSV 
capsid assembly was not achieved in the experiments 
described here.
11 ASSEMBLY OF THE MAJOR CAPSID PROTEIN, VP5
Although assembly of viral capsids typically involves the 
ordered interaction of a number of components/ individual 
structural proteins are capable of self-assembly into 
recognisable structures. The polyomavirus MCP VP1 has 
been purified after expression of the recombinant gene in 
an Eshcherichia coli vector. It was found that the 
purified VP1 had not undergone the extensive post- 
translational processing (acetylation and
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phosphorylation) seen in virus-infected eukaryotic cells 
(Leavitt et al. / 1985), Image analysis of low-dose
electron micrographs revealed that the purified VP1 
existed as pentamers which resembled the capsomers 
derived from dissociated capsids. At high ionic strength/ 
these pentamers associated into capsid-like assemblies. 
Thus/ neither the minor capsid proteins VP2 or VP3 nor 
post-translational processing of VP1 is essential for 
assembly of VP1. The stability of these assemblies was 
found to be increased by the addition of calcium to the 
medium (Salunke et al. / 1986). A recombinant baculovirus 
expressing VP1 alone was found to assemble capsid-like 
particles in the nuclei of infected cells. However/ 
treatment of infected cells with the calcium ionophore 
ionomycin led to formation of these particles in the 
cytoplasm also (Montross et al. / 1991). These authors
suggested that nuclear assembly might result from 
increased available calcium in this subcellular 
compartment. Increased calcium ion concentration has also 
been shown to improve the assembly of rotavirus-like 
particles in a recombinant baculovirus (Sabara et al./
1991).
Further interesting work on the assembly of the 
polyomavirus MCP VP1 was reported by Salunke et al. 
(1989). In these experiments it was found that by varying 
the ionic strength/ pH and calcium concentration of 
preparations of purified VPl, a variety of structures 
would assemble from the pentameric VP1 subunits. Thus 
under certain conditions elongated tubules of VP1 could 
be formed. By varying the conditions/ 12-capsomer 
icosahedral assemblies and 24-capsomer octahedral 
assemblies could be made. Cryoelectron microscopic 
analysis of these assemblies demonstrated that pentamers 
of VPl had assembled by means of several significantly 
different inter-pentamer bonding arrangements. The normal 
polyomavirus capsid is an icosahedron consisting of 72 
identical capsomers which are all pentamers of VPl. In 
this structure the 12 vertex pentamers adopt a
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pentavalent bonding arrangement while the remaining 60 
pentamers are hexavalent (Rayment et -al./ 1982). Such
changes in bonding specificity exceed the possibilities 
of the elastic distortion assumed by Caspar & Klug 
(1962)/ and in fact involve distinct changes in 
quaternary structure of oligomers (Rossman, 1984).
A site-directed deletion at the carboxy terminus of the 
gene encoding VPl resulted in the production of a mutant 
protein which was 57 amino-acid residues shorter than the 
wild-type (Garcea et al./ 1987). Although this protein 
assembled in vitro into pentamers as normal, it did not 
assemble into capsid-like assemblies or any other higher- 
order structure. Thus the carboxy-terminal region of VPl 
was shown to be involved in the specific bonding 
responsible for the non-equivalent association of 
capsomers•
Another example of polymorphism in virus structural 
assemblies is to be found in the bovine rotavirus major 
structural protein VP6. Hexameric capsomers of VP6,' when 
purified from rotavirus particles,' can be induced to 
assemble into a variety of structures according to 
conditions of ionic strength and pH. These forms include 
tubules and sheets as well as single-shelled capsids 
(Ready & Sabara,' 1987). Thus even where chaperones or 
scaffolding proteins are not necessary,- normal capsid 
assembly is not an inevitable outcome of the self- 
assembly of capsid proteins.
A feature of the lytic cycle of bacteriophage T4 is the 
appearance late in infection of polyheads. These open- 
ended tubular structures consist of a shell of the main 
coat protein gp23 built around a core of scaffolding 
proteins. Mutants in the main core protein genes do not 
produce proheads but do produce polyheads which lack a 
core. Thus gp23 is able to assemble in vivo without a 
scaffold (Steven et al., 1976). These coreless polyheads 
can be purified and used in studies of head formation.
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Purified polyheads can be dissociated into hexameric 
capsomers of gp23; these capsomers are then able to re­
assemble in vitro into polyheads without the need for a 
scaffold (Caldentey & Kellenberger,' 1986). This re­
assembly is dependent on conditions of ionic strength,
temperature and pH. T4 capsomers can be further 
dissociated into lower-order oligomers, and ultimately to 
monomers (Caldentey & Kellenberger,' 1986) .
It was also observed that assembly of purified gp23 
occurred above a critical concentration, in a manner 
comparable to crystal formation (Caldentey &
Kellenberger, 1986). A similar phenomenon has been 
demonstrated in the assembly of poliovirus. The 
poliovirus 14S structural subunit consists of five copies 
each of the structural proteins VPO,' VPl and VP3. These 
14S subunits are precursors in the poliovirus assembly 
pathway of 75S procapsids (Hellen & Wimmer 1992a)•
Purified 14S subunits have been shown to assemble in 
vitro only if their concentration exceeds a 1.6 nM
threshold. This is also true for the 14S subunits in 
infected cell extracts. Thus assembly of poliovirus 
particles appears to be driven by the supply of 14S 
subunits (Rombaut et al., 1991).
11.1 Why doesn!t VP5 self^assemble?
Although it has not yet been possible to assess whether 
cloned VP5 assembles into oligomers including hexamers,' 
it has been shown that higher-order assemblies resembling 
capsids, tubules or sheets do not occur in either 
vaccinia- or baculovirus-infected cells. The reason for 
this is not clear. HSV capsid assembly may take place by 
a process of copolymerisation. If this is the case,' the 
four capsid proteins present in the experiments reported 
in this thesis are clearly not sufficient. It is possible 
that the minor capsid proteins VP24 and/or VP26 are 
essential for the copolymerisation process.
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VP5 may not even assemble into oligomers. Like the 
adenovirus hexon monomer,' it may require a chaperone to 
assist in assembly of capsomers (Cepko & Sharp,' 1982). If 
this is the case,' such a chaperone remains to be 
identified and was not present/functional in the 
experimental systems used here.
Assembly of T4 and poliovirus subunits has been shown to 
be dependent on a concentration threshold. The high 
levels of VP5 expressed by vMJ535 and by AcUL19 would 
probably exceed such a threshold if it is a limiting 
condition in the assembly of VP5. Both vMJ535 and AcUL19 
express greater amounts of VP5 than are expressed by 
wild-type HSV-1. However,' HSV-infected cells may achieve 
higher localised concentrations of VP5. For instance,' 
assembly of VP5 in HSV occurs in the nucleus and not in 
the cytoplasm. VP5 was not present in the nucleus of 
vMJ535-infected cells. Conditions for VP5 assembly are 
not correct in the cytoplasm of HSV-infected cells, and 
presumably the same is true in the nuclei of AcULl9- 
infected cells. If certain physiological conditions are 
critical, it may be that the S.frugiperda cells used for 
the cultivation of baculoviruses do not provide the 
necessary conditions. It is interesting to note that the 
capsid-negative mutant ts2,' which has a lesion in UL38,' 
does not assemble any capsid-like structures,* despite 
synthesising normal levels of VP5 (Pertuiset et al.,' 
1989).
12 ROLE OF THE UL26 PROTEASE
The demonstration by Liu & Roizman (1991a) that a second 
ORF,' UL26.5,' is contained within the UL26 ORF was of 
great interest, and is the first of several recent 
developments in the understanding of the UL26 ORF,' the 
proteins encoded within this region and their relevance 
to capsid assembly and structure. The significant 
features of this region are that the UL26.5 ORF is
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contained entirely within the UL26 ORF/ that the two ORFs 
are in frame and 3'-coterminal/ and that the promoter 
regulatory domain of UL26.5 is entirely within the coding 
sequences of UL26. Although this is the first such 
example in HSV/ a known parallel to this nested 
arrangement is found in the overlapping pre-Sl/ pre-S2 
and S genes of hepatitis B virus. The pre-S2 gene is 
contained entirely within the pre-Sl gene/ and the S gene 
is contained entirely within the pre-S2 gene. All three 
genes are 3'-coterminal. All three gene products are 
components of HBV particles (Heerman et al./ 1984;
Neurath et al./ 1985). The paper of Liu & Roizman (1991a) 
also showed that UL26.5/ rather than UL26/ encodes VP22a. 
They also demonstrated for the first time the product of 
UL26/ which is predicted to be a 635-amino-acid protein/ 
and is of Mr 75 kDa.
Further research on the ORFs UL26 and UL26.5 demonstrated 
that the product of UL26 is a protease, and that this 
protease effects the removal of approximately 20 amino 
acids from the carboxy terminus of VP22a, and that it 
also autocatalyses the removal of its own corresponding 
carboxy terminus (Liu & Roizman/ 1991b; Preston et al./
1992). This is the first demonstration of a protease 
encoded by HSV-1.
Homologues of UL26/UL26.5 have been identified in several 
other herpesviruses/ as discussed in the Introduction. 
Further elucidation of these systems would also be of 
interest. The best characterised example is that of 
simian CMV/ which has a nested set of four in-frame 3'- 
coterminal genes/ and a protease activity localised in 
the amino-terminal 249 amino acids of the largest protein 
(Welch et al./ 1991a; Welch et al./ 1991b).
The region of the UL26 protein which contains the 
protease activity has been delineated by two sets of 
data. The mutant ts!201/ defective in this protease 
activity (Preston et al./ 1983)/ has a lesion at position
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50897 on the HSV-1 genome (refer to Figure 14)
(Al-Kobaisi/ 1989). This lesion is 89 base-pairs 
downstream of the amino terminus of UL26/ and corresponds 
to amino acid number 30 of the UL26 protein. The report 
of Liu & Roizman (1992) analyses the 635-amino-acid UL26 
protein by deletion and insertion analysis. Whilst the 
first nine amino acids could be deleted without loss of 
the protease activity, a stop codon inserted after amino 
acid 286 inactivated protease activity. A stop codon 
inserted after amino acid 306 did not. Thus the protease 
activity is localised to the region of amino acids 10 to 
306 of the 635-amino-acid UL26 protein. The protease is 
shown to be a serine protease (Liu & Roizman,' 1992).
The recent demonstration by Davison et al. (1992) that 
the capsid protein VP24 is encoded by the amino-terminal 
region of UL26 is a further interesting development. 
Their results suggest that VP24 is produced by cleavage 
of the amino-terminal 247 amino acids from the 635-amino- 
acid UL26 gene product. It has long been thought that 
VP21 is encoded by a region lying within the UL26 ORF. 
This is on the basis that VP21 is immunologically cross­
reactive with VP22a (Zweig et al. / 1979b; Braun et- -al.,» 
1984a)/ although direct demonstration of the exact region 
of UL26 which encodes VP21 is lacking. Davison et al. 
(1992) speculate that VP21 may result as a consequence of 
the production of VP24 by cleavage from the UL26 gene 
product/ i.e. that VP24 represents the amino-terminal 247 
and VP21 the carboxy-terminal 388 amino acids 
respectively of the 635-amino-acid UL26 protein. This 
suggestion is a major change from the view held prior to 
the discovery of UL26.5/ which was that VP21 was a 
precursor form of VP22a (Braun et al. ,> 1984a).
It is not clear what controls the release of VP24 from 
the UL26 protein. Following the suggestion of Welch et: 
al. (1991b)/ Davison et al. (1992) suggest that the UL26 
protein itself is responsible. However,' although the UL26 
protein has been shown to autocatalytically cleave its
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own 20 carboxy-terminal amino acids (Liu & Roizman,' 
1991b; Preston et al. 1992; Liu & Roizman,' 1992),' it has 
not yet been shown to cleave itself to release VP24 and 
VP21 •
It would also be interesting to know when these cleavages 
occur. The UL26 protein is not a recognised component of 
capsids,' but VP24 and VP21 are. Therefore release of VP24 
and VP21 from the UL26 protein must occur before capsid 
isolation. Since assembly can take place without the 
carboxy-terminal processing of VP22a (Preston et al., 
1983),' it seems likely that this proteolytic event occurs 
subsequent to assembly. This suggests that the protease 
activity is present in capsids. Davison et al. (1992) 
suggest that the 247-amino-acid VP24 molecule would 
retain the protease activity after cleavage from the UL26 
protein,' and thus would be able to effect the carboxy- 
terminal cleavage of VP22a within capsids. However,' the 
work of Liu & Roizman (1992) suggests that this is not 
the case,' as they show that a stop codon placed after 
amino acid 286 of the UL26 protein is sufficient to 
eliminate protease activity. Clearly there is a need to 
elucidate more fully the roles of VP24,- VP21 and VP22a. 
This thesis reports the expression of UL26.5 in a 
vaccinia vector,' and the cloning of UL26, providing the 
basis for further investigation of the products of these 
genes•
Proteolytic processing is a commmon phenomenon in the 
maturation of virus particles. Hellen & Wimmer (1992b) 
divide such processing into two classes: formative and
morphogenetic. Formative proteolytic processing occurs 
when structural proteins are synthesised as a large 
polyprotein and require to be cleaved to release 
individual proteins. A good example of this are the 
picornaviruses,' where the capsid proteins VPO,- VPl and 
VP3 are synthesised as a polyprotein (reviewed by 
Rueckert,' 1990). Morphogenetic proteolytic processing 
involves a conformational change in a precursor capsid
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form/ and is usually associated with aquisition of 
infectivity (Hellen & Wimmer/ 1992b) . Picornaviruses also 
exhibit morphogenetic processing/ at a later stage in the 
assembly process. A 125S provirion has been identified 
which contains 60 molecules each of VPO/ VPl and VP3. 
Conversion to mature 150S virions occurs following 
cleavage of the VPO molecules to release VP2 and VP4. The 
cleavage site appears to be inaccessible to exogenous 
viral or cellular proteases and it has been suggested 
that cleavage is effected by some part of the virion 
structure itself. Cleavage is probably concomitant with 
encapsidation of RNA (Hellen & Wimmer,' 1992a).
Bacteriophage T4 is an example of a large DNA virus which 
exhibits morphogenetic proteolytic processing,' and which 
has some parallels with HSV. The complex prohead of T4 
contains over 20 proteins. Conversion of the prohead to a 
mature head involves cleavage of most of these proteins,' 
several conformational changes, and packaging of DNA 
(reviewed by Black & Showe/ 1983). The protease 
responsible for the cleavages is contained within the 
prohead/ and is an 18.5-kDa molecule produced by 
autocleavage of a 27.5-kDa precursor. The protease is 
then inactivated by extensive self-digestion,' although 
1 to 4 intact copies of the protease remain in the mature 
head (Showe et al. ,> 1976a; Showe et al. / 1976b). The fact 
that VP24 is a component of mature HSV capsids has led to 
the suggestion that it may play an important structural 
role as well as having protease activity (Davison et al./ 
1992).
It is not clear how to classify the proteolytic events 
involved in the assembly of HSV capsids (Hellen & Wimmer,' 
1992b). It is not known what/ if any,' structural roles 
are played by VP24 and VP21. The cleavage producing these 
two proteins may even be an example of a formative 
processing event. Although no changes in morphology or 
structure are known to occur in the capsid shell/ there 
is a reduction in the size of the core associated with
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the carboxy-terminal cleavage event (Preston et al,/ 
1983). Furthermore,' the carboxy-terminal processing of 
VP22a is also known to be essential for packaging of D N A  
(Preston et al.,' 1983). The alteration of core size and 
the association with acquisition of D N A  suggest that this 
proteolytic event could be classed as morphogenetic. It 
is clear that the products of the genes UL26 and UL26.5 
play a central role in capsid morphogenesis and it is 
perhaps not surprising that the aim of capsid assembly 
was not achieved in the absence of a UL26-expressing 
vaccinia recombinant.
Viral proteases are increasingly being studied as 
potential targets for antiviral compounds,' and Liu & 
Roizman (1991b) observed that the UL26 protease is a 
potential antiviral target. The approaches taken to this 
problem can be divided into two classes: direct
inhibition of enzyme activity,' and alteration of 
substrate conformation (Korant,' 1989). With this in mind,' 
vMJ542 should prove useful for studies on VP22a,' the 
substrate of the UL26 protease.
Elucidation of the roles of the proteolytic processing 
events in HSV capsid assembly should prove to be a 
fruitful area of further enquiry.
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